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ABSTRACT 
Mechanical ventilation, essential for the support of patients with acute lung injury (ALI), causes 
exacerbation of the existing pathology, a process termed ventilator-induced lung injury (VILI).  
The pro-inflammatory cytokine tumour necrosis factor-alpha (TNF) has been consistently 
implicated in ALI/VILI.  TNF activates two receptors, TNFR p55 and p75 that act in opposition 
during VILI to promote or protect against pulmonary oedema formation, respectively, but the 
mechanisms underlying this are unknown.  Alveolar and plasma soluble TNFR (sTNFR) levels are 
elevated in ventilated ALI patients and associated with mortality.  However, the relevance of these 
increases is unclear.  This project had two main aims: to investigate kinetics and sources of 
sTNFRs in the alveoli and plasma and investigate mechanisms underlying differential TNFR 
signalling during VILI, using in vivo mouse models. 
 Investigation of intraalveolar sTNFRs during VILI, and also ALI induced by intratracheal 
administration of hydrochloric acid or bacterial toxins, showed that intraalveolar sTNFRs are 
differentially regulated during ALI: VILI/hydrochloric acid induced leakage of sTNFR p55 and 
p75 from plasma, whereas bacterial toxins induced intraalveolar p75 production.  These 
differences have important implications for TNF signalling and potential use as clinical markers. 
 Investigation of plasma sTNFRs suggests that VILI induces direct production of sTNFRs 
by the pulmonary vasculature, as opposed to leakage of intraalveolar sTNFRs into the circulation 
as previously suggested.  Development of a flow cytometry technique to study pulmonary TNFR 
expression was successfully validated using TNFR deficient tissue, but consolidation of data by 
immunohistochemistry was unsuccessful. 
Investigation of differential TNFR signalling mechanisms showed that following 
intratracheal fluid administration, p75 deficient mice exhibit physiological changes consistent with 
impaired fluid reabsorption, implicating p75 in lung fluid reabsorption during VILI. 
These data offer new, potentially clinically applicable insights into the involvement of 
TNFR biology in VILI/ALI and the novel methodologies developed herein constitute useful tools 
for future research. 
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1.  INTRODUCTION 
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Acute lung injury (ALI) is a major cause of mortality in the intensive care setting.  Despite 
this, successful treatments aimed at reducing ALI-associated mortality have not been 
forthcoming.  Patients often require mechanical ventilation as a supportive therapy, but 
this can actually exacerbate the existing injury, producing ventilator-induced lung injury 
(VILI).  Recent advances in ventilation strategies have successfully reduced mortality, but 
are ultimately of limited benefit.  Additional approaches likely include modulating the 
inflammatory response that develops during mechanical ventilation, but this first requires 
a greater appreciation of the various processes involved. 
The pro-inflammatory cytokine tumour necrosis factor alpha (TNF) has been 
consistently implicated in both ARDS and VILI, but its precise role is uncertain.  Recent 
evidence suggests that the diverse roles of TNF are due in part to differential signalling 
through each of its two cell-surface receptors, TNFR p55 and p75.  It has been shown that 
TNFR p55 promotes oedema formation during VILI in mice, whilst p75 confers protection 
from this, by as yet unknown mechanisms.  Furthermore, soluble forms of these receptors, 
produced by proteolytic cleavage of the receptor ectodomains (sTNFRs) have been 
implicated in ARDS and VILI, as levels are increased in both the circulation and the 
alveolar space.  Soluble TNFRs are generally thought to be anti-inflammatory in nature, 
sequestering TNF, but the significance of such increases is not fully understood and 
despite much speculation, the precise sources of increased receptor levels during ALI are 
not known.  Identification of sources will likely help interpretation of elevated sTNFR 
levels in intraalveolar and intravascular compartments during ALI.  This introduction 
chapter will address the current understanding of ARDS, VILI and TNFR biology and 
then outline the aims of this project. 
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1.1 The Acute Respiratory Distress Syndrome 
1.1.1 Background 
Acute lung injury (ALI) and its severe form, the acute respiratory distress syndrome 
(ARDS), are major causes of mortality in intensive care patients (1).  In the US alone, 
there are estimated to be ~75,000 deaths/year associated with ALI (2).  ARDS was first 
described by Ashbaugh et al. in 1967 (3), but until 1994 there was wide disparity in the 
diagnostic criteria.  This prompted the American-European Consensus Conference on 
ARDS (4) to attempt to standardise diagnoses (Table 1.1).  Using these criteria, a recent 
study estimated US incidence at 56-82/100,000 population/year, thought to be more 
accurate than previous reports, with a mean mortality rate of ~40% (2).  There is currently 
no definitive treatment for ARDS, though many strategies have been investigated (5).  
Mechanical ventilation is used consistently, owing to its fundamental importance as a 
supportive therapy. 
 
 Onset Radiological features Oxygenation Differential diagnosis 
ALI Acute 
Bilateral pulmonary 
infiltrates on chest X-ray 
PaO2:FiO2 ratio 300 
mmHg/40 kPa 
Pulmonary artery wedge pressure 18 
mmHg/absence of clinical evidence of 
atrial hypertension 
ARDS Acute 
Bilateral pulmonary 
infiltrates on chest X-ray 
PaO2:FiO2 ratio 200 
mmHg/26.6 kPa 
Pulmonary artery wedge pressure 18 
mmHg/absence of clinical evidence of 
atrial hypertension 
 
Table 1.1.  Diagnostic criteria for ALI/ARDS.  ALI and ARDS differ only with respect to hypoxaemia, 
which is more severe for ARDS, requiring mechanical ventilation (4). 
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1.1.2 Aetiology 
ARDS can develop from a variety of insults, both pulmonary, by a direct insult to the 
lungs, and extra-pulmonary, where there is a systemic cause.  Pneumonia and sepsis are 
the most common pulmonary and extra-pulmonary insults, respectively (Table 1.2).  
Consequently, studying ARDS is particularly difficult because it is a syndrome with a 
broad set of characteristics rather than a disease with a single defined pathophysiology.  A 
further complication is the impact of therapies such as mechanical ventilation that can 
contribute to injury. 
 
 Pulmonary causes (% of cases) Extra-pulmonary causes (% of cases) 
Most common 
Pneumonia (24-42%) Sepsis (16-42%) 
Aspiration (4-22%) Transfusion (<1-27%) 
 Trauma (<1-11%) 
Less common 
(<1-26%) 
Pulmonary contusions Cardiopulmonary bypass 
Fat emboli Drug overdose 
Near-drowning Acute pancreatitis 
Inhalational injury  
Reperfusion following lung transplant  
 
Table 1.2.  Common conditions associated with ALI/ARDS.  Six recent clinical studies were used to 
show the range of the relative levels of the most common causes of ALI (1, 6-11).  It is clear that sepsis and 
pneumonia are the dominant causes. 
 
1.1.3 Pathogenesis 
The progression of ARDS can be separated into stages.  In the acute, exudative stage, the 
main features are: hypoxia, caused primarily by mismatch between ventilation and 
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perfusion, producing intrapulmonary shunt (12), and the formation of protein-rich 
pulmonary oedema, i.e. permeability oedema as opposed to hydrostatic oedema, caused by 
leakage of fluid and plasma proteins from the pulmonary microcirculation into the 
interstitium and airways across a dysfunctional alveolar barrier, resulting in alveolar 
flooding (1).  This produces the radiological features of ARDS (13).  Histologically, the 
injury manifests as: diffuse alveolar damage, hyaline membrane formation and denudation 
of basement membranes, and there is decreased lung compliance (Crs), caused by oedema, 
alveolar collapse and increased surface tension at the fluid-air interface (1, 5). 
 The acute stage of ARDS is also characterised by significant intraalveolar 
inflammation, consisting of neutrophil infiltration and inflammatory mediator production 
(1, 14, 15).  Despite neutrophilic alveolitis being a hallmark of ARDS, it is important to 
note that ARDS can occur without this, as in severely neutropenic patients, demonstrating 
that neutrophil-independent mechanisms of lung injury are also important (16, 17).  
Persistent elevation of bronchoalveolar lavage fluid (BALF) levels of pro-inflammatory 
cytokines, such as tumour necrosis factor alpha (TNF), interleukin(IL)-1, IL-8 and IL-6, 
most likely due to intraalveolar production, predict poor outcome in ARDS patients (18).  
Conversely, anti-inflammatory mediators are present in the alveolar space, such as the 
endogenous cytokine inhibitors: IL-1-receptor antagonist (IL-1Ra), soluble IL-1 receptor 
II and soluble TNF receptors (sTNFRs), presumably in an attempt to counter-
balance/regulate the inflammatory response (19, 20). 
Pro- and anti-inflammatory mediators are also elevated in the circulation during 
ARDS including TNF, IL-6, sTNFRs and IL-1Ra (7, 18, 20, 21).  This is especially 
relevant as the majority of ARDS-related mortality is not from primary respiratory failure, 
but from multiple system organ failure (MSOF), critically mediated by the presence of 
circulating inflammatory cytokines (22).  Despite this, the precise sources of increased 
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soluble mediators in the circulation during ARDS are not well defined.  Specifically, 
whether mediators originate within the alveolar space is unclear.  The pro-inflammatory 
milieu, compartmentalised within the airways in the early stages of ALI, could 
disseminate systemically following dysfunction of the epithelial/endothelial barrier 
enabling “decompartmentalisation” of mediators into the circulation (22-24).  The extent 
to which this actually occurs in the clinical situation has yet to be properly investigated, 
but it has been reported that proteins produced by the pulmonary epithelium such as 
surfactant protein(SP)-A, KL-6 and receptor for advanced glycation end products (RAGE) 
are increased in the circulation during ARDS (6, 25, 26).  However, such mediators may 
have sources other than the pulmonary epithelium.  Furthermore, this phenomenon may 
not necessarily be true for all soluble mediators.  Nevertheless, it is clear that the 
inflammation associated with ARDS is not solely localised to the lungs and can 
produce/propagate systemic inflammation with dramatic effect. 
Other features of ARDS include the development of coagulation abnormalities, 
where expression of pro-coagulant and anti-fibrinolytic factors (e.g. tissue factor and 
plasminogen activator inhibitor (PAI)-1)) increase and anti-coagulant factor (e.g. protein 
C) levels fall, creating a pro-coagulant environment (13).  In addition, inactivation of 
surfactant and decreased surfactant production occurs, increasing alveolar collapse (13). 
The next stage of ARDS progression, for patients that do not show spontaneous 
resolution or do not survive, is the fibroproliferative stage (13).  It is worth noting that 
despite this being a feature of late ARDS, the early intraalveolar pro-inflammatory milieu 
is accompanied by an early pro-fibrotic component (14).  The fibroproliferative stage 
features chronic inflammation with fever and leukocytosis and substantial infiltration of 
fibroblasts into the alveolar space with increased deposition of connective tissue (13, 27).  
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In addition to sepsis/MSOF, this is a major cause of death in patients and the presence of 
pulmonary fibrosis correlates with mortality (27, 28). 
 
1.1.4 Treatment 
Despite many investigations, there has been little success in treating ARDS, which may be 
due in part to its heterogeneous nature.  The main aim has been to support patients, avoid 
complications, maintain oxygenation and treat the precipitating insult (13).  Attempts to 
develop adjunctive treatments have focussed on specific aspects of ARDS.  For example, 
to decrease pulmonary oedema development, i.v. fluid restriction was proposed to 
decrease hydrostatic pressure in the pulmonary circulation.  One small study showed that 
reducing the pulmonary capillary wedge pressure (Ppw) by at least 25% produced a 
significant improvement in survival (29).  A subsequent larger study comparing restrictive 
and liberal fluid management showed that restrictive fluid management reduced net fluid 
balance, intravascular pressures, lung injury scores and plateau pressures, with better 
oxygenation and more ventilator free and ICU free days (30).  However, there were no 
significant differences in mortality between the two approaches. 
Another approach has been to use beta-adrenergic agonists to induce clearance of 
oedema fluid to help promote resolution of ARDS.  A recent UK clinical study, the -
Agonist Lung Injury Trial (BALTI) was conducted to investigate this (11).  This trial 
tested the effect of i.v. salbutamol on extravascular lung water, lung injury, plateau 
pressure, oxygenation, ventilator-free days and 28-day mortality.  At day 7, patients 
treated with salbutamol had significantly lower lung water and plateau pressures, 
suggesting enhanced fluid reabsorption, with a trend for lower lung injury.  However, all 
other variables, including mortality, were not significantly different between salbutamol 
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and placebo treated groups.  Manocha et al. compared two doses of inhaled salbutamol, 
and showed that patients receiving a higher dose had significantly more days free of ALI 
(31).  The higher dose was also associated with more days free of severe hypoxaemia, but 
was not associated with more days free of non-pulmonary organ dysfunction.  Moreover, 
there were no differences in mortality between groups and this study did not investigate 
reabsorption of lung fluid or other underlying mechanisms (31).  Furthermore, a trial by 
the, US National Heart, Lung and Blood Institute ARDS network using inhaled 
salbutamol treatment in ARDS patients was terminated in 2008 due to futility of the 
treatment.  Thus, the effectiveness of β2 agonist treatment in the management of ARDS is 
not clear. 
Surfactant therapy has been suggested as a treatment for ARDS due to the 
surfactant dysfunction observed in the lungs of ARDS patients and the success of this 
therapy in the neonatal respiratory distress syndrome.  However, this has not proved 
beneficial in adults (32).  Vasodilators such as nitric oxide and prostaglandin E1, aimed at 
reducing the pulmonary arterial hypertension often seen in ARDS patients, have also been 
proposed as possible therapeutic agents, but have been largely unsuccessful (5).  Denuded 
basement membranes, produced by loss of the pulmonary epithelium, are a histological 
feature of ARDS.  Promoting re-epithelialisation of basement membranes with epithelial 
mitogens including keratinocyte growth factor has therefore been suggested to help 
promote fluid clearance (mediated by type II epithelial cells) and resolution of ARDS (5).  
However, beneficial effects have only been shown experimentally. 
The inflammatory nature of ARDS has prompted the trial of anti-inflammatory 
treatments with various rates of success.  For example, the general anti-inflammatory 
agents ketoconazole, lisofylline, ibuprofen and prostaglandin E1, have not shown 
beneficial effects in clinical trials (5, 33, 34).  Similarly, high dose glucocorticoid 
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treatment, has previously been unsuccessful in the treatment of ARDS (35), but using 
lower doses shows promise.  A study using low dose methylprednisolone (intravenous 
(i.v.), then oral administration) showed improved lung injury score, oxygenation, multiple 
organ dysfunction score, ventilator-free days and ICU mortality (10).  Similarly, in sepsis, 
a major cause of ARDS, treatment with activated protein C that exhibits both anti-
inflammatory and anti-coagulant properties, has shown potential in decreasing mortality 
(36). 
In addition to generalised anti-inflammatory therapies, inhibition of specific pro-
inflammatory mediators in ARDS has been investigated, but with little success.  Opal et 
al. investigated the use of i.v. administered IL-1Ra to inhibit IL-1 signalling in septic 
patients, including those with ARDS (37).  However, no significant differences were 
observed in mortality rates between IL-1Ra and placebo treated patient groups.  Similarly, 
investigations using i.v. anti-TNF therapies including an anti-TNF monoclonal antibody 
(38) and a sTNFR-immunoglobulin fusion protein (39) have failed to show significant 
improvements in mortality rates in septic patients with ARDS.  Therefore, modulation of 
the inflammatory response in ARDS using both general and specific treatments is a 
controversial approach.  While it is clear that ARDS is an inflammatory syndrome, the 
precise involvement of individual mediators will potentially require further understanding 
for future therapies to show more compelling beneficial effects. 
The only therapy so far to have a significant impact on patient mortality from 
ARDS has been altering the approach to mechanical ventilation, which will be discussed 
later in this chapter. 
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1.1.5 Animal models of ALI/ARDS 
Studying ARDS in the clinical setting is difficult because of the many variables in patients 
that cannot be controlled for.  The use of in vivo animal models of ALI is the best way to 
test clinical hypotheses and validate data generated by in vitro studies, but importantly no 
single animal model faithfully recreates all of the features of the clinical syndrome (40).  
Most of the models currently in use are based upon 1 or 2 methods of injury, unlike 
clinical ARDS where there are many complex risk factors involved (40).  Furthermore, 
there are important differences between certain animals and humans and issues specific to 
each model also exist.  The main models of ALI currently in use will be briefly discussed 
below. 
 
1.1.5.1 Oleic acid-induced lung injury 
The oleic acid model of ALI is very commonly used.  This model attempts to reproduce 
ALI induced by lipid embolism (40).  Oleic acid is injected into the pulmonary circulation 
and produces injury by direct necrosis of the pulmonary endothelium and epithelium (41).  
The injury produced displays similar features to clinical ARDS, but unlike ARDS, oleic 
acid-induced ALI displays areas of micro-infarction (41).  Furthermore, few cases of 
ARDS are associated with lipid injury (40).  In summary, oleic acid-induced lung injury 
models have features consistent with ARDS, but have questionable clinical relevance. 
 
1.1.5.2 Acid aspiration-induced lung injury 
Hydrochloric acid aspiration models aim to reproduce aspiration of gastric contents, which 
is a major risk factor for ARDS (Table 1.2) (40).  This model therefore has a high degree 
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of clinical relevance.  In such models, hydrochloric acid is instilled into lungs via an 
endotracheal tube, through which the animals are ventilated (42).  Like ARDS, the injury 
produced features alveolar apoptosis, with alveolar and interstitial pulmonary oedema, 
neutrophilic inflammation, haemorrhage and fibrosis (40, 42).  However, during gastric 
aspiration in humans a complex mixture of bacterial products, cytokines and a less acidic 
aspirate are introduced into the lungs, which is different from the more acidic bolus of 
pure hydrochloric acid used in the models (40).  Consequently, acid aspiration models 
have strong clinical relevance in that they attempt to model a common pulmonary insult, 
but also have limitations.  
 
1.1.5.3 Surfactant depletion-induced lung injury 
In ARDS, the surfactant system is considerably compromised, due to inhibition of 
surfactant production and dysfunction of any surfactant that is already present (43).  
Surfactant depletion models aim to reproduce this.  In such models, a series of saline lung 
lavages are performed in order to deplete pulmonary surfactant (44, 45).  The saline lavage 
itself is not thought to be injurious, but the surfactant depletion causes injury by 
atelectrauma (see section in Ventilator-induced lung injury), and by reducing intraalveolar 
host defences, (40) in part because SP-A and -D exhibit immunosuppressive behaviour on 
alveolar macrophages (46).  However, the injury caused by surfactant depletion is very 
small, and almost always used in combination with mechanical ventilation in order to 
cause substantial injury similar to ARDS (40).  An additional caveat is that surfactant 
depletion is usually a consequence of lung injury rather than a cause (40). 
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1.1.5.4 Sepsis/endotoxaemia-induced lung injury 
Sepsis is one of the main risk factors for ARDS.  It is therefore not surprising that there 
are numerous animal models of sepsis/endotoxaemia-induced lung injury, produced by 
bacteria or bacterial products.  The most common include i.v. administration of 
lipopolysaccharide (LPS, a gram negative endotoxin) or live bacteria, and caecal ligation 
and puncture (CLP). 
For LPS administration, the degree of inflammation/injury is dependent on 
whether the species used has pulmonary intravascular macrophages (as in sheep and pigs, 
but not mice or humans), which increases their susceptibility to LPS (40).  Systemic LPS 
treatment models typically produce recruitment of inflammatory cells to the lungs, but 
unlike the clinical scenario there is little migration of neutrophils to the airspaces, and 
negligible changes in the pulmonary epithelial barrier/alveolar flooding (47).  As with 
LPS, administration of live bacteria produces only mild lung injury (40).   
CLP models feature peritonitis followed by sepsis and lung injury (40).  The 
mouse caecum is ligated and the intestinal wall perforated with a needle the desired 
number of times (normally 3-5) (48).  The number of perforations and the size of the 
needle will determine the severity of the injury (40).  The injury has similar features to 
ARDS, but there is less intraalveolar inflammation and hyaline membrane formation, and 
this model is subject to significant biological variability, because the size of the bacterial 
inoculum is not known (40). 
In summary, apart from CLP, sepsis models generally do not cause severe lung 
injury, as in clinical ALI.  However, CLP models are complex and also have limitations. 
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1.1.5.5 Intratracheal lipopolysaccharide/bacteria 
Pneumonia is another major cause of ARDS and consequently the pulmonary response to 
bacteria and their products is used to model this in animals.  In such models, agents are 
administered in bolus form via an intratracheal (i.t.) cannula into the lungs of 
anaesthetised animals.  Alternatively, an aerosol can be administered (49).  Intratracheal 
LPS produces pulmonary inflammation with up regulation of intraalveolar cytokines and 
substantial alveolar neutrophil infiltration, and epithelial injury, thickened alveolar walls 
and hyaline membrane formation (49, 50).  At extremely high doses of LPS mild 
pulmonary oedema can develop after 6 h, progressing to 24 h, and permeability changes 
are present up to 5 days after challenge (49, 51).  With i.t. administration of live bacteria 
such as Escherichia coli, permeability and neutrophil infiltration develop within 6 h (52).  
Generally speaking, i.t. LPS and live bacteria models produce sufficient intraalveolar 
inflammation, but do not produce the required degree of lung injury compared to clinical 
ALI. 
 
1.1.5.6 Bleomycin-induced lung injury 
Bleomycin treatment is a common method used to model ALI.  Bleomycin is an anti-
neoplastic antibiotic originally isolated from Streptomyces verticillatus and is thought to 
generate injury and fibrosis through its ability to cause DNA strand breakages and cell 
death (53).  Administered either i.v. or i.t. it causes pulmonary epithelial and endothelial 
cell damage with the initial site of injury being dependent on the route of administration 
(53).  Bleomycin-induced lung injury features neutrophilic alveolitis and fibrosis (53).  
Pittet et al. showed that transforming growth factor beta (TGF-) mediates the 
development of pulmonary oedema following i.t. bleomycin and LPS challenge in vivo 
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(51).  However, hyaline membrane formation is absent in this model, unlike clinical 
ARDS and its clinical relevance is often questioned (40).  Since bleomycin models are 
directed towards fibrosis they may be more suitable for modelling the 
fibroproliferative/fibrotic stages of ARDS and injury resolution. 
 
1.1.5.7 General considerations 
Animal models of ALI vary greatly in their clinical relevance.  The limitations of each 
model should always be considered when choosing models to address hypotheses.  The 
nature of the model is also extremely important when interpreting data and extrapolating 
findings to the clinical setting.  Importantly, models of ventilator-induced lung injury that 
attempt to reproduce the injury caused by mechanical ventilation of ARDS patients are 
unique, as they alone have yielded insights that have been used to successfully reduce 
ARDS-associated mortality.  This phenomenon will now be discussed. 
 
1.2 Ventilator-Induced Lung Injury 
1.2.1 Overview 
Mechanical ventilation has been a vital tool in the intensive care setting for decades.  Yet 
despite its recognition as essential in the support of patients with various types of 
respiratory failure, especially ARDS, it is thought to produce effects that are deleterious to 
the patient, termed ventilator-induced lung injury (VILI).  This concept is not actually 
novel.  In 1745 when comparing mouth-to-mouth inflation of patients’ lungs with the use 
of bellows, the physician John Fothergill stated “the lungs of one man may bear, without 
injury, as great a force as another man can exert; which by the bellows cannot always be 
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determin’d” (54).  However, the injury caused by mechanical ventilation is not simply due 
to excessive ventilation.  Laboratory-based models of mechanical ventilation that attempt 
to recreate VILI are the only models of ALI that have significantly contributed to patient 
care and helped improve survival in ARDS (40). 
 
1.2.2 Models of VILI 
The concept of VILI mainly originated from animal models.  The first example of this is 
work by Webb and Tierney in 1974, who showed that a more rapid and severe pulmonary 
oedema developed when rats were ventilated with higher peak airway pressures (55), a 
finding later confirmed by Dreyfuss et al. (56). 
VILI models show pulmonary oedema development and histological changes 
consistent with clinical ARDS, such as epithelial damage and hyaline membrane 
formation (40), making VILI indistinguishable from ARDS in the clinical setting (57).  
There are however, different types of VILI models, those that produce injury solely 
through the use of injurious ventilation, usually through high VT ventilation (one-hit 
models), and models that introduce an additional insult (two-hit models).  Two-hit models 
commonly use inflammatory stimuli such as LPS that can be administered systemically 
(58) or i.t. (59).  Other insults such as surfactant depletion by saline lavage can also be 
performed (44, 45).  Such models arguably have more clinical relevance than pure 
injurious mechanical ventilation models.  Important considerations when comparing two-
hit and one-hit models of VILI, and also when comparing different types of two-hit 
models, include the site of injury, and its relation to the clinical situation.   
For example, i.v. and i.p. LPS treatments, producing endotoxaemia, followed by 
injurious mechanical ventilation, are akin to sepsis-induced lung injury in the presence of 
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mechanical ventilation.  Similarly, models featuring i.t. LPS followed by injurious 
mechanical ventilation are akin to gram-negative bacterial pneumonia-induced ALI in the 
presence of mechanical ventilation.  These examples both employ LPS treatment, but 
because the route of administration is different, the initial site of injury also differs, i.e. 
intravascular vs. alveolar.  This can generate inflammation in the circulation and alveolar 
compartments, respectively.  Injurious ventilation can perpetuate inflammation and 
produce injury to the alveolar capillary barrier, causing the compartmentalised 
inflammatory milieu to disseminate to unaffected compartments 
(decompartmentalisation), and allowing soluble mediators to cross from the alveolar space 
to the pulmonary circulation and vice versa.  Consequently, different models of VILI 
feature model-specific pathophysiology. 
 
1.2.3 Mechanisms of VILI 
VILI is caused by a complex combination of insults with various mechanisms.  These will 
be discussed separately as: volutrauma, atelectrauma, mechanotransduction and 
biotrauma. 
 
1.2.3.1 Volutrauma 
In early models of VILI, lung injury was thought to develop in response to the high 
pressures employed.  However, in 1988 Dreyfuss et al. conducted a study comparing high 
and low tidal volume (VT) ventilation, in the presence of high and low pressures in rats 
(56).  Low VT ventilation was facilitated at high pressures by thoracoabdominal strapping, 
preventing over-distension of the lungs and high VT at low pressures was achieved with 
negative pressure ventilation.  The main finding of this study was that high VT, rather than 
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high pressures, caused the resulting pulmonary oedema (56).  This led to the term 
volutrauma (injury caused by excessively high VT/end inspiratory lung volume and lung 
over-distension, determined by the transpulmonary pressure), as opposed to barotrauma 
(injury caused by excessively high airway pressures) (60, 61). 
Despite studies demonstrating the injurious effects of ventilation in animals, 
whether this contributed to morbidity/mortality in patients was unclear until relatively 
recently.  The traditional approach to the ventilation of ARDS patients was to use high VT 
of 10-15 ml/kg in order to achieve normal blood gases and pH, but the high inspiratory 
pressures generated by this approach, were suggestive of lung over-distension (7).  A 
number of studies investigated altering ventilation strategies to prevent lung over-
distension and improve mortality in patients.  One approach was to use high frequency 
oscillation (HFO) ventilation, where extremely low VT are delivered to patients at high 
respiratory rates of up to 900 breaths/min (62).  This method of ventilation can improve 
oxygenation in ARDS patients and is particularly beneficial in neonates, but most adult 
studies have failed to show a reduction in mortality over conventional ventilation (62, 63). 
Another approach was to simply reduce over-stretching of the lungs without large 
increases in respiratory rates.  In the late 1990s, numerous small clinical trials investigated 
the use of lower VT than those used traditionally.  Brochard et al. investigated limiting 
plateau pressure to  25 cmH2O when ventilating ARDS patients, in order to reduce VT, 
but it was found that this produced no reduction in complications such as pneumothorax 
and organ failure or the duration of mechanical ventilation and ICU stay, and also caused 
hypercapnia (64).  Importantly, there was no reduction in mortality.  Brower et al. also 
assessed the impact of low VT ventilation by limiting plateau pressures (<30 cmH2O) (65).  
Low VT ventilation was safe, causing no significant problems in gas exchange, but did not 
produce any beneficial effects in terms of recovery from respiratory failure and mortality 
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(65).  Stewart et al. also used pressure-limited ventilation in their experimental group, but 
limited peak inspiratory pressure (PIP) as opposed to plateau pressure, as they claimed this 
is more commonly limited by physicians (66).  This study also failed to show a significant 
decrease in mortality or organ dysfunction.  Conversely, Amato et al. found beneficial 
effects using low VT ventilation and higher PEEP on 28-day mortality, ventilator weaning 
and barotrauma, compared with traditional higher VT ventilation, but had very high 
mortality in their control group (71%) (67).  Hence these studies showed that ventilation 
with lower VT was safe, but showed disparity in their findings, and due to their size, most 
were unable to show significant benefits in patients. 
In 2000, a large multi-centre trial by the ARDS network was published in the New 
England Journal of Medicine (7).  This study showed that ventilation with lower VT (6 
ml/kg) dramatically improved mortality in ARDS patients compared to ventilation with 
higher VT (12 ml/kg) (mortality rates 31% and 40%, respectively).  Patients ventilated 
with lower VT also had a greater number of days without the need for a ventilator, and 
more days free of complications including organ failure (7).  Normoxia was maintained, 
but arterial CO2 was higher and pH lower in the lower VT group, although bicarbonate 
treatment and increases in respiratory rate were employed when there was mild acidosis.  
Interestingly, low VT ventilated patients had a greater decrease in plasma IL-6 from day 0 
to day 3 compared to the traditionally ventilated group, showing attenuation of the 
pulmonary/systemic inflammatory response that potentially contributed to the beneficial 
effects of low VT ventilation on organ failure (7). 
This study was extremely important in clarifying the effects of lung protective, low 
VT ventilation, and thus the manifestations of VILI in humans.  Due to its large size it was 
able to show real benefits of low VT ventilation in contrast to previous studies.  However, 
this study was also controversial due to a number of reasons.  For example, the high VT 
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ventilated group had VT of 12 ml/kg (7), which was arguably higher than common clinical 
practice (68), although it was similar to other trials (7).  The high VT group was also 
double that of the low VT group, which had VT that were even lower than normal 
breathing at rest (6 ml/kg vs. 7-8 ml/kg), a much larger difference between groups than 
used previously (7).  Therefore both low and high VT could have potentially put patients at 
risk (68).  Furthermore, the effects of hypercapnia seen in this study are not known (61).  
Despite these possible issues, the ARDS network study successfully addressed the 
controversy surrounding VILI in humans. 
Ventilation with lower VT is beneficial and attenuates the inflammation and injury 
in ARDS, facilitating recovery and resolution.  Unfortunately, the use of lower VT has a 
number of limitations and does not completely abrogate VILI.  In the ARDS network trial 
and in the study by Amato et al., even in the lung-protective low VT groups, mortality was 
relatively high (31% and 38%, respectively) (7, 67).  Some degree of mortality would 
always be expected, i.e. the worst cases of ARDS may never resolve even with low VT 
ventilation.  Yet, some of this residual mortality could still be due to over-distension of 
lungs causing VILI.  Gattinoni and Pesenti proposed that lung over-distension could occur 
at lower VT via a phenomenon termed the “baby lung” (69).  This originated from the 
observation that computed tomography (CT) images of the lungs of ARDS patients 
exhibited only small regions of aerated tissue, having the dimensions of the lung of a 5- to 
6-year-old child (300-500 g). 
It was previously thought that in ARDS the lungs are homogenously stiff and 
heavy, due to oedema fluid.  Instead it was shown that the lungs are heterogeneously 
atelectatic (collapsed) and not uniformly aerated (69).  Aerated regions were situated in 
the non-dependent areas of the lung (towards the anterior of the lungs in the supine 
position), with dependent (towards the posterior of the lungs in the supine position) areas 
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appearing denser on CT (69).  The aerated regions were originally thought to be healthy 
and that the baby lung was an anatomically defined structure.  Consequently, prone 
positioning was recommended to increase blood flow to the non-dependent areas of the 
lung, which did improve oxygenation (69).  However, the altered pattern of aerated lung 
regions observed in the prone position indicated that the non-aerated regions were simply 
collapsed alveoli and the baby lung is not a distinct healthy aerated region, but rather a 
functional structure, consisting of non-healthy aerated lung units (69). 
The baby lung model explains why the use of low VT ventilation has limited 
effects in reducing ARDS-associated mortality.  VT are delivered to patients based on the 
predicted size of their lungs (ideally based on the patient’s body height (70)).  However, if 
some lung regions are collapsed the aerated regions will receive disproportionately large 
volumes of gas.  This can lead to regional over-stretching and increased stress/strain on 
the baby lung, with subsequent injury and inflammation.  The smaller the baby lung, the 
more potential there is for this to occur.  This is supported by the observation that VT 
reduction may be beneficial even when plateau pressures are within “safe” limits (71). 
To reduce distension of the baby lung, an obvious approach would be to further 
reduce the VT.  The implications for such an approach are not clear, but the use of VT 
lower than 6 ml/kg are generally not advocated as low VT may cause increased atelectasis, 
hypoxaemia, hypercapnia, pulmonary hypertension, decreased cardiac contractility and 
reduced renal perfusion (71).  Some of these deleterious effects could be reduced using 
arteriovenous extracorporeal CO2 removal or extracorporeal membrane oxygenation (72, 
73).  Such approaches are promising for patients with severe respiratory failure (72, 73), 
but are associated with substantial risks, including infection and bleeding (13).  
Alternatively, approaches aimed at modulating the active cellular processes that contribute 
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to VILI may be required in order to develop novel therapies that can be used as adjuncts to 
low VT mechanical ventilation. 
 
1.2.3.2 Atelectrauma 
Aside from volutrauma at high lung volume ventilation, there are other mechanisms via 
which mechanical ventilation can damage the lungs, one of which is atelectrauma at low 
lung volumes (61).  Adjacent alveoli support one another, a phenomenon termed 
interdependence (74).  This helps prevent collapse or atelectasis of lung units. Surfactant, 
produced by type II alveolar epithelial cells, also helps prevent complete collapse of 
alveoli and reduces the surface tension of the epithelial lining fluid, decreasing the force 
needed to inflate the alveoli upon inspiration (74).  In ARDS, surfactant dysfunction partly 
due to pulmonary oedema formation, predisposes lung units to collapse (43).  
Furthermore, mechanical ventilation can cause further surfactant dysfunction (61).  Once 
collapsed, the force (and subsequent pressure) required to open an airway is inversely 
proportional to its diameter, i.e. it is the distal airways that are more likely to collapse (43).  
Injury is thought to occur due to shear stress caused by the repetitive opening and closing 
of these lung units (43). 
 The main approach used to minimise atelectrauma is by applying positive end-
expiratory pressure (PEEP).  Webb and Tierney were the first to show that the use of 
PEEP protected against atelectrauma in mechanically ventilated rats (55).  This was shown 
by decreased development of pulmonary oedema.  Consequently, an “open lung” approach 
has been used where artificially applied PEEP is set 2 cmH2O above the lower inflection 
point on the pressure-volume curve of the lung (43, 67).  The lower inflection point 
indicates the opening pressure at which lung units rapidly open and lung 
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expansion/recruitment begins, which is followed by linear increases in volume with 
increasing pressures until the upper inflection point is reached, where the lung is near 
maximum capacity, defined by the elastic limits of the fibrous structure of the lung (43, 
54, 69).  Beyond the upper inflection point, no further recruitment occurs and larger 
pressures are required in order to further inflate the lungs even with relatively small 
increases in volume, which can cause lung over-distension.  If PEEP is set above the lower 
inflection point, this prevents collapse of lung units and the shear stress that results from 
their re-opening, but the production of a static pressure volume curve for ARDS patients is 
often difficult and the benefits of this approach are unproven (43).  However, a low 
amount of PEEP is given to most mechanically ventilated patients, as it reduces 
intrapulmonary shunt and improves oxygenation (13).  A recent study by the ARDS 
Network (ALVEOLI Trial) focussed on investigating the use of higher PEEP (13 cmH2O) 
vs. lower PEEP (8 cmH2O), using lung-protective VT of 6 ml/kg, as it was thought that 
this would improve oxygenation and attenuate VILI, but failed to show any beneficial 
effects of higher PEEP on duration of unassisted breathing and mortality (75).  It is 
possible that the beneficial effects of low VT ventilation could have masked those from the 
use of higher PEEP, but also highlights importance of low VT ventilation because 
mortality rates were low in this study.  
 Repetitive opening and closing of airways can also cause rupture of the 
epithelial/endothelial barrier (stress failure), which promotes dissemination of the 
intraalveolar milieu into the circulation and allows systemic content to enter the airspaces 
(decompartmentalisation) (23).  This could be attenuated by using lower respiratory rates, 
decreasing the injury caused by cyclical opening and closing of collapsed lung units.  
Hotchkiss et al. compared ventilation of isolated perfused rabbit lungs with a plateau 
pressure of 30 cmH2O and a respiratory rate of 20 breaths/min with ventilation with the 
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same plateau pressure and a respiratory rate of 3 breaths/min (76).  Results showed a 
beneficial effect of the lower respiratory rate, with less oedema formation and fewer 
histological changes.  However, the respiratory rate used was extremely low and 
consequently unphysiological. 
 
1.2.3.3 Mechanotransduction 
Volutrauma results in epithelial and endothelial damage and permeability changes 
manifested as pulmonary oedema (56).  Despite being initiated by mechanical stress, this 
is mediated in part by active cellular processes and not simply due to mechanical trauma. 
Parker et al. showed in isolated perfused rat lungs that the administration of 
gadolinium into the perfusate attenuated microvascular permeability induced by injurious 
ventilation, by non-selective blocking of stretch-activated cation channels (77).  This 
suggested that permeability changes in this model were due to active cellular processes 
dependent on intracellular calcium, as opposed to passive breaks in the 
epithelial/endothelial barrier.  Similarly, apoptosis is an active process, requiring ATP.  
Therefore, tissue damage caused by apoptosis is not simply due to mechanical destruction 
of tissue.  Le et al. showed that VILI increased executioner cysteine-aspartate directed 
protease (caspase)-3 and -7 activities and increased apoptosis in endothelial cells, and in 
type I and type II alveolar epithelial cells and identified p38 mitogen-activated protein 
kinase (MAPK) and xanthine oxidoreductase as mediators (78).  Moreover, inhibition of 
apoptosis prevented increases in W:D weight ratios.  Similarly, Damarla et al. showed that 
high VT ventilation caused increased capillary leakage/pulmonary oedema and this was 
mediated by p38 MAPK and MAPK activated protein kinase 2 (MK2), potentially via 
heat-shock protein 25 (HSP25)-mediated actin cytoskeleton polymerisation (79).  
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Therefore, the injury caused by mechanical ventilation involves active cellular responses, 
a concept termed mechanotransduction. 
A number of molecules associated with the plasma membrane have been suggested 
to sense mechanical stress, including mechanosensitive ion channels, growth factor 
receptors, cell adhesion molecules (integrins, connexins and cadherins) and intracellular 
molecules such as the cytoskeleton and related proteins (77, 80, 81).  Such molecules are 
termed mechanoreceptors.  Once activated, mechanoreceptors can act on downstream 
effectors to generate cellular responses. 
 
1.2.3.4 Biotrauma 
Like ARDS, the development of VILI relies on active processes, which could therefore be 
targeted therapeutically.  One aspect of this is the generation of a pro-inflammatory state, 
referred to as biotrauma (82).  MSOF is the main cause of mortality in ARDS patients, 
mediated by systemic inflammation (22).  Biotrauma could contribute to MSOF, since it 
has been reported that injurious high VT ventilation of i.t. hydrochloric acid-treated rabbits 
induces end-organ apoptosis in the kidneys and small intestine villi, potentially via FasL 
(42), and increased circulating inflammatory mediators induced by high VT ventilation are 
associated with organ dysfunction in ALI patients (83).  It is therefore particularly 
important to understand the mechanisms of inflammatory mediator production during 
VILI.  Indeed, this is an intensely researched area, as reduction of biotrauma by 
modulating the actions of inflammatory mediators could greatly reduce ARDS-associated 
mortality.  However, an understanding of the key mediators, their sources and their 
modulation by other factors is first needed. 
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There is an increasing body of literature supporting the role of various 
inflammatory mediators in VILI.  Clinically, it has been shown that ventilation of patients 
with higher, more traditional VT increases bronchoalveolar lavage and plasma levels of 
pro-inflammatory cytokines such as IL-1, IL-6, IL-8 and TNF (7, 20, 84) and 
inflammation is associated with poor outcome in ARDS patients (18, 83).  Numerous in 
vivo and ex vivo studies have also demonstrated the up regulation and involvement of pro-
inflammatory mediators in systemic and alveolar compartments during injurious 
mechanical ventilation including: TNF, IL-1, IL-6, MIP-2, KC, MCP-1, IFN-, platelet-
activating factor (PAF) and thromboxane B2 (57, 85-92).  However, the precise source of 
mediators is unclear. 
It has been suggested that lung injury can induce systemic dissemination of 
intraalveolar mediators, or vice versa (with leakage of circulating mediators into the 
alveoli), via decompartmentalisation due to alveolar barrier dysfunction by either stress 
failure or mechanotransduction (22-24).   However, in many studies the sources of soluble 
mediators are not clear.  For example, clinical studies that show increased plasma levels of 
cytokines during high VT ventilation cannot differentiate between production by the lungs, 
either in the pulmonary circulation or alveolar space, or by other systemic organs (7, 20, 
84).  Moreover, in the laboratory setting using isolated perfused mouse lungs, 
hyperventilation increased perfusate levels of TNF, IL-6, MIP-2, MCP-1, MIP-1 and 
prostacyclin, but in these studies the precise cellular source of mediators e.g. intraalveolar 
parenchyma/leukocytes vs. intravascular parenchyma/leukocytes was not specifically 
investigated (87, 91).  Haitsma et al. showed in rats that in response to pulmonary or 
systemic LPS in vivo, TNF was produced in the alveolar and vascular compartments 
respectively (93).  Following high VT without PEEP, TNF levels were also increased in 
the untreated compartment.  However, the mechanical ventilation strategy was extremely 
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short and severe, which could have resulted in translocation of LPS into the untreated 
compartment, as previously demonstrated (59), where it could induce TNF production.  
This study therefore cannot conclude that passive leakage of TNF from one compartment 
to the other occurs during clinical ALI. 
Another aspect of VILI is the generation of a pro-coagulant state within the lungs 
similar to ARDS, thought to be influenced by the inflammatory response, namely by TNF 
(94).  Here, mechanical ventilation can up regulate pulmonary levels of PAI-1 and tissue 
factor, producing decreased fibrinolytic activity and subsequent increased fibrin 
deposition. 
 
1.2.3.4.1 Mechanisms of biotrauma 
Mechanotransduction could produce biotrauma through abnormal stretch of many cell 
types including alveolar epithelial cells, pulmonary microvascular endothelial cells and 
alveolar macrophages, caused by over-distension of the lung.  A number of mainly in vitro 
cell-based studies therefore investigated various pulmonary cells as sources of 
inflammatory mediators in VILI. 
The lung parenchyma has been the focus of some studies.  Cyclic stretch of human 
pulmonary microvascular endothelial cells, foetal rat lung cells and A549 cells (a human 
adenocarcinoma (type II alveolar epithelial) cell line) in vitro results in production of IL-8, 
macrophage inflammatory protein-2 (MIP-2, the murine functional homologue of human 
IL-8, important in neutrophil recruitment), IL-6 and monocyte chemoattractant protein-1 
(MCP-1), suggesting these cells play a role in inflammation and recruitment of leukocytes 
to the lung in VILI (95-98).  Production of inflammatory mediators by the pulmonary 
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endothelium also suggests that lung stretch can induce inflammation in the circulation 
without the need for decompartmentalisation of the intraalveolar inflammatory milieu. 
Other studies have investigated pulmonary leukocytes.  It has been reported that in 
vitro stretch of alveolar macrophages induced IL-8 and nitrite production (98, 99).  LPS 
and cellular stretch had a synergistic effect on IL-6 and TNF production (98), suggesting 
that inflammation and mechanical stretch could synergise to propagate inflammation.  
Macrophage activation in VILI has also been studied in vivo.  Imanaka et al. showed that 
CD11b and ICAM-1 expression was increased on alveolar macrophages recovered from 
rats subjected to injurious ventilation (100) and Frank et al. showed in an in vivo rat model 
of VILI that alveolar macrophage depletion attenuated pulmonary oedema and 
epithelial/endothelial permeability increases and neutrophil recruitment (99).  These 
studies indicate an important role for alveolar macrophages in the promotion of 
inflammation in response to stretch. 
Neutrophilic alveolitis is a hallmark of ARDS and VILI is thought to be at least 
partly neutrophil-dependent (40).  Choudhury et al. showed that margination of 
neutrophils to the lung vasculature is a relatively early event in the progression of VILI 
and can occur after 1 h of injurious mechanical ventilation, mediated by changes in 
neutrophil deformability and endothelial interactions with neutrophil L-selectin (101).  
Furthermore, neutrophil depletion attenuates VILI (44), and the neutrophil 
chemoattractants, KC and MIP-2 and their receptor (CXCR2) are up regulated and play a 
critical role in the development of VILI (102). 
Neutrophils are not the only circulating leukocyte population that can be 
recruited/marginate to the lungs during VILI.  Recent evidence suggests that lung-
marginated monocytes are important in VILI and may have been previously overlooked in 
the past, partly due to phenotypic characteristics shared with neutrophils, but also due to 
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the ease of studying neutrophils, which readily appear in the bronchoalveolar lavage.  In 
both humans and mice, there are at least two phenotypically and functionally distinct 
subpopulations of monocytes (103).  Phenotypically, these subpopulations are separated 
by their expression of Gr-1 in mice and CD14 and 16 in humans.  Functionally, monocytes 
that express high levels of Gr-1 (Gr-1
high
 monocytes) are thought to be a short-lived more 
inflammatory subset, actively involved in the inflammatory response, whereas monocytes 
that express lower levels of Gr-1 (Gr-1
low
 monocytes), termed the tissue resident subset, 
are thought to migrate to non-inflamed tissue.  Wilson et al. showed that high VT 
ventilation produced lung-margination of monocytes as well as neutrophils (104).  This 
study demonstrated that Gr-1
high
 monocytes marginate to the lungs following injurious 
ventilation and are involved in injury development.  Enhancing margination in a two-hit 
model where mice received LPS 2 h prior to low or high VT ventilation exacerbated 
pulmonary oedema induced by high VT ventilation and monocyte depletion attenuated 
this.  Therefore, Gr-1
high
 monocytes are involved in the development of pulmonary 
oedema during VILI. 
 
1.2.3.4.2 Novel insights into biotrauma 
Given the limitations of protective ventilation strategies and the large inflammatory 
component of VILI, recent studies have focussed on elucidating the mechanisms of 
biotrauma.  However, these studies are numerous, investigating a wide variety of 
mediators and only a few will be discussed.  For example, some studies have focussed on 
individual cytokines including IL-1 and IL-10 to determine whether they may be useful 
targets/therapies.  Frank et al. investigated the involvement of IL-1 signalling in VILI, by 
using IL-1 receptor antagonism in rats and IL-1 receptor knock-out (KO) mice (105).  
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Inhibition of IL-1 signalling reduced injury and BALF neutrophil counts following high 
VT ventilation.  This study gives further evidence that pro-inflammatory cytokines such as 
IL-1 are central to injury induced by high VT.  However, IL-1 antagonism in ARDS has 
largely been unsuccessful (37).  Similarly, Hoegl et al. investigated the therapeutic effect 
of IL-10 in an in vivo rat model of VILI (106).  They found that lung injury, inflammation 
and mortality were reduced by pre-treatment with inhaled aerosolised IL-10, suggesting 
therapeutic potential. 
In addition to studying the roles of traditional soluble inflammatory mediators in 
VILI, various studies have implicated the involvement of a wide degree of potentially 
important molecules, including reactive oxygen species (ROS) (107), adenosine receptors 
(108, 109), lipid derived mediators (110), and angiotensin converting enzyme (ACE) (111, 
112).  All of these studies show interesting insights into biotrauma, but their usefulness 
may ultimately dependent on consolidation of their findings by identification of common 
pathways. 
One mediator that has been consistently implicated in VILI in clinical and 
experiment studies, including those listed above, is TNF (20, 57, 86-92, 107-109, 111, 
113, 114).  TNF is an early response cytokine, upstream of many implicated mediators 
such as IL-1β, IL-10, ROS and various lipid mediators (115-118).  Thus, TNF signalling 
may represent an important common pathway.  Its roles will now be discussed in more 
detail. 
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1.3 Tumour Necrosis Factor Alpha 
1.3.1 Overview 
The pro-inflammatory cytokine tumour necrosis factor alpha (TNF, cachectin) was first 
identified in 1975, by its ability to cause the necrosis of tumours in a similar manner to 
LPS (119).  TNF has since been identified as a central mediator in a number of 
physiological and pathophysiological processes, but will primarily be considered here with 
respect to ALI. 
The TNF ligand superfamily comprises of approximately 20 similar proteins 
including: TNF, TNFβ (lymphotoxin-), receptor activator of NF-κB ligand (RANKL) 
and TNF-related apoptosis-inducing ligand (TRAIL) (120).  TNF is expressed as two 
forms, a membrane-bound 26 kDa type II transmembrane protein (cell-surface TNF), and 
a 17.5 kDa soluble form (sTNF), produced by cleavage of cell-surface TNF mainly by 
tumour necrosis factor alpha converting enzyme (TACE, ADAM17), but also by 
proteinase-3 (120-123).  It was previously thought that cell-surface TNF was simply a 
precursor molecule, acting as a reservoir for sTNF.  However, cell-surface TNF is also 
bioactive and can elicit biological responses independently of sTNF (124-127).  Both 
forms of TNF are thought to form non-covalently linked homotrimers that constitute the 
bioactive forms (120, 128). 
 
1.3.2 General sources and roles 
TNF is mainly produced by leukocytes such as monocytes, macrophages, neutrophils, 
lymphocytes, but also by non-leukocytes including fibroblasts and endothelial cells (120, 
128).  TNF release can be inhibited by cytokines such as IL-4 and IL-10 and by 
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glucocorticoids (129, 130).  IL-10 inhibition of TNF represents a negative feedback loop, 
since its production is stimulated by TNF (118). 
 TNF biology is a prime example of pleiotropism.  TNF mediates many biological 
responses that often seem conflicting.  Its first identifiable role was inducing cell death in 
tumour cells.  Indeed, this is one of the chief functions of TNF; it can induce both necrosis 
and apoptosis, but is also involved in cellular proliferation and differentiation (120).  TNF 
is considered a major early-acting pro-inflammatory cytokine, initiating the inflammatory 
cytokine cascade by inducing up regulation of pro- and anti-inflammatory cytokines such 
as IL-1, IL-6 and IL-10, chemokines such as IL-8 and MCP-1, and adhesion molecules 
such as ICAM-1, VCAM-1 and E-selectin, playing a pivotal role in regulating the immune 
response (115, 118, 128, 131).  TNF is also involved in bacterial killing, viral replication 
and tumourigenesis (120). 
TNF is associated with many pathophysiological processes.  Increased levels are 
produced during septic shock/sepsis and lower, more sustained levels are responsible for 
cachexia seen in cancer patients (128).  TNF is involved diseases such as type II diabetes 
mellitus, meningitis, chronic heart failure and multiple sclerosis (120).  TNF is particularly 
important in mediating autoimmune diseases such as Crohn’s disease, ulcerative colitis, 
ankylosing spondylitis and rheumatoid arthritis, where anti-TNF therapies have produced 
significant clinical improvements (132, 133). 
 
1.3.3 TNF in ARDS/VILI. 
Many studies have investigated TNF in ALI and have reported changes in its levels in 
ARDS/VILI.  However, its precise role is contentious.  Armstrong et al. reported that 
compared to at risk patients, ARDS patients exhibited increased TNF levels in lung 
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epithelial lining fluid, but with only a trend for increased TNF bioactivity, and a trend for 
increased BALF levels (134, 135). Plasma TNF levels were not increased. Similarly, 
Pugin et al. showed that bioactive TNF was up regulated in oedema fluid from ARDS 
patients, but not in plasma (14).  Parsons et al. reported that there was no association 
between plasma TNF levels and the development of ARDS or patient outcome (21, 136).  
However, Meduri et al. showed that sustained high BALF levels of TNF (and other pro-
inflammatory cytokines) were associated with poor patient outcome and BALF levels 
were mirrored in plasma (18).  Moreover, ARDS patients ventilated with higher more 
deleterious tidal volumes (VT) (11 ml/kg) showed increased BALF and plasma levels of 
TNF with higher mortality, compared to patients ventilated with lower VT (8 ml/kg) (20), 
and alveolar macrophages from ARDS patients express higher levels of bioactive cell-
surface TNF with a trend for increased sTNF production (134, 135). 
TNF has been implicated in many experimental models of VILI (57, 86-92, 107-
109, 111, 113).  However, there is still some controversy surrounding it roles.  Verbrugge 
et al. reported that high pressure ventilation of surfactant-depleted rats, achieved by saline 
lung lavage, did not up regulate BALF or serum TNF (137).  Similarly, Ricard et al. 
showed that high VT ventilation in rats or isolated rat lungs did not up regulate BALF TNF 
(138).  Yoshikawa et al. showed that TNF was not elevated in BALF from mice ventilated 
with high pressures and TNFR deficiency did not alter injury progression (139), but TNF 
was released into the perfusate from mouse isolated perfused lungs ventilated with high 
pressures, consistent with other reports (87, 91).  Conversely, it has been shown that high 
VT ventilation increases BALF levels of TNF in non-perfused isolated rat lungs (57, 90) 
and Takata et al., showed that traditional ventilation of surfactant-depleted rabbits, 
induced increases in lavage cell TNF mRNA compared to lung-protective high frequency 
oscillation ventilation (86).  Using a similar model, Imai et al. showed that TNF was 
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increased in BALF following conventional ventilation and i.t. treatment with an anti-TNF 
antibody increased PaO2, respiratory system compliance, and reduced neutrophil 
infiltration into the lung airspaces and lung injury scores (92). 
Some of these inconsistencies were clarified by Wilson et al., using a model of 
pure VILI without pre-existing injury/inflammation (88).  They showed that TNF was up 
regulated in the alveolar space early during the progression of VILI, but was later 
undetectable, suggesting its transient nature may account for disparity in the literature 
regarding its expression in VILI (88).  TNF bioactivity was present at later time points.  
This group later showed that TNF was involved in the pathophysiology of VILI, using a 
similar one-hit mouse model of VILI in conjunction with mice deficient in both TNFR 
subtypes and wild-type (WT) mice treated i.t. with an anti-TNF antibody (89).  Antibody 
treated and TNFR deficient mice showed a significant attenuation in neutrophil infiltration 
to the alveoli induced by injurious ventilation, whereas i.v. anti-TNF antibody treatment 
had no effect, implicating intraalveolar TNF signalling in VILI. 
Endothelial barrier dysfunction, leading to pulmonary oedema formation is an 
important feature of ARDS and VILI.  In vitro studies have suggested that TNF may play 
an important role in this, since TNF induces vascular barrier dysfunction (140, 141). 
These studies, coupled with TNF’s known inflammatory roles would suggest that 
blockade of TNF would produce substantial clinical benefits in ARDS/VILI, as in 
inflammatory bowel disease, ankylosing spondylitis and rheumatoid arthritis.  However, 
this has not been the case (38, 39), and experimentally there is disparity in the 
effectiveness of such approaches (89, 92, 114).  Success in attenuating deleterious effects 
of TNF in ALI may thus lie in understanding the complexity of TNF signalling through its 
cell-surface receptors. 
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1.4 Cell-surface Tumour Necrosis Factor Alpha Receptors 
1.4.1 Overview 
The TNFR superfamily consists of at least 41 cell-surface proteins including: CD27, 
CD30, CD40, OX40, receptor activator of NF-κB (RANK), FAS receptor, nerve growth 
factor receptor (NGFR), tumour necrosis factor-like apoptosis inducing ligand (TRAIL) 
receptors and death receptors (DR) (116, 121).  TNF exerts the vast majority of its effects 
through just two superfamily members: the 55 kDa glycoprotein TNF receptor 1 (TNFR 
p55, CD120a, TNFRSF1A) and the 75 kDa glycoprotein TNF receptor 2 (TNFR p75, 
CD120b, TNFRSF1B) (116).  Both receptors can also be activated by lymphotoxin-. 
 
1.4.2 Structure 
TNFR p55 and p75 share a number of structural similarities.  Firstly, like all members of 
the TNF receptor superfamily they are type I transmembrane proteins (121).  Secondly, 
both receptors can each be divided into extracellular, transmembrane and cytoplasmic 
portions (121).  Thirdly, all TNFR superfamily members have multiple cysteine-rich 
domains in their extracellular portions, involved in oligomerisation and ligand binding 
(121, 142).  Both TNFR p55 and p75 have four of these domains each in their 
extracellular portions in which they share most of their homology (28% overall) (116).  
Fourthly, cell-surface TNFRs are expressed as pre-existing oligomers that form 
independently of ligand binding (142, 143).  Fifthly, both TNFRs also exist as cognate 
soluble forms produced by proteolytic cleavage of their extracellular portions (see 
“Soluble Tumour Necrosis Factor Alpha Receptors” section, below). 
Differences in the structures of TNFR p55 and p75 allow each receptor to act 
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uniquely.  For example, due to differences in homology between their extracellular 
portions, their affinity and avidity for TNF are quite different, as is the efficacy of TNF 
activation.  Moreover, the amino acid sequences of the intracellular domains of p55 and 
p75 show almost no homology (144).  TNFR p55 is a death receptor, containing death 
domain (DD) that recruits specific signalling complexes, whereas TNFR p75 does not 
possess a DD and associates directly with TNF receptor associated factors (TRAFs), in 
order to produce the majority of its cellular effects (116).  These differences led to the 
early assumption that the two subtypes could act independently via different pathways 
(144). 
 
1.4.3 Cell-surface TNFR p55 
1.4.3.1 Expression 
TNFR p55 is thought to be constitutively expressed at low levels on all nucleated cells 
(128).  TNFR p55 expression has been reported on B- and T-lymphocytes (144-146), 
neutrophils (147), macrophages (148, 149) monocytes (146, 150-153), endothelial cells 
(154, 155) and epithelial cells (124). 
TNFR p55 can be shed from the surface of cells (129, 130, 147, 153, 156) by 
membrane-bound metalloproteases (sheddases) such as TACE (147, 157), but can also be 
internalised upon ligation for induction of signalling pathways and potentially inhibiting 
its long-term actions (156, 158, 159).  TNFR p55 expression can also be up regulated 
under certain conditions (148, 150, 160, 161), but not as readily as TNFR p75. 
Though expressed on the cell surface there is evidence to support a large degree of 
localisation of TNFR p55 to the Golgi (162-164).  These intracellular TNFR receptors 
could act as a reservoir for release into the extracellular environment (165, 166). 
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There is limited literature specifically describing TNFR expression in lung tissue.  
It has been reported that A549 type II pulmonary epithelial cells express TNFR p55 only 
(161), but this is contentious (167), and whole human lung tissue expresses both p55 and 
p75 mRNA (161).  Human small airway epithelial cells express TNFR p55 (166) and 
MLE-Kd cells and primary rat pulmonary epithelial cells express both TNFR p55 and p75 
cell-surface receptors (124).  Conversely, in human and rat lung tissue sections, Ermert et 
al. reported that TNFR p55 was not expressed on the alveolar septum (168).  Ermert et al. 
also found that TNFR p75 was expressed on nearly all cell types studied including, 
alveolar epithelial cells, with stronger signals than for p55, inconsistent with Liu et al. 
(124).  Ermert et al. reported expression of both TNFR p55 and p75 on pulmonary 
endothelial cells, consistent with Grau et al. (169).  However, Ermert et al. employed 
immunohistochemistry, as opposed to flow cytometry used by Liu et al. and Grau et al., 
and with such qualitative/semi-quantitative measurements, it is hard to determine the 
relative expression of each receptor subtype.  Furthermore, validation of specific staining 
with TNFR KO tissue was not employed in any of these studies.  Thus, the precise 
expression of TNFRs in the lung is unclear and needs further investigation using 
appropriate techniques.  Consequently, this will be investigated in this project. 
 
1.4.3.2 TNFR p55-associated signalling 
TNFR p55 appears to be the main mediator of TNF signalling and produces many diverse 
effects (128).  It is activated equally well by both cell-surface TNF and sTNF (116).  Due 
to differences in their intracellular domains, activation of TNFR p55 and p75 recruit 
different signalling complexes that trigger different intracellular signalling pathways, but 
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with significant overlap in both the intermediates involved and in overall biological 
function (Figure 1.1). 
 
Figure 1.1.  Simplified schematic of major TNFR signalling pathways.  Both TNFR p55 and p75 are 
capable of activating distinct signalling pathways.  However, it is clear from the above schematic that this is 
occurs with significant overlap.  Despite this, TNFR subtype-specific pathways do exist (116, 159, 170-177). 
 
TNFR p55 is a death receptor, possessing a DD of ~70-80 amino acids, which 
interacts with a number of other proteins to cause apoptosis and NF-B activation (170).  
There are at least two models regarding TNFR p55 activation.  In one model, TNFR p55-
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mediated cell death is thought to occur via two signalling complexes (171).  Upon 
activation, membrane bound TNFR p55 recruits TNFR1-associated death domain 
(TRADD), TRAF2 and receptor interacting protein (RIP), forming Complex I, required 
for NF-B activation, which promotes cell survival (171, 172).  Extracellular signal-
related kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK are also activated 
by TNFR p55 (176, 177) and TRAF2 and RIP are required for activation (173).  
Following initial recruitment and possible anti-apoptotic pathway activation, TNFR p55 is 
internalised and Complex I dissociates from p55 and recruits fas-associated death domain 
(FADD) and caspase-8 and -10, forming Complex II that triggers apoptosis (171).  In a 
second model, TNFR p55 is internalised into a receptosome and associates with TRADD, 
FADD and caspase-8 to trigger apoptosis (159).  Lack of TNFR p55 internalisation biases 
TNF signalling through NF-B and cell survival, rather than cell death. 
It is well established that TNF stimulation up regulates intracellular ROS 
production, mainly from the mitochondria, that can cause damage to DNA and cellular 
proteins and lipids (117).  There is a large amount of evidence to support the role of ROS 
as second messengers in TNF-mediated cell death, but their role is complex.  ROS may 
promote cell survival as well as cell death, given that ROS also mediate TNFR p55-
induced transcription via NF-B and JNK/activator protein-1 (AP-1), but this is 
controversial (117, 178).  It has recently been shown that TNFR p55 can recruit riboflavin 
kinase (RFK) via TRADD that activates NADPH oxidase (NOX), to generate ROS and 
cause cell death (179).  Thus, TNF-induced ROS production seems mainly cytotoxic. 
The balance between pro- and anti-apoptotic signalling is vital for efficient TNFR 
p55-mediated cytotoxicity.  TNFR p55-mediated death often requires inhibition of NF-B 
(171), demonstrating that although a death receptor in the classical sense, TNFR p55 
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activation can have other effects, including proliferation of natural killer cells and 
generation of lymphocyte activated killer cells (180). 
TNFR p55 also binds other signalling molecules to sites on its cytoplasmic tail 
distinct from the DD that can result in a variety of effects including brain and reproductive 
organ-expressed (TNFRSF1A modulator) (BRE) that inhibits receptor signalling (116) 
and factor associated with neutral sphingomyelinase activation (FAN) that produces the 
signalling intermediate ceramide that can activate the MAPKs and NF-B (116).  Thus, 
even without its DD interactions TNFR p55 can activate a wide variety of cellular 
signalling machinery, contributing to its numerous and complex roles. 
 
1.4.3.3 Roles of TNFR p55 
In addition to its important role in TNF-mediated cytotoxicity (125, 181), TNFR p55 is a 
major pro-inflammatory receptor/immune modulator.  This is exemplified in TNFR1-
associated periodic syndrome (TRAPS) where mutation of TNFR p55 leads to impaired 
TNFR p55 shedding causing decreased sTNFR p55 levels and increased cell-surface p55 
expression (170).  This results in periodic fever and severe localised inflammation. 
TNFR p55 is involved in the recruitment of inflammatory leukocytes, mediating 
production of IL-6, IL-8, MIP-2, KC, MCP-1 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) and up regulation of MHC Class I and II (125, 131, 180, 
182, 183).  Following chemotaxis of inflammatory cells, TNFR p55 is involved in 
endothelial-leukocyte interactions such as leukocyte rolling and firm adhesion to the 
endothelium and transmigration of cells from the vasculature, via increased ICAM-1, 
VCAM-1, E-selectin and P-selectin adhesion molecule expression that promotes the 
inflammatory response (131, 155, 184, 185).  TNFR p55 also mediates oxidative burst in 
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neutrophils (147) and is critically involved in cell-surface TNF-mediated arthritis (126).  
TNF-mediated immune responses to certain bacterial infections are severely 
compromised in TNFR p55 deficient mice, causing death with an otherwise sublethal 
infection of Listeria monocytogenes (186).  This is also true in Legionella pneumophila 
infection, where TNFR p55 mediates a protective response in concert with p75 (187).  
Conversely, the absence of p55 is protective against an otherwise lethal dose of LPS 
(186), showing that depending on the context i.e. whether there is an active infection, p55-
mediated inflammation can be both deleterious and protective. 
 
1.4.4 Cell-surface TNFR p75 
1.4.4.1 Expression 
Expression of TNFR p75 was historically thought to be more highly conserved than p55, 
being predominantly expressed on cells of the immune system, but like TNFR p55, it is 
expressed on a variety of cells (128).  TNFR p75 has been reported to be expressed on B- 
and T-lymphocytes (145, 146, 174), neutrophils (147), macrophages (148-150), 
monocytes (146, 150-153), epithelial cells (124) and endothelial cells (154, 155). 
Like TNFR p55, TNFR p75 surface expression can be down regulated to some 
degree by internalisation (156, 158, 162), but it is more liable to shedding than TNFR p55 
(130, 150, 156, 158, 183), via metalloproteases such as TACE, but also by elastase, a 
serine protease (157, 188).  TNFR p75 shedding is mediated in part by TNFR p55 (158, 
183).  Expression of the TNFRs subtypes seems to be differentially regulated.  Expression 
of p75 seems more readily inducible than p55, but the reason for this is unknown (15, 144, 
150, 183, 189).  This complicates investigating its levels, but could also suggest an 
important function of this receptor. 
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1.4.4.2 TNFR p75-associated signalling 
Soluble TNF associates 20 times more rapidly with TNFR p75 than p55 (181), but 
dissociates 20-30 times faster from p75 than p55 (116).  Furthermore, sTNF does not 
effectively activate TNFR p75 signalling, but increases the association of sTNF to TNFR 
p55 ~10 times (125, 181).  Consequently, it was thought that p75 binds and then 
immediately dissociates from TNF in close proximity to p55, resulting in ligand passing of 
TNF to p55 and promoting p55 activation, especially when TNFR p75 and sTNF levels 
are low (181).  However, there is growing evidence that TNFR p75 can modulate TNFR 
p55 signalling pathways and even activate signalling pathways of its own (116).  
Furthermore, it has been shown that cell-surface TNF, not sTNF, activates TNFR p75 
effectively (125), which could account for the apparent dominance of p55 signalling 
reported in vitro, and suggests that the role of p75 may have previously been 
underestimated (116). 
Unlike TNFR p55, TNFR p75 does not possess a death domain, and mediates 
many of its cellular effects via TRAF adaptor proteins, 6 of which have been identified in 
mammals (116).  TRAF2 is mainly thought to be the only TRAF to interact directly with 
TNFR p75, but it can also indirectly associate with TNFR p55 via TRADD (120).  TRAF2 
is a key TNFR adaptor protein, allowing recruitment of many factors to TNFR p75 that 
would otherwise only associate with TNFR p55.  For example, RIP and FADD are able to 
associate with TNFR p75 via TRAF2 enabling TNFR p75 to trigger apoptosis as opposed 
to NF-B activation (174).  However, TNFR p75 activation also leads to recruitment of 
cellular inhibitor of apoptosis (cIAP)-1 and -2 (173) and activation of NF-B (by a 
potentially distinct mechanism from p55-mediated NF-B activation) (175) and JNK (176, 
177), allowing transcription of anti-apoptotic and pro-inflammatory genes. 
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There is a seemingly wide degree of overlap between TNFR p55 and p75 
signalling, primarily because TRAF2 can directly associate with p75 in addition to its 
indirect interaction with p55.  Yet, TNFR p75 can activate subtype-specific molecules, 
much like BRE and FAN for TNFR p55.  For example, the endothelial/epithelial tyrosine 
kinase (Etk/Bmx), involved in cell adhesion, migration, proliferation and maintenance of 
epithelial barrier permeability (190), is associated constitutively with and activated by 
TNFR p75, independently of TRAF2 (177).  Thus, TNFR p75 signalling does not 
necessarily require TRAF2-dependent signalling pathways. 
 
1.4.4.3 Roles of TNFR p75 
Both TNFR p75 and p55 are involved in proliferation of natural killer cells and 
lymphocyte activated killer cells (180).  Moreover, TNFR p75 can independently induce 
thymocyte and kidney tubular cell proliferation and GM-CSF production (191, 192).  
Conversely, TNFR p75 can promote cytotoxicity via ligand passing (181), up regulation 
of cell-surface TNF and subsequent autocrine/paracrine activation of TNFR p55 (193), 
and by promotion of caspase activation (174, 194). 
Like TNFR p55, p75 is involved in modulation of the immune/inflammatory 
response.  TNFR p75 promotes expression/production of IL-6, KC, ICAM-1, VCAM-1, 
E-selectin, GM-CSF and MHC Class II, mainly in concert with p55 (125, 131, 180, 183).  
Similarly, endothelial cell TNFR p75 has been reported to be critical for TNF-induced 
VCAM-1 and E-selectin expression and is also critical and sufficient for TNF-induced 
ICAM-1 expression, mediating TNF-induced leukocyte adhesion and migration (184).  It 
has also been shown that TNFR p75 deficiency in mice with cerebral malaria is associated 
with the absence ICAM-1 induction on brain microvessels and protection from brain 
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damage and mortality (15), and that parenchymal cell-expressed TNFR p75 is critically 
involved in the development of glomerulonephritis in mice (195).  TNFR p75 can also 
cooperate with p55 in TNF-induced neutrophil oxidative burst (189), and in cell-surface 
TNF-mediated arthritis (126), and p75 signalling is required for the migration of activated 
Langerhans’ cells from the skin to lymph nodes (196). 
 
1.4.5 Novel aspects of cell-surface TNFR signalling 
1.4.5.1 Differential TNFR signalling 
TNFR p55 and p75 are capable of activating different intracellular signalling pathways, 
but many of their biological effects overlap.  Conversely, it has also been shown that in a 
given physiological scenario, TNFR p55 and p75 have the capacity to act in apparent 
opposition.  There are studies supporting this concept of differential TNFR signalling from 
fields as disparate as ischaemia reperfusion injury, sepsis and heart failure (160, 197-199). 
Ebach et al. investigated the role of TNF in a CLP model of sepsis.  They found 
that TNFR p55 KO mice had prolonged survival and less hypothermia, with the opposite 
effect for TNFR p75 KO mice, suggesting that p75 may play a protective role.  TNFR p75 
KO mice also had increased peritoneal and serum levels of TNF, indicating that this 
receptor is involved in regulation of TNF levels (197).  Similarly, Higuchi et al. showed 
by breeding transgenic mice that over-express cardiac TNF and develop heart failure that 
the absence of TNFR p55 improved survival.  Conversely, the absence of TNFR p75 was 
deleterious, with mice showing reduced survival (198).  Fontaine et al. investigated the 
role of TNFR in a retinal ischemia model, with TNFR KO, and TNF KO mice.  TNF 
deficiency did not affect neurodegeneration, but in TNFR p55 KO mice, this was reduced, 
whereas it was enhanced in TNFR p75 KO mice (160). 
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These studies generally attribute more deleterious roles to p55 and 
protective/beneficial roles to p75, but the mechanisms underlying these differences are not 
well defined.  This phenomenon has also been described in the field of ALI and will be 
discussed separately. 
 
1.4.5.2 Reverse signalling 
A further role for TNFRs has been proposed.  It has been suggested, that cell-surface 
TNFRs are able to transduce a signal through cell-surface TNF.  The roles of ligand and 
receptor are reversed and thus referred to as “reverse signalling” (200).  Eissner et al. 
suggested that cell-surface TNF on monocytes/macrophages, ligated by endothelial TNFR 
p55 (and soluble receptors and anti-TNF antibodies), mediates resistance to LPS, by 
reducing LPS-induced cytotoxicity and inflammatory mediator production (200).  Rossol 
et al. also described reverse signalling through cell-surface TNF on monocytes by TNFR 
p75 on T lymphocytes (and via the TNFR p75-IgG fusion protein etanercept) (201).  In 
this study, TNF production by monocytes was decreased by cell-surface TNF ligation by 
TNFR p75.  This concept, is not actually new to the TNF superfamily, and has been 
described for other members including CD40L and FasL (200).  Despite such studies, the 
physiological role of reverse signalling through cell-surface TNF is not known. 
 
1.5 Soluble Tumour Necrosis Factor Alpha Receptors 
1.5.1 Overview 
In addition to transcriptional/translational control, the expression of cell-surface TNFRs is 
regulated by the action of proteases that cleave the receptor ectodomains.  Shedding by 
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proteases reduces cell surface TNFR expression, but the cleaved receptor fragments retain 
their ability to bind TNF (albeit with lower affinities) and are termed soluble TNFRs 
(sTNFRs) (128).  Soluble TNFRs were first identified in blood and urine due to their 
ability to inhibit TNF-induced cytotoxicity (202-204).  Both cell-surface TNFR p55 and 
p75 are cleaved to produce monomeric 28 kDa and 40-42 kDa soluble fragments, 
respectively (156, 205).  In addition, it has been shown for p55 at least, that uncleaved, 
full-length receptor can be released via exosome-like vesicles, bypassing ectodomain 
cleavage by TACE, to give another form of sTNFR p55 (165, 166).  It has been reported 
under normal conditions that the dominant form of the p55 receptor in human serum, lung 
epithelial lining fluid and HUVEC culture supernatants is uncleaved p55 and these TNFR-
containing vesicles could also act as intracellular stores of TNFR p55 (165).   Conversely, 
stimulation of HUVEC and human small airway epithelial cells with IL-1 induces 
ectodomain shedding of TNFR p55, but without increases in TNFR p55-containing 
exosome-like vesicles (166).  Therefore, vesicle release of TNFR p55 may not account for 
the increased levels of sTNFR p55 seen in disease. 
The physiological sheddase responsible for sTNFR production is under some 
debate, but it is known that at least two proteases, TACE and elastase are involved in cell-
surface TNFR cleavage (157, 188).  TACE can cleave both cell-surface TNFRs, whereas 
elastase can cleave TNFR p75, but not p55, which could account for the apparent 
increased susceptibility of TNFR p75 to be shed (130, 150, 156, 158, 183).  Two cleavage 
sites adjacent to the transmembrane domain have been identified on TNFR p55, between 
asparagine-172 and valine-173 and a minor cleavage site between lysine-174 and glycine-
175 (165, 206).  Cleavage sites on TNFR p75 are less clear.  Several have been suggested 
including between alanine-177 and valine-178 and between amino acids 151 to 153, 162 
to 163, and 177 to 178 (206).  However, removal of these sites has been shown to have no 
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effect on LPS/PMA induced TNFR p75 shedding.  Conversely, point mutation of proline-
211 has been shown to be crucially involved in TNFR p75 shedding suggesting a potential 
cleavage site (206). 
 
1.5.2 Expression 
Soluble TNF receptor release can be induced by various mediators including: TNF, IL-1, 
IL-1β, IL-2, IL-6, IL-10, TGF-β, IFN-β, IFN-γ, GM-CSF, C5a, PMA and LPS (21, 129, 
146, 147, 150, 151, 153, 156, 161, 166, 180, 205-208) and be inhibited by IL-4, PKC 
inhibition and glucocorticoids (129, 130, 150, 209), but it has also been shown that 
TNFRs are constitutively shed in vivo and in vitro (21, 129, 130, 146, 156, 161, 205), and 
hence sTNFRs are present in many biological fluids under baseline conditions, with 
sTNFR p55 produced mainly by parenchymal cells and sTNFR p75 by leukocytes (180, 
210).  The primary interest in this thesis is expression in fluids related to the lung, i.e. lung 
lavage fluid and blood levels.  Generally, sTNFR p75 is expressed at higher levels than 
TNFR p55, but there appears to be substantial variability. 
In humans, normal baseline sTNFR levels in BALF have been reported over a 
wide range, from ~60 pg/ml to ~230 pg/ml for sTNFR p55 and ~30 pg/ml to ~330 pg/ml 
for sTNFR p75 (19, 211, 212).  Plasma/serum baseline levels are also varied, with reports 
for sTNFR p55 ranging from 400 pg/ml to 2,200 pg/ml and for sTNFR p75 from 800 
pg/ml to 4,800 pg/ml (21, 180, 213-216). 
In mice, normal baseline BALF sTNFR levels are reported as being ~40 pg/ml to 
~90 pg/ml for sTNFR p55 and ~300 pg/ml for sTNFR p75 (113).  In serum, values are 
~100 pg/ml for sTNFR p55 and range from ~1,000 pg/ml to ~5,500 pg/ml for sTNFR p75 
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(205, 217).  The dominant route of clearance for both sTNFRs, is thought to be by the 
kidney (218). 
Soluble TNF receptors have also been implicated in a wide variety of disease 
states.  BALF sTNFR levels are elevated in patients with sarcoidosis (211, 212), as well as 
patients with ALI, discussed below.  Increased plasma levels are associated with, 
sepsis/endotoxaemia (213, 219, 220), inflammatory bowel disease (Crohn’s disease and 
ulcerative colitis) (214) rheumatoid arthritis (215), cancer (216) and systemic lupus 
erythematosus (180).  However, the biological significance of these increases is not fully 
understood. 
 
1.5.3 Possible roles 
Though not able to transduce signals from TNF, sTNFRs could still have important 
biological functions.  From their initial identification, sTNFRs were originally thought to 
have one role - neutralising TNF as decoy receptors and thus limiting TNF responses.  
Indeed, there is a great deal of evidence for this (19, 127, 167, 202-205, 213, 215, 216, 
221, 222).  This concept is also supported by the use of sTNFR-based therapies.  Edwards 
et al. showed that in transgenic mice that over express cell-surface TNF, but lack sTNF, an 
aggressive inflammatory response leading to arthritis occurs (127).  This was attenuated 
by treatment with p55-PEG (sTNFR p55 linked to polyethylene glycol) and etanercept (a 
fusion protein consisting of dimeric sTNFR p75 linked to the Fc binding portion of IgG1).  
Similarly, etanercept has been used with success in rheumatoid arthritis as an anti-TNF 
drug (132). 
A number of other roles have also been proposed.  Aderka et al. reported a 
potential role in perpetuating TNF bioactivity, as both sTNFRs enhanced TNF-mediated 
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cell growth at low concentrations (223).  This study found that TNF formed aggregates 
with sTNFRs, which dissociated over time to yield bioactive sTNF and concluded that 
sTNFRs stabilise bioactive TNF, which would otherwise dissociated into inactive 
monomers, acting as a reservoir that can be slowly released, prolonging the half-life of 
TNF (223).  The same group has since reported in isolated perfused limbs in cancer 
patients that sTNFRs potentially prolong the half-life of sTNF in the circulation (224). 
It has been suggested that like cell-surface TNFRs, sTNFRs can act as ligands via 
reverse signalling.  Eissner et al. described the ability of sTNFR IgG constructs to inhibit 
cytotoxic factor production induced by LPS (200) and Rossol et al. reported etanercept-
induced TNF production from monocytes (201).  Similarly, Waetzig et al. reported that 
sTNFR p55 can trigger apoptosis in primary human monocytes and THP-1 cells (225). 
The specific role of sTNFRs in a given biological context may be linked to their 
levels relative to TNF.  When levels are much higher than TNF, they could be 
antagonistic, which may prevent aberrant TNF signalling, but also be deleterious since a 
total blockade of TNF is undesirable as it may have protective functions (180, 224).  At 
moderate levels sTNFRs may serve as buffers by inhibiting the effects of high 
concentrations of TNF, but also facilitating TNF signalling in a controlled manner (180).  
These theories however, remain to be fully elucidated.  Logically, at least in the short 
term, TNF increased during an inflammatory response, when bound to sTNFRs would not 
be able to activate cell-surface receptors, potentially giving more credence to an anti-
inflammatory role. 
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1.6 TNF Receptor Subtypes in Acute Lung Injury 
Both cell-surface TNFRs and sTNFRs have been implicated in ALI in both clinical and 
laboratory settings, either by associated changes in expression or by the use of anti-TNFR 
interventions/genetic knock-outs. 
 
1.6.1 Cell-surface TNFRs in ALI 
In addition to studies implicating the TNF ligand, cell-surface TNFRs have been 
implicated in clinical ARDS.  It has been shown that TNFR p75, but not p55 is up 
regulated on cultured pulmonary microvascular endothelial cells from ARDS patients 
(169).  These cells exhibited increased production of IL-6 and -8 upon TNF stimulation, 
implicating TNFR p75 as a mediator.  Endothelial cells also exhibited increased ICAM-1 
expression at baseline and upon stimulation with TNF, implicating the involvement of 
TNFR p75 (169).  Liu et al. showed that TNFR p75 is involved the development of lung 
injury induced by T lymphocyte-mediated pulmonary viral clearance (124).  A recent 
study showed that in mice infected with Pneumocystis carinii, parenchymal-expressed 
TNFRs were largely responsible for the pathophysiology of lung injury (210).  However, 
the authors did not investigate the specific involvement of each receptor subtype. 
Other studies have focussed on the role of TNFR p55.  Mizgerd et al. showed that 
mice lacking both TNFR p55 and IL-1 receptor 1 (IL1R1) had significantly less oedema 
formation, BALF KC levels and neutrophil infiltration compared to WT mice in response 
to i.t. E. coli treatment (52).  In mice lacking IL1R1 only, there was no decrease in 
neutrophil infiltration, suggesting an important role for p55 in neutrophil infiltration to the 
alveolar space in this model (52).  This is in opposition to a previous study by this group 
that showed negligible involvement of TNFR signalling in pulmonary inflammation using 
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mice deficient for both TNFRs (226), which may have been due to neglect of differential 
TNFR subtype signalling.  Neumann et al. showed that WT mice subjected to i.p. TNF 
challenge produced VCAM-1 and E-selectin up regulation and leukocyte recruitment in 
the lungs (227).  This was significantly attenuated in p55 KO mice.  Xu et al. showed that 
alveolar TNFR p55 mediated lung injury in mice, induced by adoptive transfer of T 
lymphocytes activated by intraalveolar viral antigens (182).  These studies demonstrate the 
predominantly inflammatory nature of TNFR p55 signalling in ALI. 
Some studies have attempted to investigate the role of both TNFR subtypes in 
ALI.  Ferrero et al. showed that TNFR p55 (and p75 to a small extent) was responsible for 
cytoskeletal rearrangement in endothelial monolayers associated with increased 
permeability, mediated via p38 MAPK (228).  This suggests that p55 promotes endothelial 
barrier dysfunction and the formation of pulmonary oedema in ALI. Calkins et al. 
investigated the effect of the individual TNFRs on pulmonary chemokine levels and 
neutrophil accumulation in response to i.p. LPS (229).  They found that TNFR p55, but 
not p75, was responsible for increased levels of MIP-2 and KC and neutrophil 
accumulation in response to i.p. LPS, again showing the dominance of TNFR p55, with no 
apparent role for TNFR p75.  However, Wilson et al. showed that TNFR p75 and TNFR 
p55 play important roles in pulmonary oedema formation in response to injurious high VT 
ventilation (113).   This study used TNFR p55 and p75 receptor single KO mice as well as 
mice deficient for both receptors (TNFR double KOs, DKOs).  It was found that WT mice 
ventilated with high VT developed substantial pulmonary oedema after 2 h, compared to 
WT mice ventilated with low VT.  This pattern was similar for DKO mice.  TNFR p75 KO 
mice displayed an accelerated oedema development with many mice not surviving to 2 h.  
Conversely, TNFR p55 KO mice exhibited protection from oedema formation, with all 
mice surviving the protocol.  The differences between the single TNFR KO mice and 
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similarities between WT mice and TNFR DKO mice suggest that TNFR p55 and p75 play 
opposing roles in the development of pulmonary oedema formation in response to high VT 
ventilation (113). 
This was the first time differential TNFR signalling was reported in ALI.  
Importantly, this could potentially help explain the lack of success of anti-TNF therapies 
in ALI, as inhibition of both protective and deleterious effects could occur with a complete 
TNF blockade.  Despite these novel findings, the mechanisms underlying differential 
TNFR signalling have not been elucidated.  Further investigation is required in order to 
support this concept and identify the mechanisms involved.  For example, pulmonary 
oedema induced by mechanical ventilation involves the opposing processes of barrier 
dysfunction and lung fluid reabsorption, which could be mediated by the different TNFRs.  
Ultimately, therapeutic targeting the receptor subtypes could therefore potentially be used 
to attenuate the deleterious effects of mechanical ventilation in patients.  Consequently, 
part of this project will investigate mechanisms of differential TNFR signalling in oedema 
formation.   
 
1.6.2 Soluble TNFRs in ALI 
Soluble TNFRs have also been implicated in ALI/ARDS.  Park et al. reported that BALF 
sTNFR levels were elevated at least 10-fold at the onset of ARDS compared to normal 
volunteers, with a gradual decrease over time (19).  This was mirrored in the bioactivity of 
TNF in BALF from ARDS patients that increased in the first 7 days after onset of ARDS.  
This study also observed significant relationships between BALF total protein and sTNFR 
p55 and p75 levels and speculated that elevation of sTNFRs in BALF was due to leakage 
of receptors from the plasma across the epithelial/endothelial barrier or intraalveolar 
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production (19).  Conversely, Armstrong et al.  reported that sTNFRs were not elevated in 
BALF in ARDS patients and cultured alveolar macrophages obtained from ARDS patients 
released less sTNFR p75 into cell culture supernatants than those obtained from patients at 
risk for ARDS, but with increased p75 mRNA levels (135). 
Parsons et al. reported that ARDS patients and patients at risk for ARDS had 
increased plasma levels of both sTNFR p55 and p75, which were strongly associated with 
morbidity and mortality, indicating that plasma sTNFR levels might predict patient 
outcome in ARDS (21).  It has also been reported that increased plasma levels of sTNFRs 
are associated with acute kidney injury in ALI patients (230). 
In clinical and experimental ALI, it has been reported that sTNFR levels can be 
influenced by different ventilation strategies, implicating their involvement in VILI. 
Ranieri et al. reported that sTNFRs were elevated in plasma from patients ventilated with 
conventional, high VT that produced higher mortality, compared to low VT (20).  Parsons 
et al. found that patients ventilated with higher VT, again associated with higher mortality, 
had increased plasma levels of sTNFR p55, with a similar trend for sTNFR p75, and 
speculated that this could reflect increased pulmonary inflammation/pulmonary epithelial 
damage, because A549 cells produced sTNFR p55 upon stimulation (21).  Increases in 
plasma sTNFR p55 levels would therefore occur via leakage from the alveolar 
compartment to the circulation, in contrast to the suggestion that sTNFRs leak into the 
alveolar space from the plasma (19).  Plasma sTNFRs are increased in a number of other 
inflammatory conditions where the lung is not the prime site of insult, such as in sepsis, 
Crohn’s disease, ulcerative colitis and rheumatoid arthritis (213-215, 219, 220).  Thus, 
there may be sources of increased plasma sTNFRs during ARDS other than the pulmonary 
epithelium.  In addition to high VT ventilation producing increased plasma levels of 
sTNFRs, Ranieri et al. also reported that BALF levels of sTNFRs were elevated from 
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patients ventilated with deleterious high VT (20).  Similarly, Wilson et al. showed that 
injurious high VT ventilation significantly increased BALF levels of sTNFRs in mice 
(113).  However, the source of BALF sTNFRs was not elucidated in either study. 
Despite studies showing changes in BALF and plasma levels of sTNFRs, the 
relevance and sources of increased sTNFRs in ALI are not known.  Soluble TNFRs may 
be up regulated in BALF and plasma by either local production or leakage from one 
compartment to another via decompartmentalisation.  This active vs. passive increase in 
receptor levels could be very important in interpreting elevated sTNFR levels and could 
also influence TNF signalling very differently. 
Active TNFR production, via cell-surface receptor shedding, could not only inhibit 
excessive TNF signalling by sTNFR-mediated TNF sequestration, but also desensitise 
cells to activation by TNF.  Production of sTNFRs in this way could indicate cellular 
activation/inflammation.  Moreover, if shedding of cell-surface TNFRs is unbalanced due 
to the different propensities of TNFR p55 and p75 to be shed, this could modulate TNF 
signalling, by altering the p55:p75 expression ratio on cells.  Given the differential roles of 
TNFR p55 and p75 during VILI, this could have extremely important effects on TNFR 
signalling.  Conversely, increased levels of sTNFRs induced by passive processes such as 
decompartmentalisation of receptors from an adjacent compartment, would theoretically 
leave cell-surface TNFR expression unaffected and not indicate inflammation/cellular, 
activation, although increased the sTNFRs could still inhibit TNF signalling.  Therefore, 
investigation of changes in sTNFR levels and identification of sources of sTNFRs will 
help to establish their clinical relevance and provide valuable insights into the underlying 
disease process in VILI. 
 The potential of sTNFR expression kinetics/shedding to modulate differential 
TNFR could be pivotal to the outcome of TNF signalling, but the mechanisms that 
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underlie differential TNFR signalling remain to be elucidated.   One possible mechanism 
for p55-mediated promotion and p75-mediated protection from pulmonary oedema 
formation during VILI could be differences in lung fluid reabsorption and/or alveolar 
barrier integrity.  Investigating the processes via which TNFRs produce their differential 
effects will help identify novel targets for therapies in ARDS, such as subtype-specific 
TNFR blockade/stimulation or activation/inhibition of downstream mechanisms.  These 
approaches could ultimately be used with low VT ventilation as adjunctive therapies to 
help attenuate the heavy burden of ARDS-associated mortality. 
 
1.7 Hypothesis and Aims 
The main objective of this project was to investigate the biological relevance of increased 
levels of sTNFRs in the alveoli and circulation and the mechanisms underlying differential 
TNFR signalling during VILI.  This PhD thesis has been divided into two main parts.  
Firstly, this thesis will investigate changes in sTNFR levels (kinetics) and sources of 
sTNFRs in both the alveolar space and plasma during VILI, and thus help elucidate their 
clinical relevance.  Secondly, this thesis will investigate possible mechanisms underlying 
differential TNFR signalling in VILI.  These 2 main aims have the following sub-divisions 
and specific hypotheses: 
 
1. Relevance of sTNFRs in VILI: 
 Investigate the kinetics, sources and relevance of increased intraalveolar 
sTNFRs during VILI, using in vivo and ex vivo mouse models in WT mice.  
I hypothesise that sTNFRs are elevated in BALF during VILI by either 
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intraalveolar production or leakage of systemically produced receptors into 
the alveolar space. 
 Investigate the kinetics, sources and relevance of increased plasma sTNFRs 
during VILI, using in vivo and ex vivo mouse models in WT mice.  I 
hypothesise that sTNFRs are elevated in plasma during VILI by either 
leakage of sTNFRs from the intraalveolar compartment or by production 
by the pulmonary microvasculature or non-pulmonary organs.  
2. Differential TNFR signalling in VILI: 
 Investigate mechanisms underlying protective TNFR p75 signalling in 
VILI, using an in vivo mouse model to assess lung fluid reabsorption in 
WT and TNFR KO mice.  I hypothesise that TNFR p75 promotes the 
reabsorption of fluid from the lungs and its absence therefore inhibits this 
process. 
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2.  METHODS 
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This chapter will describe the various methodologies employed in this project, including 
protocols for animal models of ALI, flow cytometry and immunohistochemistry. 
The majority of this project has been based upon the use of in vivo mouse models.  
A custom-made mouse mechanical ventilation system is described that has been used to 
model VILI induced by the use of injurious high VT ventilation, hydrochloric acid 
aspiration-induced ALI (in collaboration with Dr Brijesh Patel), and also for the 
assessment of lung fluid reabsorption in vivo.  I have also made use of an ex vivo model of 
VILI in an isolated perfused lung system (in collaboration with Dr Kenji Wakabayashi) 
and used in vivo mouse models of ALI induced by i.t. administration of bacterial toxins in 
non-ventilated mice.  Protocols for each of these models is described below.  
Sampling/harvesting of BALF, plasma and lungs from animal models is described with 
specific assays and in vitro culture of macrophages to investigate LPS-induced 
macrophage sTNFR production is also described.  
A flow cytometry protocol for quantifying the expression of cell-surface TNFRs in 
normal lung tissue was successfully developed and TNFR expression was studied on 
various pulmonary cell types under baseline conditions and during VILI/ALI.  The 
development of this technique will be discussed in detail below, including protocols for 
identification of different the pulmonary cell types investigated during this study, and 
validation of specific TNFR staining.  In addition, various immunohistochemistry 
protocols, used to investigate pulmonary TNFR expression, are described. 
In addition to the methods described in this chapter, specific protocols will be 
outlined where appropriate in subsequent chapters. 
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2.1 Animal models 
2.1.1 Animals 
All protocols were approved by the United Kingdom Home Office in accordance with the 
Animals (Scientific Procedures) Act 1986, United Kingdom. WT C57BL6 (Charles River 
Laboratories, Margate, UK), TNFR p55
-/-
 KO, TNFR p75
-/-
 KO, or TNFR p55
-/-
, p75
-/-
 
double KO  (DKO) (generous gifts from Amgen, Thousand Oaks, CA (186)) mice aged 9-
13 weeks (20-30 g) were used.  DKO mice were generated by crossing mice heterozygous 
for p55 and p75 (p55
+/-
 and p75
+/-
, respectively).  TNFR p55 KO mice were C57BL6 
inbred, whereas the p75 KO and DKO mice were backcrossed onto their WT C57BL6 
strain for five generations.  Genotyping of KOs was regularly performed to confirm TNFR 
deficiencies.  
 
2.1.2 In vivo mechanical ventilation in mice 
2.1.2.1 Overview 
The in vivo mouse mechanical ventilation system has previously been described in detail 
(88, 89, 101, 104, 113).  In this project, mechanical ventilation has been used in various 
settings.  Injurious mechanical ventilation was used to model pure VILI by the use of high 
VT ventilation.  Conversely, non-injurious ventilation strategies have been used in 
conjunction with i.t. administration of acid during acid aspiration-induced ALI and with 
i.t. administration of isotonic fluid in order to assess lung fluid reabsorption in vivo. 
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2.1.2.2 In vivo mouse mechanical ventilation system 
All aspects of this system can be altered to produce the desired ventilation regimen.  The 
ventilator is a custom-made jet ventilator, using positive pressure ventilation, as described 
previously (231).  A flow regulator between the gas supply (gas cylinder) and the 
ventilator is used to control the flow and thus the volume of gas (VT) used for ventilation 
(Figure 2.1).  Delivery of gas to the lungs (inspiration), and subsequent expiration, is 
regulated by two electronically controlled solenoid valves.  Upon opening of the 
inspiratory solenoid valve, gas enters the lungs.  This valve closes preventing any further 
gas flow, with the simultaneous opening of the expiratory solenoid to facilitate gas flow 
out of the lungs.  This expiration is passive, relying on the elastic recoil of the chest wall 
and lungs.  The expiratory solenoid then closes and the respiratory cycle repeats.  The 
respiratory rate was electronically controlled, with the inspiratory to expiratory ratio fixed 
at 1:2. 
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Figure 2.1.  Photograph and schematic diagram of the in vivo mouse ventilation system.  High-pressure 
gas from the gas supply passes through a flow regulator (1), which can be adjusted to give a desired constant 
VT throughout the experiment.  When open, gas flows through the inspiratory solenoid (2), through the 
pneumotachograph (3) and into the mouse via the endotracheal tube (4).  After inspiration, the inspiratory 
solenoid closes, the expiratory solenoid (5) opens and the mouse exhales passively.  A pressure transducer 
(6) for measurement of airway pressure and a differential pressure transducer (7) for monitoring of airway 
flow, enable determination of respiratory mechanics.  There is also an arterial line (8) for blood pressure and 
blood gas analyses and for maintenance fluid infusion, and an i.p. line for maintenance of anaesthesia (9). 
 
2.1.2.3 Animal preparation 
In addition to the mechanical ventilation component, the strength of this system is based 
upon the fact that mice are kept physiologically stable, much like a ventilated patient in 
intensive care. 
Mice were anaesthetised by i.p. injection of ketamine (60 mg/kg) and xylazine (6 
mg/kg).  Anaesthesia was maintained throughout experiments via an i.p. line, and body 
temperature is maintained at 36C using a heated bed and monitored with a temperature 
probe (Figure 2.1).  After induction of anaesthesia, a tracheostomy was performed to allow 
insertion of an endotracheal tube for ventilation.  Mice were ventilated using low VT of 8-
9 ml/kg, a positive end-expiratory pressure (PEEP) of 2.5 cmH2O and a respiratory rate of 
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120 breaths/min. The left carotid artery was cannulated to allow periodic arterial blood gas 
analysis, constant monitoring of arterial blood pressure and administration of normal 
saline (with 10 U/ml heparin to prevent clotting) at a rate of 0.4 ml/h (Figure 2.1), as 
maintenance fluid and to compensate for increased evaporation from the airways due to 
dry gas ventilation. Airway pressure and gas flow were monitored continually via 
transducers, connected to a PowerLab data acquisition system (AD Instruments, 
Chalgrove, UK).  Data was analysed using Chart software (version 5.5.6, AD 
Instruments).  Respiratory system compliance (Crs) and resistance (Rrs) were determined 
by end-inflation occlusion (231) at 30 min intervals.  With this technique, a constant flow 
of gas is delivered to the lungs (as during normal mechanical ventilation in this system), 
followed by an inspiratory pause, i.e. closing of the inspiratory solenoid valve, with 
expiratory valve still occluded.  Zero flow is achieved in the pneumotachograph and the 
lungs remain inflated with a constant VT.  VT is calculated by integrating the flow during 
inspiration (Figure 2.2).  Calculating VT by integrating flow is normally prone to errors 
caused by frequent zero drift of the pneumotachograph/flow transducer.  However, this 
inspiratory pause enables real-time correction for this, as occlusion of both solenoid valves 
physically produces zero flow.  Differences between this and flow transducer values allow 
a correction factor to be calculated (Figure 2.2).  This allows accurate measurement of VT 
and respiratory system mechanics.  Blood gas analyses were carried out 5 min after 
surgery, after 1 h of ventilation and/or at the end of the protocol (~70 µl/sample, with 
bolus administration of saline to replace fluid).  Upon termination of experiments, mice 
were overdosed with anaesthetic, administered via the arterial line, and exsanguinated 
prior to tissue sampling/harvesting. 
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Figure 2.2.  Measurement of respiratory mechanics using end-inflation occlusion in the in vivo mouse 
mechanical ventilation system.  Using pressure transducers, pressure and flow traces are obtained similar 
to those shown above.  Using end-inflation occlusion and the gas flow trace, zero drift can be corrected and 
VT accurately measured. Using the pressure trace, peak and plateau pressures (Pplat) can be accurately 
measured.  Lung mechanics can thus be monitored throughout experiments. 
 
2.1.2.4 In vivo mouse model of ventilator-induced lung injury 
My in vivo mouse model of VILI is based upon previously published models (88, 89, 101, 
104, 113).  It is a one-hit model, i.e. lung injury is produced solely by over-stretching 
healthy lungs with high VT.  In the clinical setting, the deleterious effects of mechanical 
ventilation are difficult to distinguish from the underlying disease process.  This model 
allows the effect of injurious mechanical ventilation to be studied in the absence of any 
pre-existing pathology. 
The VT can be set at the beginning of the protocol to alter the progression of lung 
injury.  Ventilation with a higher VT will result in rapid injury development, whereas low 
VT produces no injury.  However, at lower VT the lung is prone to collapse.  Therefore, 
PEEP and lung recruitment manoeuvres (sustained inflations) are employed to avoid 
atelectrauma.  Eventually, decreasing the VT will not cause sufficient lung-stretch and 
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lung injury will not develop, as shown in low VT groups (88).  Mice receiving low VT, 
were ventilated with medical air, whilst those receiving high VT were ventilated with air 
supplemented with 4% CO2 to avoid hypocapnia. 
Surgery was followed by a 5 min equilibration period.  Baseline values were 
recorded and high VT ventilation initiated or low VT settings maintained.  High VT 
ventilation produced considerable pulmonary oedema, developing between 1 and 2 h, 
before infiltration of neutrophils to the lung airspaces.  Injury was standardised by 
ventilating mice until PIP increased by 30% of its initial value (value at the start of high 
VT ventilation), indicating substantial oedema development, or until 2 h, whichever 
occurred first.  Upon termination of experiments, increases in PIP are usually 
accompanied by a significant decline in BP, indicating that cardio-respiratory collapse is 
imminent (88).  This does not occur with low VT ventilation.  After termination, BALF, 
plasma and lungs were sampled/harvested and either stored at -80C or used for 
immediate analysis. 
 
2.1.2.5 In vivo mouse model of acid aspiration 
Experiments using various in vivo and ex vivo ALI models produced surprising effects on 
intraalveolar sTNFR expression.  For validation and comparison, I used an in vivo mouse 
model of acid aspiration in collaboration with Dr Brijesh Patel.  This model also uses the 
in vivo mouse mechanical ventilation system for maintenance of treated animals.  The 
model is based on previously published models (42, 232). 
After surgery, 5 min equilibration and baseline measurements, animals were 
temporarily disconnected from the ventilator for i.t. bolus administration of 50 µl of 
hydrochloric acid (0.15 M, pH 1.5) or saline using a fine catheter via the endotracheal 
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tube.  Mice were reconnected to the ventilator and lungs recruited by a series of sustained 
inflations (35 cmH2O for 5 s, 4 times with 30 s intervals).  Mice were ventilated with 
parameters used during surgery (low VT with sustained inflations every 30 min).  Both 
saline and acid instilled mice were ventilated with 100% oxygen to avoid hypoxia. 
In this model, acid instillation produced pulmonary oedema formation by 3 h, and 
due to the early time point, neutrophil infiltration into the alveolar space was not observed.  
Saline treated animals showed no injury.  Upon termination, saline lavage was performed 
and samples stored at -80C. 
 
2.1.2.6 Lung fluid reabsorption 
To study the involvement of TNFR p75 signalling in lung fluid reabsorption, which may 
contribute to the protective effects of this receptor in pulmonary oedema formation, an in 
vivo mouse model was developed to assess lung fluid reabsorption.  This model used the 
in vivo mouse mechanical ventilation system for maintenance of animals during which 
mice were instilled i.t. with a custom-made instillate. 
Previous studies investigating lung fluid reabsorption have used a variety of 
techniques.  To assess the degree of fluid reabsorption from the lungs, some studies have 
instilled fluid into one lung and then re-sampled this upon termination of experiments to 
measure the change in the concentration of protein or a labelled tracer (109, 233-238).  
This can be influenced by changes in alveolar protein permeability and may not be 
reproducible.  Changes in lung W:D weight ratios or changes in the weight of the heart 
and lung en bloc have also been used to calculate fluid reabsorption (233-235, 238).  
These techniques do not specifically measure fluid reabsorption from the airspaces and are 
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relatively insensitive.  In addition, dead animals or isolated perfused lungs are often used 
(233, 234, 238), which lack the physiological relevance of in vivo preparations. 
Some studies have used changes in lung mechanics to assess lung fluid 
reabsorption (233, 234).  The advantage of this technique is that measurements can be 
recorded throughout physiologically relevant in vivo preparations.  However, these studies 
used either ex vivo or in vivo rat preparations, and to my knowledge, no in vivo mouse 
models of lung fluid reabsorption have used lung mechanics to assess lung fluid 
reabsorption.  I therefore developed an in vivo mouse model of lung fluid reabsorption in 
ventilated mice, assessed in part by respiratory mechanics. 
Following preparation of animals and equilibration for 5 min, baseline 
measurements were taken.  Mice were momentarily disconnected from the ventilator for 
i.t. administration of a bolus of an isotonic instillate using a fine catheter via the 
endotracheal tube.  Mice were reconnected to the ventilator and lungs recruited by a series 
of sustained inflations (35 cmH2O for 5 s, 4 times with 30 s intervals).  Mice were 
ventilated with parameters used during surgery (low VT and sustained inflations every 30 
min, with 100% oxygen to avoid hypoxia).  Respiratory systemic elastance (Ers), 
specifically, the % change in Ers from baseline values, was used to assess lung water 
content during protocols.  Upon termination, lungs were excised for W:D weight ratios, as 
a further measure of lung water content. 
 
2.1.3 Ex vivo mechanical ventilation in mice 
In order to study mechanical ventilation without systemic influences, an isolated perfused 
lung (IPL) system (Hugo Sachs Elektronik - Harvard Apparatus GmbH, March-
Hugstetten, Germany) was used, in collaboration with Dr Kenji Wakabayashi.  This 
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system has been described previously (239, 240).  This ex vivo model, although less 
physiologically relevant than the in vivo VILI model, is a very useful tool.  It allows 
investigation into specific aspects of the in vivo model that cannot be specifically studied 
in live animals.  For example, here it was used to model a scenario where plasma was 
devoid of soluble mediators. 
 
2.1.3.1 Ex vivo mouse model of ventilator-induced lung injury 
This model is based upon the same principles as the in vivo VILI model.  Injury is 
produced using high VT ventilation, without pre-existing pathology.  Mice were 
anaesthetised by an i.p. injection of ketamine (60 mg/kg) and xylazine (6 mg/kg), 
tracheostomised and ventilated using a similar custom-made mouse ventilator system to 
the in vivo ventilation models, with medical air supplemented with 5% CO2 at a 
respiratory rate of 120 breaths/min, VT of 8 ml/kg and a PEEP of 2.5-3 cmH2O.  Sustained 
inflations (20 cmH2O for 5 seconds) were introduced every 5 min.  After 
thoracotomy/laparotomy and heparinisation (100 IU), animals were exsanguinated and the 
pulmonary artery and left atrium cannulated.  Lungs were perfused with a constant flow 
(25 ml/kg body weight/min; Ismatec REGLO Digital Tubing pump; Laboratoriumstechnik 
GmbH, Wertheim-Mondfeld, Germany) in a non-recirculating manner at 37°C (Figure 
2.3).  Perfusate consisted of RPMI 1640 without phenol red (Invitrogen, Paisley, UK) 
supplemented with 4% bovine serum albumin (Sigma, Poole, UK) and sodium chloride 
(Sigma) to increase osmolarity, as previously described (87).  Sodium bicarbonate (Sigma) 
was added to adjust the perfusate pH to 7.35-7.45.  Left atrial pressure was set at 2.5 to 3 
mmHg during perfusion and the system was equilibrated for 15 min. 
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Low or high VT ventilation was carried out for 2 h or until PIP increased by ~30%, 
as in the in vivo model.  Airway pressure, gas flow and pulmonary artery pressure were 
monitored continually via transducers.  Respiratory system compliance (Crs) and 
resistance (Rrs) were determined every 30 min by end-inflation occlusion.  Perfusate was 
sampled from the reservoir (Figure 2.3) for gas analysis at baseline and at termination. 
 
Figure 2.3.  Schematic of the mouse isolated perfused lung perfusion circuit. Mice were anaesthetised, 
tracheostomised and ventilated with a custom-made mouse ventilator (VT 8 ml/kg).  After 
thoracotomy/laparotomy and heparinisation (100 IU), animals were exsanguinated and the pulmonary artery 
and left atrium cannulated.  Lungs were perfused with constant flow (25 ml/kg body weight/min) in a non-
recirculating manner: peristaltic pumps draw up perfusate, which is warmed to 37C and any bubbles 
removed using a bubble trap.  Perfusate enters the pulmonary circulation via the pulmonary artery and leaves 
via the left atrium.  Upon leaving the pulmonary circulation, perfusate enters the reservoir, where it can be 
sampled or discarded as waste.  After a 15 min equilibration period, ventilation was changed to high VT or  
maintained at low VT ventilation. 
 
 
2.1.4 In vivo intratracheal instillation models 
Intratracheal instillations were also used in anaesthetised animals in the absence of 
mechanical ventilation.  This method of treatment was used specifically to target cells 
within the alveolar space using various agents.  In this project, this technique was used to 
produce in vivo models of pulmonary inflammation and in vivo alveolar macrophage 
depletion. 
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Mice were anaesthetised by i.p. injection of ketamine (60 mg/kg) and xylazine (6 
mg/kg) and suspended ~20 from the vertical axis by their front teeth.  The mouth was 
gently opened and the tongue carefully drawn outwards.  A fine catheter was inserted 
orally into the trachea by direct visualisation of the vocal cords under a microscope, 
allowing bolus administration of agents.  Mice were monitored during recovery from 
anaesthesia, and body temperature maintained using a heated pad.  After recovery, mice 
had access to food and water ad libitum.  At desired time points, mice were exposed to 
further interventions or euthanised by isoflurane overdose for sampling/harvesting. 
 
2.1.4.1 Lipopolysaccharide and lipoteichoic acid-induced pulmonary inflammation 
To compare data obtained from VILI and acid aspiration models that produce substantial 
pulmonary oedema, i.t. LPS (InVivoGen, Toulouse, France) or lipoteichoic acid (LTA, 
InVivoGen) was administered as described above.  This produced two models of ALI that 
have strong intraalveolar inflammatory components as evidenced by large neutrophil 
recruitment to the alveolar space.  As these models are both relatively acute, they do not 
produce high levels of pulmonary oedema, in contrast to that observed following acid 
instillation or VILI. 
 
2.2 In vivo/ex vivo sampling 
2.2.1 Bronchoalveolar lavage 
BALF was obtained as described previously (88).  Sterile saline (750 µl) was flushed into 
the lungs via an endotracheal tube and gently sucked out.  This was repeated twice.  
Samples were immediately centrifuged at 1500 rpm for 5 min at 4C.  Supernatants were 
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aliquotted and stored at -80C for analysis by ELISA, and cell pellets resuspended in 600 
µl sterile saline.  Cells were analysed by flow cytometry and/or differential cytology, 
using a Diff-Quik staining kit (Medion Diagnostics AG, Duedingen, Switzerland).  For 
flow cytometry, some lavage sampling was performed with flow cytometry buffer in the 
presence of protease inhibitors (see section on “Preparation of lung tissue for flow 
cytometry”). 
 
2.2.2 Plasma 
Plasma samples were obtained by cardiac puncture with a heparinised needle and syringe.  
Heparinised blood was centrifuged at 4000 rpm for 5 min at 4C.  Plasma was removed 
and aliquotted for storage at -80C.  Cell pellets were resuspended and stored on ice for 
flow cytometry. 
 
2.2.3 Preparation of lungs for wet:dry weight ratios 
Following exsanguination of mice, lungs were excised and briefly rinsed in saline.  Lungs 
were weighed and placed in an oven to dry overnight.  Lungs were re-weighed and W:D 
weight ratios calculated. 
 
2.3 In vitro cell culture  
2.3.1 In vitro production of sTNFRs from stimulated primary alveolar macrophages 
LPS-induced sTNFR production by primary alveolar macrophages was studied in vitro.  I 
found that alveolar macrophages rapidly down regulate cell-surface TNFRs following 
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recovery by lung lavage and therefore assessing LPS-induced shedding from freshly 
recovered cells is difficult.  24 h culture was therefore used since this could allow 
stabilisation of surface TNFR expression.  A similar technique has been used previously to 
study primary alveolar macrophage sTNFR production (241).  Alveolar macrophages were 
obtained by lung lavage performed using RPMI 1640 media (supplemented with 10% 
foetal calf serum (FCS) and 1% penicillin, streptomycin and glutamate).  Cells were 
centrifuged at 1500 rpm for 5 min at 4C and pellets resuspended in fresh media.  Samples 
were plated in duplicate at a densities of ~2x10
4
 cells/well.  Samples were incubated at 
37C overnight in an atmosphere of 5% CO2 in air.  Media was replaced to remove 
spontaneously produced sTNFRs and cells were stimulated with LPS (100 μg/ml in saline) 
or saline alone, and incubated for 2 h at 37C.  After incubation, supernatants were 
centrifuged at 2000 rpm for 5 min at 4C to remove cells and stored at -80C for later 
quantification of sTNFRs by ELISA. 
 
2.3.2 In vitro production of sTNFRs from stimulated RAW 264.7 cells 
LPS-induced sTNFR production was also investigated using the RAW 264.7 murine 
leukaemia virus-transformed peritoneal macrophage cell line.  RAW 264.7 cells 
(European Collection of Cell Cultures, Salisbury, UK) were cultured in RPMI 1640 (with 
10% FCS and 1% penicillin, streptomycin and glutamate) and incubated at 37C in an 
atmosphere of 5% CO2 in air until confluent.  The adherent cells were then removed using 
cell scrapers and centrifuged at 1300 rpm for 7 min at room temperature.  Cell pellets were 
resuspended in 1 ml fresh media and counted.   Cells were plated in quadruplicate at a 
density of 5x10
5
 cells/well and incubated overnight at 37C.  Media was replaced to 
remove spontaneously shed sTNFRs and equilibrated for 2 h in an incubator.  Cells were 
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then treated with LPS (0.1 µg/ml or 100 μg/ml in saline) or saline and incubated at 37C 
for 2 h.  Supernatants were centrifuged at 2000 rpm for 5 min at 4C to remove cells and 
stored at -80C for quantification of sTNFRs by ELISA. 
 
2.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
Colorimetric sandwich ELISA was used to quantify soluble mediators in BALF, plasma 
and cell culture supernatants, in accordance with manufacturer’s instructions.  ELISA kits 
were purchased for murine sTNFR p55, p75, macrophage inflammatory protein-2 (MIP-2) 
and keratinocyte-derived chemokine (KC) (R&D Systems, Abingdon, UK), and analysed 
using a colorimetric plate reader (MRX II absorbance reader, Dynex Technologies, 
Magellan Biosciences, Worthing, UK). 
 
2.5 Protein Assay 
2.5.1 Overview 
A standard Bradford assay (Bio-Rad Laboratories, Hemel Hempstead, UK) was used to 
quantify total protein levels in BALF samples.  In the Bradford assay, proteins bind to the 
dye, Coomassie Brilliant Blue G-250, which causes a shift in its absorption, i.e. a colour 
change, which is relative to the quantity of protein (242).  This is analysed by a 
colorimeter and compared to a set of standards with known protein concentrations. 
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2.5.2 Procedure 
Samples were diluted so that predicted protein concentrations would fall within the limits 
of the standard curve.  Standard preparations of bovine serum albumin (BSA) were 
prepared by serial dilution (range 0.0156 mg/ml – 1 mg/ml, linear range 0.05 mg/ml – 0.5 
mg/ml).  Both samples and standards were plated in triplicate.  Bradford reagent was 
added to each well and gently mixed.  Plates were analysed using a colorimetric plate 
reader (MRX II absorbance reader, Dynex Technologies, Magellan Biosciences). 
 
2.6 Flow cytometry 
2.6.1 Overview 
Flow cytometry is a sensitive technique using immunofluorescence to measure expression 
of cell-associated antigens on a per cell basis.  It is arguably the most quantitative way to 
assess this, because fluorescent signals are converted to numerical values.  Cells are 
stained with antibodies specific for antigens of interest, conjugated to fluorescent dyes.  A 
number of dyes can be used simultaneously, enabling co-staining for multiple antigens.  
Different cell types are identified based on their antigen expression and by their size and 
granularity.  A disadvantage of flow cytometry is that samples have to consist of single 
cells, thus solid tissues have to be processed into single cell suspensions prior to scanning. 
I used flow cytometry to address the controversy surrounding normal cell-surface 
TNFR expression in the lung.  This involved development of a flow cytometry protocol to 
investigate TNFR expression on pulmonary leukocytes and parenchymal cells in naïve 
WT mouse lungs.  This technique would also allow investigation of cell-surface TNFR 
expression during in VILI.  
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2.6.2 Preparation of lung tissue for flow cytometry 
Mice were exsanguinated by cardiac puncture and/or transection of the inferior vena cava.  
This encourages draining of blood from the pulmonary circulation.  Mice were 
tracheostomised and their lungs instilled i.t. with 1 ml of ice-cold protease inhibitor 
solution (10 µM BB94 (a metalloprotease inhibitor; British Biotech, Abingdon, UK) and 1 
mM phenylmethanesulphonyl fluoride (PMSF, a serine protease inhibitor; VWR, Leighton 
Buzzard, UK) in flow cytometry buffer (2% foetal calf serum (FCS), 5mM EDTA and 
0.1% sodium azide in D-PBS; Invitrogen)) via an endotracheal tube.  During development 
of this technique, I found that the presence of these inhibitors during lung tissue 
processing is critical for preservation of cell-surface TNFR expression on pulmonary 
epithelial and endothelial cells, as without this no staining is observed.  After 2 min, lungs 
were excised and briefly rinsed in sterile saline to remove surface blood.  Lungs were 
placed in inhibitor solution and processed into cell suspensions using a GentleMACS 
tissue dissociator (Miltenyi Biotec Ltd, Bisley, UK).  Cell suspensions were filtered 
through a 40 µm cell strainer (Becton Dickinson, Oxford, UK).  Dissociator tubes were 
rinsed with inhibitor solution and residual tissue filtered and collected.  This was then 
repeated and the filter rinsed through with inhibitor solution.  Resulting cell suspensions 
were centrifuged at 1300 rpm for 7 min at 4C and resuspended in 900 ml inhibitor 
solution.  Suspensions were kept on ice until ready for antibody staining. 
 
2.6.3 Staining protocols 
BALF, blood and lung cell suspensions were stained for flow cytometry as previously 
described (101, 104, 239, 243).  Cell-surface TNFR expression was quantified using 
fluorescent dye-conjugated antibodies for TNFR p55 (clone: 55R-286), p75 (clone: TR75-
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89) or an appropriate isotype control (Armenian hamster IgG) (AbD Serotec, Oxford, 
UK).  This allowed quantitative determination of cell-surface TNFR expression on a wide 
range of cell types.  Different cell populations were identified based on size, granularity 
and expression of surface markers using the following antibodies: anti-F4/80 (clone: 
CI:A3-1, AbD Serotec), anti-CD11b (clone: M1/70), Gr-1 (clone: RB6-8C5), CD11c 
(clone: HL3), ICAM-1 (clone: 3E2), VCAM-1 (clone: 429 (MVCAM.A)), PECAM-1 
(clone: MEC 13.3) (Becton Dickinson Pharmingen, Oxford, UK), endoglin (clone: 
MJ7/18, eBioscience, Hatfield, UK), CD45 (clone: 30-F1, Biolegend, Uithoorn, The 
Netherlands), epithelial cell adhesion molecule (Ep-CAM, clone: G8.8, Santa Cruz 
Biotechnology), epithelial cadherin (E-cadherin, clone: 114420, R&D systems).  Cells 
were stained in the dark at 4°C for 30 min and then washed with flow cytometry buffer to 
remove unbound antibodies.  Red cells in blood samples were lysed prior to analysis.  
Where appropriate, cell numbers were determined using microsphere beads (Caltag 
Medsystems, Buckingham, UK), as previously described (104, 239, 243). 
Samples were scanned using a FACSCalibur™ flow cytometer (Becton Dickinson 
Biosciences, Oxford, UK) or a CyAn™ ADP Analyser flow cytometer (Beckman Coulter, 
High Wycombe, UK).  Acquisition was performed until totalling at least 5,000 events.  
Data were analysed with CellQuest™ software (version 3.1, Becton Dickinson 
Biosciences) or FlowJo software (version 8.8.6, Tree Star, Ashland, Oregon, US). 
 
2.6.4 Identification of pulmonary cell types for TNFR quantification 
2.6.4.1 Pulmonary macrophages 
Alveolar and lung macrophages (residual macrophages present in lung tissue following 
lavage) were identified in BALF and lung cell suspensions respectively by their 
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characteristic low positive CD11b expression and high F4/80 expression.  This was 
confirmed with positive staining for CD11c (Figure 2.4).  
 
 
Figure 2.4.  Identification of pulmonary macrophages in lavage and lung single cell suspension 
samples by flow cytometry.  (A) Lavage was performed and stained with fluorescent-conjugated antibodies 
for flow cytometry. Alveolar macrophages were identified in BALF as CD11b
+
, F4/80
+
 events, confirmed 
with CD11c
+
 staining (dark line: isotype control, light line: CD11c staining). For lung cell suspension 
samples, the same gating strategy was employed, using the BALF population for reference. 
 
2.6.4.2 Pulmonary epithelial cells 
Pulmonary epithelial cells were identified in lung cell suspensions using a combination of 
antigens (Figure 2.5 and Table 2.1).  Pulmonary epithelial cells have not previously been 
investigated using flow cytometry in this laboratory.  I therefore developed a staining 
protocol to characterise pulmonary epithelial cells and validate their identification.  I used 
general epithelial markers that are expressed on a wide degree of epithelial cell lineages to 
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identify pulmonary epithelial cells.  The use of such markers would allow me to study all 
epithelial cells in the lungs without specifically investigating the various subpopulations.  
In addition, these markers could also be used to study epithelial cells in other tissues if 
required.  The pan-epithelial cell marker Ep-CAM (244) was used.  Ep-CAM is a 40 kDa 
type I transmembrane glycoprotein expressed by a variety of epithelial cell types (244, 
245).  It mediates homotypic interactions between the basolateral membranes of epithelial 
cells (244).  Importantly, it is expressed in the lung by both type I and type II alveolar 
epithelial cells, but also by the bronchial epithelium (244).  To further strengthen 
identification of pulmonary epithelial cells, I used another pan-epithelial marker, E-
cadherin (246).  E-cadherin is another epithelial cell adhesion molecule, involved in tight 
junction formation between epithelial cells (190).  In the lung, it has been shown to be 
preferentially expressed on alveolar type II cells and the bronchial epithelium (245). 
Staining of lung single cell suspensions with an anti-Ep-CAM antibody and an 
anti-CD45 antibody produced an Ep-CAM positive population negative for the pan-
leukocyte marker CD45 and a population positive for both markers, identified as 
macrophages by high CD11c staining (data not shown).  Macrophages were positive for 
CD45, but negative for Ep-CAM compared to an appropriate isotype control.  Therefore 
the observed high Ep-CAM signal on these cells was due to autofluorescence (Figure 2.5).   
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Figure 2.5.  Identification of pulmonary epithelial and endothelial cells in lung single cell suspensions 
by flow cytometry.  Following tracheostomy, mouse lungs were instilled with protease inhibitors in a flow 
cytometry buffer.  Lungs were excised, rinsed and cells dissociated using a tissue dissociator.  Samples were 
stained with fluorescent dye-conjugated antibodies for flow cytometry.  Isotype antibodies were used as 
controls.  Pulmonary epithelial cells were identified as Ep-CAM
+
, CD45
-
 events (top panels), confirmed 
with high E-cadherin staining, and low CD31 and endoglin staining (Table 2.1).  Lung macrophages were 
seemingly positive for both CD45 and Ep-CAM.  However the positive Ep-CAM staining was due to 
autofluorescence of these cells (top panels).  Pulmonary endothelial cells were identified as high PECAM-1
+ 
(bottom panels), confirmed with positive endoglin and VCAM-1, and low CD45 staining (Table 2.1). 
 
 
 
True Ep-CAM positive cells also expressed very high levels of E-cadherin (Table 
2.1) and are therefore of epithelial origin.  In addition, these cells expressed high levels of 
intercellular adhesion molecule-1 (ICAM-1), which is expressed on alveolar epithelial 
cells, especially type I cells (247).  These cells were not leukocytes, as they had low 
staining of the pan-leukocyte marker CD45.  Furthermore, these cells exhibited 
comparatively low staining for the endothelial markers endoglin and PECAM-1, showing 
that they were not pulmonary endothelial cells (Table 2.1). 
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Future investigations could attempt to identify the many specialised epithelial cell 
subpopulations within the lungs, including alveolar epithelial cell subtypes, bronchial 
epithelial cells and Clara cells.  For example, surfactant proteins can be used to identify 
alveolar type II cells with a flow cytometry protocol using permeabilised, and 
RTI40/podoplanin and aquaporin V can be used to identify alveolar type I cells (247). 
 
 
 
Cell type PECAM-1 Ep-CAM CD45 Endoglin E-cadherin VCAM-1 ICAM-1 
Pulmonary 
endothelium 
3110±104 107±17.8 51.9±7.78 1180±237 508 34.7 - 
Pulmonary 
epithelium 
35.2±18.3 843±150 27.2±11.1 79.5±13.6 4700±1520 - 1690±895 
 
Table 2.1.  Characterisation of pulmonary endothelial and epithelial cells by flow cytometry.  WT mice 
were sacrificed and lungs processed for flow cytometry.  Cells were identified and characterised for 
expression of a number of antigens.  Both endothelial and epithelial cells expressed negligible levels of the 
pan-leukocyte marker CD45.  PECAM-1
+
 endothelial cells expressed high levels of endoglin and low levels 
of VCAM-1, known to be expressed on cells of endothelial lineage, and low levels of Ep-CAM and E-
cadherin, confirming their endothelial cell identity.  Ep-CAM
+
 epithelial cells expressed high levels of the 
pan-epithelial cell marker E-cadherin and high levels of ICAM-1, with low levels of PECAM-1 and 
endoglin, confirming their epithelial lineage.  Values are mean fluorescent intensity (MFI); (-): not done; 
n=1-15. 
 
 
2.6.4.3 Pulmonary endothelial cells 
Pulmonary endothelial cells were identified in lung cell suspensions using their 
characteristic expression of PECAM-1 (Figure 2.5), as previously described (243).  
PECAM-1 positive cells were further characterised as endothelial cells by positive 
staining for endoglin and VCAM-1 and negligible levels of CD45 (Table 2.1). 
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2.6.4.4 Lung-marginated leukocytes 
Lung-marginated and circulating leukocytes were identified in lung cell suspensions and 
blood respectively, as previously described (239).  Lung-marginated and circulating 
neutrophils were identified by their high expression of CD11b and Gr-1 and absence of 
F4/80 expression (Figure 2.6).  Lung-marginated and circulating monocytes were 
identified by their expression of CD11b and F4/80 (Figure 2.6).  Monocyte Gr-1
high
 and 
low
 
subpopulations were identified based on the relative expression of this antigen. 
 
Figure 2.6.  Identification of circulating and lung-marginated monocytes and neutrophils in blood and 
lung single cells respectively, using flow cytometry.  Mice were euthanised by anaesthetic overdose.  (A) 
Blood was sampled via a heparinised syringe by cardiac puncture.  Whole blood was stained with 
fluorescent-conjugated antibodies for flow cytometry.  Circulating neutrophils and monocyte subpopulations 
were identified by positive staining for CD11b and differential staining of F4/80 and Gr-1.  (B) After 
tracheostomy, mouse lungs were instilled with protease inhibitors in flow cytometry buffer.  Lungs were 
excised, rinsed and cell suspensions prepared using a tissue dissociator.  For lung-marginated leukocyte 
identification, the same method was used as in whole blood. 
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2.6.5 Baseline TNFR expression on pulmonary cells 
Following identification of pulmonary macrophages, lung-marginated leukocytes and lung 
parenchymal cells, I quantified cell-surface TNFR expression.  This technique was 
developed throughout the project to maximise TNFR staining.  The following represent 
data acquired towards final optimisation of this technique.  All cells investigated 
expressed both TNFRs to varying degrees. 
Pulmonary macrophages obtained by lavage showed a trend for decreased TNFR 
expression compared to those in lung cell suspensions (data not shown), potentially 
reflecting stimulation by the lavage procedure or alternatively, selective recovery of 
alveolar macrophages that may not be reflective of the macrophage population as a whole.   
Total lung macrophages in lung tissue, from non-lavaged lungs were therefore used to 
determined baseline TNFR expression.  Macrophages exhibited relatively high signals for 
TNFR p75, but also expressed measurable TNFR p55 (Figure 2.7), consistent with other 
studies using flow cytometry to quantify TNFR expression on synovial macrophages (148, 
150). 
Pulmonary epithelial cells expressed low levels of both TNFRs, but with higher 
signals for TNFR p75 than p55 (Figure 2.7).  A previous immunohistochemistry-based 
study investigating pulmonary TNFR expression reported p75, but with no p55 expression 
on alveolar epithelial cells (168), whereas a study using flow cytometry to quantify TNFR 
on primary rat type II alveolar epithelial cells and MLE-Kd cells showed TNFR p55 and 
p75 expression, but with stronger signals for p55 (124), which is consistent with my 
finding that pulmonary epithelial cells express both TNFRs. 
Pulmonary endothelial cells also expressed low levels of both TNFR p55 and p75, 
which is consistent with other flow cytometry-based studies investigating TNFRs on a 
variety of endothelial cell types (154, 155, 163) (Figure 2.7). 
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Lung-marginated Gr-1
high
 and 
low
 monocytes expressed high levels of both 
receptors, with stronger signals for TNFR p75 (Figure 2.7), consistent with the literature 
(150-153).  Expression levels were similar between Gr-1
high
 and 
low
 subpopulations.  Lung-
marginated neutrophils showed high TNFR p55 signals with moderate signals for TNFR 
p75 (Figure 2.7).  The inverse has previously been reported on granulocytes (153). 
Circulating monocytes expressed similar relative expression levels of TNFR p55 
and p75, but exhibited a generally larger signal for both compared to lung-marginated 
monocytes. Differences between lung-marginated and circulating monocytes may reflect 
activation of the adherent lung-marginated cells.  Adherence of neutrophils to fibrinogen-
coated plates induces shedding of TNFR p55 and p75 (209) and adherence of neutrophils 
to activated endothelial cells induces neutrophil sTNFR p75 shedding (248).  These data 
could therefore indicate a higher activation status of lung-marginated monocytes, but 
could also be an artifact of tissue processing to which circulating leukocytes are not 
exposed. This makes interpretation of this piece of data difficult.  Interestingly, circulating 
Gr-1
high
 monocytes exhibited stronger signals for p55 and p75 compared to circulating Gr-
1
low
 monocytes (Figure 2.7).  Circulating neutrophils expressed similar levels of TNFRs to 
lung-marginated neutrophils. 
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Figure 2.7.  Cell-surface TNFR expression on lung cells using flow cytometry.  WT mice were sacrificed 
and their lungs processed for flow cytometry.  Cells were identified as described previously.  TNFR p55 and 
p75 expression was quantified on lung macrophages, pulmonary epithelial cells, pulmonary endothelial cells 
and lung-marginated and circulating monocytes and neutrophils.  All cells expressed both TNFR p55 and 
p75 to varying degrees.  Leukocytes exhibited the highest staining of TNFRs, with lower staining on 
epithelial and endothelial cells.  Values are mean fluorescent intensity (MFI) with isotype control values 
subtracted; n=4-11. 
 
TNFR p55 and p75 staining was validated in TNFR p55 or p75 KO mice.  TNFR 
p55 and p75 staining on all leukocytes was found to be entirely specific for the respective 
receptor subtype (Figure 2.8).  A small degree of TNFR staining on pulmonary endothelial 
and epithelial cells appeared to reflect non-specific binding (Figure 2.8). 
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Figure 2.8.  Validation of TNFR staining on WT pulmonary cells using samples from TNFR p55 and 
p75 deficient mice.  Single TNFR p55 and p75 KO mice were sacrificed and their lungs processed for flow 
cytometry in parallel.  Cells were identified as previously described.  TNFR p55 and p75 staining was 
compared between strains to validate quantification of TNFRs by flow cytometry.  An isotype control was 
also used.  (A) Accordingly, the TNFR p55 KO lung sample did not show any degree of TNFR p55 staining 
compared to the isotype.  (B) The TNFR p75 KO sample showed negligible levels of TNFR p75 on all cells, 
with a small signal on pulmonary epithelial and endothelial cells, indicating some non-specific binding 
(~50%).  Circulating leukocyte TNFR expression was also validated in KOs, and found to be specific (data 
not shown).  Values are mean fluorescent intensity (MFI) with isotype control values subtracted; n=1/each 
group. 
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2.7 Immunohistochemistry 
2.7.1 Overview 
Cell-surface TNFRs on lung tissue were also analysed by immunohistochemistry in an 
attempt to consolidate data obtained using flow cytometry, which could be subject to 
artifacts due to processing of the tissue into single cell suspensions.  This technique also 
uses antibody-based detection of antigens.  Antibodies were either directly conjugated to 
fluorescent dyes or enzymes, or unconjugated, in which case secondary conjugated 
antibodies were used.  Staining was visualised using fluorescence or light microscopy. 
 
2.7.2 Tissue preparation 
Two main techniques were used to prepare lungs for immunostaining: i.t. instillation of 
fixative or OCT embedding medium (VWR) into lungs  (fixed and non-fixed lungs, 
respectively). 
For the fixation technique, WT mice were sacrificed by isoflurane overdose and a 
tracheostomy was performed.  Intact lungs and heart (with the endotracheal tube in place) 
were then removed en bloc and gently instilled with 700 µl of 4% paraformaldehyde via 
the endotracheal tube.  Tissue was left in additional fixative for 24-48 h at 4°C and then 
cryoprotected in 30% sucrose for 24-48 h.  Lung lobes were separated and embedded in 
OCT via freezing in isopentane (2-methylbutane) (Sigma), cooled to -160-150°C in liquid 
nitrogen. 
For the non-fixed technique, WT mice were sacrificed by isoflurane overdose and 
a tracheostomy performed.  Lungs and heart were removed en bloc and the lungs instilled 
with 700 µl 50% OCT solution in D-PBS.  Lobes were separated and immediately snap 
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frozen in liquid nitrogen and then embedded in 100% OCT compound by freezing in 
cooled isopentane.   
For both techniques, lung lobes were chosen at random and 10 µM sections cut at -
22°C, and transferred to slides, which were stored at -20°C until stained.  Lungs from 
TNFR p55 knock-out and TNFR p55 and p75 double knock-out (DKO) mice served as 
biological negative controls. 
 
2.7.3 Staining 
Slides were wrapped in aluminium foil and slowly brought to room temperature.  Slides 
were then washed in D-PBS for 5 min 3 times.  Non-specific binding was blocked by 20% 
normal goat serum for 30 or 60 min.  Primary antibodies for TNFR p55 (rabbit polyclonal 
IgG) and TNFR p75 (rat monoclonal) (Abcam, Cambridge, UK) were incubated with 
sections for 1 or 2 h, in the dark at room temperature or overnight at 4°C at 1:100 to 
1:1000 dilutions.  An anti-ICAM-1 (rabbit polyclonal) (Santa Cruz, Heidelberg, Germany) 
antibody served as an internal positive control as it is expressed at very high levels on 
pulmonary cells, particularly the pulmonary epithelium (247).  Isotype controls were used 
where appropriate. 
After washing, the appropriate fluorescent dye- or horseradish peroxidase (HRP)-
conjugated secondary antibodies were applied to sections for 1 h in the dark at room 
temperature at dilutions of 1:50 to 1:400 (goat-anti-rabbit fluorescent dye-conjugated 
(Invitrogen), goat-anti-rat fluorescent dye-conjugated or goat-anti-rabbit HRP-conjugated 
(Abcam)).  Alternatively, if primary antibodies directly conjugated to fluorescent dyes 
were used, sections were washed and immediately mounted for visualisation as described 
below. 
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Following washing of sections, HRP antibody stained sections were developed using 
a 3, 3-diaminobenzidine (DAB) enzymatic immunohistochemistry kit (Vector 
Laboratories, Peterborough, UK) according to manufacturer’s instructions and mounted 
with a xylene-based mounting medium (VWR) for visualisation by light microscopy.  
Fluorescent antibody stained sections were mounted with VectaShield with 4, 6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories), for nuclear counterstaining and 
visualisation by fluorescence microscopy. 
 
2.8 Data Analysis 
Data are expressed as means±SD.  Prior to statistical analysis, data were tested for 
normality, using Kolmogorov-Smirnov tests with Dallal-Wilkinson-Lillie for P values.  
Where data passed normality tests, statistical analysis was carried out by t-tests or 
ANOVA and Bonferroni tests where appropriate.  Where data did not pass normality tests, 
Mann-Whitney tests, Kruskal-Wallis tests with Dunn’s tests, or Friedman tests with 
Dunn’s tests were used where appropriate.  A P value of <0.05 was considered significant.  
Correlations were assessed using Pearson’s Product-moment correlation or Spearman’s 
Rank test.  All statistical analyses were performed using Prism software (version 4.0c, 
GraphPad, La Jolla, USA). 
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3.  INTRAALVEOLAR SOLUBLE 
TNFR KINETICS IN VILI 
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Soluble TNFRs (sTNFRs) are elevated in bronchoalveolar lavage fluid (BALF) from ALI 
patients ventilated with high VT, and from mice following injurious high VT ventilation in 
vivo.  Despite this, the relevance of increased BALF sTNFRs is not well defined.  In order 
to fully interpret these observations, identification of the sources of receptors is first 
required.  In this chapter, I investigated the expression kinetics and sources of BALF 
sTNFRs during high VT ventilation in in vivo and ex vivo mouse models. 
My in vivo mouse model of VILI produced significant pulmonary oedema at 2 h of 
high VT ventilation.  Interestingly, sTNFR levels in BALF were only substantially up 
regulated at this point and correlated very strongly with BALF total protein levels, 
suggesting sTNFRs were increased in BALF as a result of leakage of receptors from the 
plasma. 
Subsequent ex vivo VILI experiments, where circulating sTNFRs were 
experimentally excluded using isolated perfused lungs (IPL), showed that plasma sTNFRs 
were primarily responsible for increased BALF levels during VILI, supporting plasma 
leakage as the predominant mechanism. 
This suggests that increased BALF levels of sTNFRs during pure VILI, reflect 
only plasma leakage of receptors and pure high VT ventilation does not induce substantial 
intraalveolar shedding/production of sTNFRs in vivo. 
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3.1 Background 
Soluble TNFRs could have many roles, but are generally considered to be anti-
inflammatory mediators due to their ability to sequester TNF and inhibit its activity (19, 
127, 167, 202-205, 213, 215, 216, 221, 222).  Circulating sTNFR levels are raised or 
associated with morbidity/mortality in a number of inflammatory pathologies including: 
rheumatoid arthritis and spondylarthropathies (215), sepsis (213, 219, 220) and 
inflammatory bowel disease (214).  
BALF levels of sTNFRs are elevated in ARDS patients (19), and ventilation of 
ARDS patients with higher VT increases BALF and plasma levels, which are associated 
with morbidity/mortality (20, 21).  Similarly, ventilation of mice with high VT increases 
BALF sTNFR levels (113), suggesting that VILI in the absence of underlying 
inflammation can produce effects consistent with those observed clinically.  Despite 
associations with inflammation/injurious ventilation, the precise role of sTNFRs and what 
increases in their levels actually reflect are not well defined. 
Understanding the relevance of increased sTNFR levels in a given physiological 
context may lie in identification of their sources, because this could indicate which 
tissues/cells are responding/activated.  For example, increased circulating levels could 
reflect a systemic anti-TNF response, but also the degree of cellular TNF activation, as 
cell-surface TNFRs can be shed upon stimulation with TNF (147, 156, 158).  The 
selective production of sTNFR subtypes could also reflect specific shedding of TNFR p55 
and p75, which could alter the relative cellular expression of each receptor subtype.  In 
view of recent data that suggests TNFR p55 and p75 mediate completely different, 
potentially opposing biological functions (160, 197-199), this process could be important 
in regulation of TNF signalling.  It is therefore essential to understand kinetics and sources 
of sTNFRs during ALI, as they may reflect shifts between pro- and anti-inflammatory 
103 
 
milieu within a given biological compartment and potentially define balances between p55 
and p75-mediated signalling.   
Previous studies have proposed that during ALI, sTNFR production by alveolar 
cells is responsible for increased levels of sTNFRs in BALF (19) and also plasma, via 
leakage of increased intraalveolar receptors, which subsequently leak into the circulation 
(21).  Alternatively, an opposite mechanism has been suggested whereby pulmonary 
oedema during ALI may produce leakage of plasma sTNFRs into the alveoli (19).  
Clinically, it is not known which of these contributes to increased BALF sTNFR levels, 
but these two mechanisms, i.e. active production vs. passive increases, could have 
different effects on alveolar cell-surface TNFR expression and thus intraalveolar TNF 
signalling.  Hence, understanding which processes actually occur clinically is important to 
properly interpret changes in BALF levels of sTNFRs in patients. 
Clinical VILI occurs in the presence of a pre-existing pathology.  Furthermore, 
VILI produces injury/inflammation homologous to ARDS (40).  Therefore, the specific 
effects of mechanical ventilation are difficult to separate from the underlying disease 
process.  Consequently, mouse models of “pure” VILI were used produced by high VT 
ventilation of initially healthy lungs. 
 
3.2 Aims 
I attempted to investigate the expression of the individual sTNFRs in BALF during the 
course of VILI in order to help interpret raised BALF sTNFRs observed in ventilated 
ARDS patients.  I used both in vivo and ex vivo mouse models of VILI, induced by high 
VT ventilation.  There were 2 main aims: 
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1. Investigate the temporal expression (kinetics) of intraalveolar sTNFRs during VILI 
in mice. 
2. Investigate possible sources of increased intraalveolar sTNFRs in VILI in mice. 
 
3.3 Protocols 
3.3.1 Models 
3.3.1.1 In vivo ventilator-induced lung injury 
I investigated the kinetics of intraalveolar sTNFRs during VILI in order to establish their 
source and relevance, using an in vivo mouse model (chapter 2).  Following surgical 
preparation for the in vivo mouse mechanical ventilation system (during which animals 
were ventilated with 8-9 ml/kg) and baseline measurements, mice were divided into 2 
main groups: 
 
 Ventilation maintained with low VT (non-injurious) 
o VT:  8-9 ml/kg (determined by setting the initial PIP at 10 cmH2O) 
o PEEP:  2.5 cmH2O 
o Respiratory rate:  120 breaths/min 
o Recruitment manoeuvres:  sustained inflations (35 cmH2O for 5 s) 
every 30 min to prevent atelectasis 
o Gas:  medical air 
 Ventilation changed to high VT (injurious) 
o VT:  36-41 ml/kg (determined by setting the initial PIP at 35 
cmH2O) 
105 
 
o PEEP:  none 
o Respiratory rate:  90 breaths/min 
o Recruitment manoeuvres:  none 
o Gas:  4% CO2 in air to achieve physiological blood gases 
 
Each group was further divided into 3: ventilation for 0.5, 1 or 2 h, to create 6 groups in 
total.  In the case of the 2 h high VT group, mice were ventilated for the duration or until 
PIP increased by ~30%, whichever occurred first (mean duration: 114 ± 10 min; n=7).  
Since high VT are used, there should be minimal ongoing alveolar collapse, hence PIP 
should reflect the degree of pulmonary oedema formation in this acute model.  An 
approximate 30% increase in PIP has previously been shown to reflect substantial 
injury/pulmonary oedema formation in a similar VILI model (88).  
Airway pressures and BP were recorded throughout and respiratory system 
mechanics (Crs and Rrs) recorded every 30 min.  Upon termination of experiments, mice 
were euthanised by anaesthetic overdose and saline lavage performed, as described in 
chapter 2.  Samples were centrifuged and BALF supernatants aliquotted and stored at -
80C.  Thawed samples were quantified for sTNFR p55 and p75 by colorimetric sandwich 
ELISA, and for total protein as a further indicator of pulmonary oedema/alveolar barrier 
dysfunction.  In some animals ventilated for 2 h, cell pellets from BALF samples were 
used to assess the degree of alveolar neutrophil infiltration using differential cytology.  
Alternatively, non-lavaged lungs were excised for lung wet:dry weight ratio analysis. 
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3.3.1.2 Ex vivo ventilator-induced lung injury 
An ex vivo isolated perfused lung system was utilised in order to investigate intraalveolar 
sTNFRs without the influences of systemically produced receptors.  The IPL system is 
described in detail in chapter 2.  Mice were anaesthetised, ventilated, and after 
thoracotomy/laparotomy, heparinised and exsanguinated.  Lungs were then ventilated with 
VT of 8 ml/kg and perfused in a non-recirculating manner.  After equilibration of the 
system for 15 min and baseline measurements, mice were divided into 2 groups: 
 
 Ventilation maintained with low VT (non-injurious) 
o VT:  8 ml/kg (determined by setting the initial PIP at 10 cmH2O) 
o PEEP:  2.5-3 cmH2O 
o Respiratory rate:  120 breaths/min 
o Recruitment manoeuvres:  sustained inflations (20 cmH2O for 5 s) 
every 5 min 
o Gas:  medical air supplemented with 5% CO2 to achieve 
physiological gases in the lungs/perfusate 
 Ventilation changed to high VT (injurious) 
o VT:  20-25 ml/kg (determined by setting the initial PIP at 25 
cmH2O) 
o PEEP:  none 
o Respiratory rate:  80 breaths/min 
o Recruitment manoeuvres:  none 
o Gas:  medical air supplemented with 5% CO2 
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Lungs were ventilated for 2 h or in the case of the high VT group, until PIP increased by 
~30%, as in the in vivo VILI model (mean duration: 109 ± 14 min; n=4). 
 Airway pressures and pulmonary artery pressures were recorded throughout.  
Perfusate was sampled for gas analysis at the start and end of the protocol.  Upon 
termination, saline lavage was performed.  Samples were centrifuged and BALF 
supernatants aliquotted and stored for quantification of sTNFR p55 and p75, and MIP-2 
and KC by colorimetric sandwich ELISA, and total protein. 
 
3.4 Results 
3.4.1 Injurious mechanical ventilation increases BALF levels of sTNFR p55 and p75. 
To help interpret raised intraalveolar sTNFRs seen in ventilated ARDS patients, I utilised 
a previously described in vivo mouse model of pure VILI induced by injurious high VT 
ventilation in the absence of any pre-existing pathology (88, 89, 101, 104, 113).  This 
allows investigation of the deleterious effects of high VT ventilation.  This model uses a 
sterile (where exogenous pathogens/pathogen products are absent) mechanical insult to 
produce acute pulmonary oedema, with minimal neutrophil infiltration into the alveolar 
space for the initial 2 h. 
Consistent with previous studies, high VT ventilation produced progressive 
increases in PIP and Rrs as well as decreases in Crs, indicating significant pulmonary 
oedema formation (Table 3.1 and Figure 3.1).  Low VT ventilation did not show these 
changes.  The development of pulmonary oedema was further confirmed in this model by 
increased wet:dry weight ratio of the lungs at 2 h (5.030.09 vs. 7.710.52 for low and 
high VT ventilation, respectively; P<0.05; Mann-Whitney tests; n=4/each group).  Mean 
BP and blood gases were well maintained during both ventilation protocols. 
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 0 h 1 h 2 h 
L
o
w
 V
T
 
PIP (cmH2O) 10.2±0.5 10.3±1.5 10.8±0.8 
Rrs (cmH2O · ml
-1
 s
-1
) 1.76±0.12 1.68±0.10 1.68±0.23 
Crs (ml/cmH2O) 0.033±0.004 0.033±0.004 0.032±0.004 
Mean BP (mmHg) 86±10 96±6* 88±9 
pO2 (mmHg) - 103±11 101±14 
pCO2 (mmHg) - 42±5 41±5 
H
ig
h
 V
T
 
PIP (cmH2O) 35.4±0.3 37.2±1.4 45.4±3.0* 
Rrs (cmH2O · ml
-1
 s
-1
) 1.69±0.29 1.59±0.21 2.41±0.32
†
 
Crs (ml/cmH2O) 0.035±0.005 0.033±0.005 0.028±0.002
†
 
Mean BP (mmHg) 88±14 96±8 79±10 
pO2 (mmHg) - 147±3 108±27
‡
 
pCO2 (mmHg) - 38±1 40±1 
 
Table 3.1.  Physiological parameters in the in vivo VILI model.  Mice were ventilated with low (8-9 
ml/kg) or high VT (36-41 ml/kg) for up to 2 h.  Data shown above is from mice terminated between 1 and 2 
h (2 h ventilation group).  With high VT, increases in PIP and Rrs were observed with decreases in Crs, 
consistent with the formation of pulmonary oedema. This was not observed in the low VT group.  BP and 
blood gases were well maintained throughout both ventilation strategies, with a decline in pO2 towards the 
end of high VT ventilation protocols only.  The high VT group was ventilated using medical air 
supplemented with 4% CO2 to avoid hypocapnia.   Values are means±SD; (-): not done; *P<0.05 vs. 0 h; 
Friedman test with Dunn’s post-hoc analysis; †P<0.05 vs. 0 h; one-way repeated measures ANOVA with 
Bonferroni tests (data are normally distributed, P>0.1; Kolmogorov-Smirnov test with Dallal-Wilkinson-
Lillie); 
‡
P<0.05 vs. 1 h; paired t-tests (data are normally distributed, P>0.1; Kolmogorov-Smirnov test with 
Dallal-Wilkinson-Lillie); n=5-7/each group. 
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Figure 3.1.  Injurious mechanical ventilation produced progressive increases in peak inspiratory 
pressure over 2 h.  Mice were ventilated with low or high VT ventilation for up to 2 h (2 h group data 
shown above).  PIP was monitored in real-time and recorded every 30 min.   Mice ventilated with high VT 
displayed only slight increases in PIP up to 1 h.  This was followed by a progressive increase until 
termination of the protocol at 2 h, indicating severe pulmonary oedema/injury.  Mice receiving low VT 
exhibited no increase in PIP.  *P<0.05 vs. 0 h; Friedman test with Dunn’s post-hoc analysis; means±SD; 
n=7.  
 
High VT ventilation induced small increases in BALF total protein at 0.5 and 1 h 
followed by a clear and large increase at 2 h compared to low VT ventilation (Figure 3.2A, 
P<0.05), consistent with changes in PIP and 2 h wet:dry weight ratios.  As with previous 
models, high VT did not enhance intraalveolar infiltration of neutrophils over this period 
(Figure 3.2B).  ELISA results demonstrated that high VT ventilation increased BALF 
levels of sTNFR p75 slightly at 1 h (P<0.05), with a similar tendency for sTNFR p55, and 
at 2 h induced substantial increases in both sTNFR p75 and p55 levels (P<0.05, Figure 
3.2C & D).  The pattern of increases in sTNFRs appeared to follow the progression of  
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Figure 3.2.  Injurious mechanical ventilation increases BALF levels of both sTNFR p55 and p75.  Mice 
were ventilated with low VT (8-9 ml/kg) or high VT (36-41 ml/kg) ventilation for up to 2 h.  Upon 
termination, BALF was analysed for sTNFRs, total protein and neutrophil infiltration.  (A) High VT 
ventilation produced small marginal increases in BALF total protein at 0.5 and 1 h, followed by a large 
increase at 2 h, indicating progressive formation of pulmonary oedema.  (B) High VT ventilation did not 
produce significant neutrophil infiltration even at 2 h.  (C) High VT ventilation substantially increased BALF 
sTNFR p55 levels at 2 h.  (D) High VT ventilation for 1 h produced a small increase in BALF sTNFR p75 
levels, with a larger increase at 2 h.  Note that increased sTNFR levels were not apparent prior to the 
substantial increase in BALF total protein.  Dashed lines indicate baseline values from non-ventilated mice. 
*P<0.05 High VT vs. Low VT; Mann-Whitney tests; n=4-7/each group. 
 
pulmonary oedema formation, as shown by increases in BALF total protein levels, 
suggesting a common mechanism between increased sTNFR levels and oedema 
formation.  This was confirmed by investigating this relationship further.  Strong 
correlations were found between total protein levels and each sTNFR at 2 h of ventilation 
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(r=0.825 for p55 and 0.762 for p75; P<0.05; n=12; Figure 3.3).  This suggests that leakage 
of sTNFRs from the plasma with oedema fluid was at least partly responsible for increases 
in BALF sTNFRs. 
 
 
Figure 3.3.  BALF sTNFR levels strongly correlated with total protein after 2 h of ventilation.  
Associations between BALF levels of each sTNFR and total protein in the in vivo VILI model were 
evaluated by Spearman’s Rank test using the data from 2 h high and low VT ventilation groups.  (A) Strong 
positive correlations were detected between BALF sTNFR p55 and total protein (r=0.825; P<0.05), (B) and 
between BALF sTNFR p75 and total protein (r=0.762; P<0.05), suggesting leakage from the plasma as the 
mechanism underlying increased BALF sTNFR levels.  Each data point represents one animal; n=12. 
 
 
 
3.4.2 Injurious ventilation in ex vivo buffer-perfused lungs does not increase BALF 
levels of sTNFRs.  
High VT ventilation in vivo increased sTNFR levels in BALF, with strong correlations 
between soluble receptors and total protein, suggesting that sTNFR p55 and p75 share a 
common source with oedema protein, i.e. sTNFR levels partly increase in the alveolar 
space due to leakage from the plasma.  To investigate this possibility, I first established 
baseline levels of plasma sTNFRs.  I found that even under normal conditions there are 
comparatively high levels of circulating sTNFRs, especially for sTNFR p75 (Figure 3.4).  
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Therefore, if the epithelial/endothelial barrier is compromised e.g. during pulmonary 
oedema formation, it is feasible that these receptors could leak into the alveolar space and 
influence intraalveolar levels.  To test this hypothesis, ex vivo high VT VILI experiments 
were performed utilising an IPL system.  In this model, lungs were perfused in a non-
recirculating manner with a buffer devoid of sTNFRs, and ventilated with either low or 
high VT. 
 
Figure 3.4.  Baseline levels of sTNFRs in plasma.  To investigate whether circulating sTNFR levels are 
high enough under normal conditions to significantly influence intraalveolar levels following increased 
alveolar permeability, I investigated plasma sTNFRs levels in untreated mice.  After mice were euthanised 
with anaesthetic overdose, blood was obtained via cardiac puncture.  Samples were centrifuged and plasma 
removed for quantification of sTNFRs by ELISA.  Baseline plasma sTNFR levels were high compared to 
BALF levels.  Therefore leakage from the plasma could be an important source of raised sTNFRs in BALF; 
n=6/each group. 
 
High VT ventilation in the IPL displayed a similar pattern for the development of 
pulmonary oedema to the in vivo high VT experiments, with progressive increases in PIP 
(Table 3.2) and BALF total protein (Figure 3.5A).  However, in contrast to the in vivo  
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 0 h 1 h 2 h 
L
o
w
 V
T
 
PIP (cmH2O) 10.2±0.6 10.5±0.6 10.9±0.6* 
Mean PAP (mmHg) 7±0 7±0 7±0 
pO2 (mmHg) 141±7 - 123±31 
pCO2 (mmHg) 29±4 - 27±3 
H
ig
h
 V
T
 
PIP (cmH2O) 25.0±0.7 28.6±0.2 33.6±0.6* 
Mean PAP (mmHg) 6±1 7±2 5±1* 
pO2 (mmHg) 125±8 - 127±5 
pCO2 (mmHg) 31±2 - 28±1 
 
Table 3.2.  Physiological parameters in the ex vivo IPL VILI model.  Mice were ventilated with low (8-9 
ml/kg) or high VT (20-25 ml/kg) for 2 h.  With high VT, large increases in PIP were observed consistent with 
the formation of pulmonary oedema.  Only a small increase was observed in the low VT group.  Pulmonary 
artery pressure and perfusate gases were consistent throughout protocols, although pulmonary artery 
pressure declined slightly towards the end of high VT experiments.  Values are means±SD; *P<0.05 vs. 0 h; 
Friedman test with Dunn’s post-hoc analysis; (-): not done; n=4/each group. 
 
 
model, ex vivo high VT ventilation did not increase BALF sTNFR levels, as compared to 
low VT ventilation (Figure 3.5B & C), indicating that the presence of sTNFRs in plasma is 
required for increases in BALF sTNFR levels in pure mechanical VILI.  Since I found that 
BALF levels of KC and MIP-2 tended to increase with high VT ventilation (KC: 930±563 
pg/ml vs. 435±288 pg/ml for high VT and low VT, respectively; n=4; MIP-2: 579±216 
pg/ml vs. 364±307 pg/ml for high VT and low VT, respectively; n=4), it was likely that the 
isolated lung preparation was viable and able to produce soluble mediators in response to 
mechanical stretch.  Thus the results support the hypothesis that high VT ventilation 
induced increases in BALF sTNFRs primarily via plasma leakage, and also suggest that 
high VT ventilation per se does not induce substantial production/shedding of sTNFRs 
within the alveolar space. 
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Figure 3.5.  Injurious ventilation in ex vivo isolated buffer-perfused lungs does not increase BALF 
levels of sTNFRs.  The mechanisms underlying increases in BALF sTNFRs during VILI were further 
investigated in an isolated buffer-perfused mouse lung system.  Lungs were perfused with a buffer devoid of 
sTNFRs, and subjected to low VT or high VT ventilation for 2 h.  Upon termination, BALF was analysed for 
sTNFR and total protein levels.  (A) High VT ventilation produced pulmonary oedema as reflected by 
increases in BALF total protein, consistent with the in vivo VILI model (Figure 3.2A).  (B) In contrast to the 
in vivo data, no increase was observed for BALF sTNFR p55.  (C) Similarly, no increases were observed for 
sTNFR p75.  These data support the hypothesis that in pure VILI, plasma leakage is the primary source of 
enhanced BALF sTNFR levels.  Dotted lines indicate respective values from 2 h in vivo VILI experiments 
from Figure 3.2. *P<0.05 High VT vs. Low VT; Mann-Whitney tests; n=4/each group. 
 
 
3.5 Discussion 
ALI/ARDS is a clinical syndrome of multiple aetiologies, characterised by common 
features including pulmonary inflammation, pulmonary oedema, histological evidence of 
tissue injury, abnormal gas exchange and altered lung mechanics.  Despite being caused 
by various insults, if severe, all cases of ALI are managed using mechanical ventilation.  
However, this can cause lung over-distension and contribute to lung injury (VILI). 
Ventilation with injurious high VT promotes an inflammatory milieu within the lungs (20, 
57, 85, 86, 88-90), but it has been shown that this is accompanied by up regulation of anti-
inflammatory mediators, such as sTNFRs and IL-1Ra (20, 113).  Increased BALF sTNFR 
115 
 
levels are associated with poor outcome in ventilated ARDS patients (20), but proper 
interpretation of raised sTNFRs in BALF is difficult because their precise role and sources 
have not been elucidated in this setting.  Using in vivo and ex vivo mouse models of VILI 
induced purely by the use of injurious high VT ventilation, I showed surprisingly that VILI 
induces increases in BALF sTNFR levels predominantly via plasma leakage, with 
negligible intraalveolar sTNFR production. 
High VT ventilation of mice in vivo produced significant increases in BALF levels 
of both sTNFR p55 and p75.  Increased sTNFR p55 and p75 correlated strongly with the 
degree of pulmonary oedema formation, suggesting that the majority of sTNFRs leaked 
from the plasma into the alveolar space with oedema fluid.  This possibility was 
investigated firstly by establishing baseline levels of circulating sTNFRs.  Comparatively 
high concentrations were found in plasma, indicating that it is conceivable that plasma 
leak could have dramatic effects on intraalveolar sTNFR levels if the alveolar barrier is 
significantly compromised.  An ex vivo isolated buffer-perfused lung system was then 
used, where lungs were perfused with a buffer (perfusate) devoid of sTNFRs.  High VT 
ventilation in this ex vivo VILI model produced no significant increases in BALF sTNFR 
levels, compared to low VT ventilation. 
I concluded that passive leakage from the plasma compartment was the primary 
mechanism underlying the increases in BALF sTNFRs during VILI.  This conclusion is 
further supported by the relative levels of sTNFR subtypes in BALF at 2 h.  The level of 
sTNFR p75 is ~3 times that of sTNFR p55 in lavage fluid at this time point, which is 
similar to the TNFR p55:p75 ratio observed in plasma under baseline conditions, 
suggesting a passive leak of plasma receptors into the airspaces. 
Increased intraalveolar sTNFR may have many roles in this setting e.g. prolonging 
the half-life of TNF, facilitating more chronic deleterious intraalveolar TNF signalling or 
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controlled, potentially protective TNF signalling (180, 223, 224) or possible reverse 
signalling through cell-surface TNF (200).  Despite this, a more immediate role of 
increased sTNFRs could be to inhibit TNF signalling.  Plasma leakage of sTNFRs during 
pulmonary oedema formation could explain the previous observation by Wilson et al. who 
found that elevation of intraalveolar TNF is only transiently detected during VILI, before 
the development of pulmonary oedema (88).  Wilson et al. used a TNF neutralisation 
antibody for detection of TNF by ELISA (88) and it is possible that the presence of 
sTNFRs could interfere with this.  Simultaneous inhibition of TNF detection (by ELISA) 
and TNF bioactivity by sTNFRs has previously been described (213).  Therefore, dramatic 
influx of sTNFRs could mask TNF detection, whilst also inhibit any further TNF 
signalling.  However, sTNFR influx from the plasma may not completely abolish 
intraalveolar TNF signalling because Wilson et al. also reported that intraalveolar TNF 
bioactivity was still detectable in the later stages of VILI (88). 
It remains possible that acute VILI induces some small degree of intraalveolar 
production of sTNFRs, by shedding, secretion of receptors, or potentially via cellular 
damage, which cannot be detected due to the presence of oedema fluid/overwhelming 
plasma sTNFR leakage.  However, the results of the ex vivo VILI model do not support 
this.  Injurious mechanical lung stretch did not induce detectable increases in BALF levels 
of either sTNFR subtype when leakage of receptors from plasma was experimentally 
excluded.  Caution is required to extrapolate such ex vivo findings to our in vivo VILI 
model, but the general viability/stability of the IPL preparation was within a reasonable 
range, shown by its capability of replicating the physiological changes of the in vivo VILI 
model as well as producing intraalveolar soluble mediators in response to high VT 
ventilation. 
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Whilst the data indicate that in the acute setting, injurious mechanical ventilation 
does not induce intraalveolar sTNFR production, this may not be true in more chronic 
models.  I did not investigate TNFR mRNA levels in the lung, but TNFR p75 mRNA can 
be up regulated after 1 h (249).  It is therefore important to consider that pulmonary TNFR 
p75 (and possibly p55) mRNA may be increased during VILI, and subsequently contribute 
to increased cell-surface TNFR expression and intraalveolar sTNFR levels in more 
chronic and clinical settings, and these effects are simply not detectable because the 
models are too acute. 
The possibility of leakage of plasma sTNFRs into the alveoli has been suggested in 
ARDS (19), but has never been properly investigated.  Given the development of 
significant pulmonary oedema in ARDS, these data provide strong evidence that this is in 
fact a major mechanism underlying increases in BALF sTNFRs in ventilated ARDS 
patients.  However, in clinical ARDS it is also possible that the presence of underlying 
pathology could also influence BALF sTNFR levels independently from the effects of 
mechanical ventilation and thus complicate extrapolation of this data to the clinical 
setting.  Therefore, my results reflect important aspects of intraalveolar sTNFR regulation, 
but may not reflect the complete picture of sTNFR kinetics in clinical ARDS. 
I have investigated elevation of intraalveolar sTNFRs during VILI, but the 
mechanisms underlying clearance of these receptor fragments from the alveolar space also 
require consideration.  In general, the removal of soluble proteins from the alveolar space 
could involve a number of mechanisms, including: clearance by the mucociliary escalator, 
phagocytosis by macrophages, intraalveolar catabolism, passive diffusion between cells in 
the alveolar barrier (paracellular diffusion to the interstitium/circulation) and endocytic 
transport across epithelial cells via vesicles (transcytosis to the interstitium/circulation) 
(250).  For albumin, low quantities are thought to be cleared via transcytosis, but at high 
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concentrations, such as during pulmonary oedema formation, paracellular pathways are 
thought to be responsible for the vast majority of alveolar clearance (250).  To my 
knowledge, specific clearance of sTNFRs from the alveolar space has not been studied, 
but may involve similar processes.  However, sTNFRs are smaller than albumin 28-42 
kDa (156, 205) vs. ~66 kDa, and therefore could exhibit vastly different clearance 
kinetics. 
Ventilation of ARDS patients with lower VT reduces patient mortality, highlighting 
the significance of VILI in determining clinical outcome.  My in vivo VILI model aims to 
reproduce this in mice, but there are a number of considerations regarding its clinical 
applicability.  The in vivo mouse model of VILI is very acute, using high VT in order to 
cause significant injury after just 2 h of ventilation.  However, whilst the VT required to 
produce the desired result are extreme, they should not be compared to human ventilation 
parameters.  Mouse respiratory system mechanics are vastly different to those of humans.  
Mouse lungs are very compliant, and may not reach a maximal volume even at high lung 
inflation pressures (251).  Therefore, larger VT are required in order to produce a 
comparatively similar injury to that observed clinically in humans.  Moreover, the degree 
of stretch induced in this model may be similar to the regional over-distension experienced 
in clinical ARDS, due to the loss of aerated lung regions, described by the baby lung 
concept (69).  This model also replicates many of the important features of clinical ARDS 
such as decreased lung Crs, and pulmonary oedema development, and a similar model also 
demonstrated hyaline membrane formation and epithelial damage (88).  Furthermore, 
VILI models are arguably among the most clinically relevant ALI models because changes 
in ventilation strategies have so far been the only successful intervention to improve 
ARDS-associated mortality (7, 40). 
Future work could consolidate these findings.  For example, the ex vivo VILI 
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model could be used to confirm the leakage of plasma sTNFRs into the alveolar space. 
TNFR DKO mice show similar lung injury to WT mice following high VT ventilation 
(113), but do not express sTNFRs.  DKO lungs could therefore be perfused with 
recombinant sTNFRs or WT mouse blood during high VT ventilation, and upon 
termination, BALF quantified for sTNFRs.  However, in view of my current data obtained 
using the IPL system, clearly showing that absence of circulating sTNFRs abolishes 
intraalveolar sTNFR up regulation, such experiments may not be essential. 
In conclusion, the current data demonstrates that pulmonary oedema induced by 
injurious ventilation increases both sTNFR p55 and p75 in BALF passively via plasma 
leakage, as opposed to active intraalveolar production.  These data help to elucidate the 
kinetics of intraalveolar sTNFRs in experimental and clinical VILI and offer novel 
insights into the regulation of sTNFRs within the alveolar space during ALI. 
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4.  INTRAALVEOLAR SOLUBLE 
TNFR KINETICS IN ALI 
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Soluble TNFRs are elevated in bronchoalveolar lavage fluid (BALF) from ARDS patients 
ventilated with high VT, but levels are also increased upon the onset of ARDS.  Therefore, 
in addition to the effects of mechanical ventilation, intraalveolar sTNFR levels are 
influenced by the underlying inflammation. 
In this chapter I investigated BALF sTNFR kinetics and sources during ALI 
induced by various insults for comparison and consolidation of VILI data from chapter 3.  
Three in vivo models of ALI were used.  Acid aspiration-induced ALI, using the current 
protocol, produced substantial pulmonary oedema formation and minimal neutrophil 
infiltration into the alveoli, like my in vivo VILI model.  Conversely, ALI induced by i.t. 
bacterial toxins, LPS and lipoteichoic acid (LTA), produced minimal pulmonary oedema 
formation with significant pulmonary inflammation/neutrophilic alveolitis.  This enabled 
investigation of the effects of two hallmarks of ARDS i.e. pulmonary oedema formation 
and neutrophilic alveolitis, on intraalveolar sTNFR levels. 
The data indicate that intraalveolar sTNFR levels are differentially regulated 
during ALI.  Pulmonary oedema formation, observed during acid aspiration-induced ALI 
(and during VILI), produced passive leakage of sTNFR p55 and p75 into the alveolar 
space from the plasma.  Conversely, i.t. bacterial toxin challenge induced selective 
intraalveolar production of sTNFR p75, but not p55, by alveolar macrophages, 
independently of leakage from the plasma. 
These different processes could diversely modulate intraalveolar TNF signalling 
and could potentially be used as markers in the clinical setting since increased levels of 
sTNFR p55 in these models simply reflect the development of pulmonary oedema 
formation, whereas sTNFR p75 could indicate intraalveolar inflammation. 
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4.1 Background 
There is strong evidence that ventilation contributes to increased sTNFR levels in BALF 
and plasma during clinical ARDS (20, 21, 113).  In chapter 3 I found surprisingly that 
sTNFR p55 and p75 were increased in BALF primarily due to leakage from plasma during 
VILI and that VILI does not appear to induce significant intraalveolar production of 
sTNFRs.  However, this may not reflect the complete picture of intraalveolar sTNFR 
regulation in ARDS.  In addition to the effects of mechanical ventilation, BALF levels are 
reported to be increased upon onset of ARDS and are influenced by the underlying disease 
activity (19).  BALF receptor levels may therefore be regulated by other mechanisms in 
addition to mechanical ventilation/plasma leakage.  Moreover, given that ARDS arises 
from a number of diverse aetiologies, these may have different effects on BALF sTNFR 
levels. 
 
4.2 Aims 
I therefore investigated BALF sTNFR levels in different aetiologies of ALI, in an attempt 
to validate my VILI data and compare this with other models.  The in vivo VILI model 
produces significant pulmonary oedema like clinical ARDS, but without the presence of 
neutrophilic alveolitis (an important hallmark of ARDS) at the time points studied.  
Consequently, I used 3 in vivo mouse models of ALI to investigate the effects of 
pulmonary oedema formation and neutrophilic alveolitis separately.  An in vivo mouse 
model of acid aspiration-induced ALI was used to produce substantial pulmonary oedema 
without early neutrophilic alveolitis, similar to my in vivo VILI model, but by a chemical 
rather than mechanical insult to the lungs.  Conversely, in vivo mouse models of 
pulmonary inflammation induced by i.t. LPS or lipoteichoic acid (LTA) were used to 
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model neutrophilic alveolitis in the absence of substantial pulmonary oedema formation.  
This would further contribute to the current understanding of the relevance of increased 
BALF sTNFRs in the pathophysiology of ALI, and significantly increase the clinical 
relevance of this study.  There were 2 main aims: 
1. Investigate the temporal expression (kinetics) of intraalveolar sTNFRs during ALI 
produced by different insults in mice. 
2. Investigate possible sources of increased intraalveolar sTNFRs in different models 
of ALI. 
 
 
4.3 Protocols 
4.3.1 In vivo models of ALI 
4.3.1.1 Acid aspiration-induced lung injury 
Acid aspiration is one of the most clinical relevant in vivo models of ALI current in use 
(40).  This model was used to further consolidate hypotheses generated from the VILI 
models, since it also produces substantial pulmonary oedema, without neutrophilic 
alveolitis in the first 3 h.  Acid aspiration also allows comparison of a sterile chemical 
insult primarily targeting the pulmonary epithelium, with a mixed epithelial/endothelial 
sterile mechanical insult as in VILI. 
Mice were prepared using the in vivo mouse mechanical ventilation system 
described in chapter 2, and following equilibration and baseline measurements, divided 
into 2 groups: 
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 i.t. treatment with 50 µl of 0.15 M hydrochloric acid (pH 1.5) 
 i.t. treatment with 50 µl of saline 
 
Ventilation was maintained with parameters used for animal preparation (low VT of 9 
ml/kg, 2.5 cmH2O PEEP and a respiratory rate of 120 breaths/min, using 100% oxygen to 
avoid hypoxia after instillation).  Both groups were ventilated for 3 h, when acid instilled 
mice exhibited substantial pulmonary oedema.  Airway pressures and BP were recorded 
throughout.  Respiratory system mechanics (Crs and Rrs) were recorded every 30 min. 
 Upon termination, mice were euthanised by anaesthetic overdose and lung lavage 
was performed (chapter 2).  BALF samples were centrifuged and supernatants stored at -
80°C until needed for assays.  Thawed samples were quantified for sTNFR p55 and p75 
by colorimetric sandwich ELISA, and total protein quantified to determine the degree of 
pulmonary oedema formation.  BALF cell pellets were used to assess the degree of 
alveolar neutrophil infiltration by differential cytology. 
 
4.3.1.2 LPS-induced pulmonary inflammation 
For comparison of intraalveolar sTNFR kinetics in VILI and acid aspiration models that 
feature substantial pulmonary oedema but without neutrophilic alveolitis, I first used an in 
vivo mouse model of LPS-induced pulmonary inflammation.  In this model, pulmonary 
oedema is minimal up to 6 h, but neutrophil infiltration into the airspaces takes place 
before this.  The LPS-induced model of pulmonary inflammation involves i.t. LPS 
treatment of anaesthetised, non-ventilated mice.  Mice were prepared for i.t. instillation 
(chapter 2) and divided into 3 groups: 
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 i.t. challenge with low dose LPS (20 ng in 50 µl) 
 i.t. challenge with high dose LPS (20 µg in 50 µl). 
 i.t. saline (50 µl)  
 
All groups were further divided into 2: treatment for 2 h or 6 h, to give a total of 6 groups. 
 Upon termination of experiments, mice were euthanised by anaesthetic overdose 
and lung lavage was performed and BALF samples centrifuged and supernatants stored 
until needed.  Samples were quantified for sTNFR p55 and p75 by ELISA, and total 
protein to determine pulmonary oedema development.  In some mice challenged with 20 
ng LPS for 2 h, MIP-2 was also quantified by ELISA to further confirm acute 
intraalveolar inflammation.  Cell pellets from BALF samples were used to assess the 
degree of alveolar neutrophil infiltration. 
To investigate the contribution of cell-surface TNFR shedding to BALF sTNFR 
levels in LPS-induced pulmonary inflammation, flow cytometry was used to quantify cell-
surface TNFR expression on pulmonary macrophages, obtained by lung lavage and in 
lung single cell suspensions, and pulmonary epithelial cells in animals treated with 20 ng 
LPS for 2 h.  Untreated mice served as controls. 
 
4.3.1.3 In vivo alveolar macrophage depletion 
To study the involvement of alveolar macrophages in intraalveolar sTNFR kinetics during 
acute pulmonary inflammation induced by i.t. LPS challenge, a separate group of mice 
was pre-treated with 50 µl of i.t. clodronate (dichloromethylene bisphosphonate; a gift 
from Roche Diagnostics GmbH, Mannheim, Germany) encapsulated into liposomes, as 
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previously described (252).  Clodronate is a cytotoxic compound that induces apoptosis.  
When encapsulated into liposomes, it is preferentially ingested by phagocytes such as 
alveolar macrophages, and the resulting apoptotic response depletes this cell population.  
In healthy lung airspaces, macrophages are the major phagocytic cell population.  Hence 
i.t. clodronate-liposome treatment produces a selective depletion in alveolar macrophage 
numbers (99).  After 48 h, mice were challenged with 20 ng LPS as described above, and 
euthanised 2 h later.  Mice challenged with 20 ng LPS for 2 h, without macrophage 
depletion, served as controls. 
 Upon termination of experiments, mice were euthanised by anaesthetic overdose 
and lung lavage performed and analysed for sTNFR p55 and p75 by ELISA, and total 
protein.  Lavage cell pellets and lung single cell suspensions were used to quantify 
macrophages by flow cytometry to determine the degree of macrophage depletion (see 
chapter 2). 
 
4.3.1.4 LTA-induced pulmonary inflammation 
As a further model of pulmonary inflammation that produces negligible pulmonary 
oedema with neutrophilic alveolitis, LTA-induced pulmonary inflammation was used.  
This model also allowed comparison between inflammation induced by a gram-positive 
bacterial toxin (LTA) and a gram-negative bacterial toxin (LPS).  Like LPS-induced 
pulmonary inflammation, this model also uses in vivo i.t. administration of anaesthetised, 
non-ventilated mice.  After preparation of animals for i.t. challenge, mice were divided 
into 2 groups: 
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 i.t. challenge with low dose LTA (10 µg in 50 µl) 
 i.t. challenge with high dose LTA (100 µg in 50 µl). 
 
Both groups were further divided into 2: LTA treatment for 2 and 6 h, to give a total of 4 
groups.  Saline challenged mice from the LPS protocol were used as controls. 
 Upon termination of experiments, mice were euthanised and lung lavage was 
performed.  BALF samples were centrifuged and supernatants stored.  Samples were 
quantified for sTNFR p55 and p75, and total protein.  Cell pellets were used to assess the 
degree of alveolar neutrophil infiltration. 
 
4.3.2 Macrophage sTNFR production in vitro 
To determine sTNFR production by alveolar macrophages in response to LPS, primary 
alveolar macrophages were isolated from naïve animals by lung lavage and cultured for 24 
h similar to published methods (241).  Alveolar macrophages were stimulated with saline 
or LPS (100 μg/ml for 2 h) in vitro (chapter 2), and sTNFR production quantified by 
ELISA.  RAW 264.7 cells were also cultured for in vitro stimulation with saline or LPS 
(0.1 µg/ml or 100 μg/ml for 2 h), and their sTNFR production assessed by ELISA. 
 
 
4.4 Results 
4.4.1 Intratracheal acid instillation increases BALF levels of both sTNFRs. 
I previously found that high VT mechanical ventilation induces increases in BALF sTNFR 
levels via leakage of plasma receptors into the alveolar space.  To consolidate this data, I 
studied BALF sTNFRs in an in vivo mouse model of acid aspiration.  This model 
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produces significant pulmonary oedema, but by a chemical, rather than mechanical, insult 
to the alveolar epithelium. 
Compared to saline controls, i.t. acid produced gradual increases in PIP, with 
decreases in Crs over 3 h, indicating pulmonary oedema formation (Table 4.1). 
 
 0 h 1 h 2 h 3 h 
S
a
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n
e 
+
 l
o
w
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T
 
PIP (cmH2O) 14.5±2.7 12.7±1.0* 11.9±0.8* 11.5±1.1* 
Rrs (cmH2O · ml
-1
 s
-1
) 2.18±0.36 1.86±0.31* 1.73±0.32* 1.91±0.27* 
Crs (ml/cmH2O) 0.026±0.006 0.031±0.003* 0.034±0.004* 0.036±0.004* 
Mean BP (mmHg) 97±12 93±11 85±10 78±13* 
pO2 (mmHg) - 435±51 436±55 419±55 
pCO2 (mmHg) - 49±7 44±5
 
 43±4
†
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PIP (cmH2O) 16.1±2.4 16.5±1.8 16.6±1.7 18.0±2.1* 
Rrs (cmH2O · ml
-1
 s
-1
) 2.12±0.29 2.03±0.40 2.05±0.50 2.05±0.59 
Crs (ml/cmH2O) 0.025±0.006 0.022±0.003 0.022±0.003 0.020±0.003* 
Mean BP (mmHg) 109±10 96±10* 85±8* 71±7* 
pO2 (mmHg) - 334±77 282±100 162±57
†
 
pCO2 (mmHg) - 58±8 62±11 72±14
†
 
 
Table 4.1.  Physiological parameters in the acid aspiration-induced ALI model.  Ventilated mice were 
challenged i.t. with hydrochloric acid (50 µl, 0.15 M, pH 1.5) or saline via the endotracheal tube, and 
ventilation maintained with low VT (9 ml/kg) for 3 h.  In the acid group, PIP increased and Crs decreased, 
consistent with pulmonary oedema formation.  In contrast, respiratory mechanics improved over time in 
saline treated animals, suggesting reabsorption of fluid.  BP was maintained within a reasonable range in 
both groups.  The acid group showed a decrease in pO2 and increase in pCO2 at 3 h, while the saline group 
displayed an improvement in pCO2.  Values are means±SD; (-): not done; *P<0.05 vs. 0 h (immediately 
after instillation of acid or saline); one-way repeated measures ANOVA with Bonferroni tests (data are 
normally distributed, P>0.1; Kolmogorov-Smirnov test with Dallal-Wilkinson-Lillie); 
†
P<0.05 vs. 1 h; 
Friedman test with Dunn’s post-hoc analysis; n=6-14/each group. 
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Acid instillation induced an increase in BALF total protein at 3 h, consistent with 
increases in PIP, indicating the formation of pulmonary oedema (Figure 4.1A), but did not 
produce significant neutrophil infiltration into the alveolar space (Figure 4.1B).  BALF 
levels of both sTNFR p55 and p75 substantially increased 3 h after acid instillation 
(Figure 4.1C & D; P<0.05).  As in the in vivo VILI model, the levels of both receptors 
correlated strongly with BALF total protein (r=0.869 for p55, n=14; r=0.903 for p75, 
n=12; P<0.0001, Figure 4.2).  This suggests that increases in BALF sTNFRs following i.t. 
acid instillation, another form of ALI that like VILI produces significant pulmonary 
oedema, are also primarily due to leakage from the plasma into the alveolar space with 
oedema fluid. 
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Figure 4.1.  Acid instillation produced increases in both BALF sTNFR p55 and p75.  Ventilated mice 
were treated with i.t. hydrochloric acid in a 50 µl saline bolus delivered via the endotracheal tube and 
ventilation maintained with low VT (9 ml/kg) for 3 h.  Saline instillation served as a control. Upon 
termination, BALF was analysed for sTNFRs, total protein and neutrophil infiltration.  (A) Acid instillation 
produced significant pulmonary oedema after 3 h, as shown by increased BALF total protein.  (B) No 
significant neutrophil infiltration was observed at 3 h. (C) Acid instillation substantially increased BALF 
sTNFR p55 levels at 3 h.  (D) Similarly, acid instillation increased BALF sTNFR p75.  As in the in vivo 
VILI model in chapter 3, increased sTNFR levels followed a similar pattern to pulmonary oedema 
development.  Dashed lines indicate baseline values from non-treated mice.  *P<0.05 Acid vs. Saline; t-tests 
(data are normally distributed, P>0.1; Kolmogorov-Smirnov test with Dallal-Wilkinson-Lillie); n=5-10/each 
group. 
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Figure 4.2.  BALF sTNFR levels strongly correlated with total protein 3 h following intratracheal 
instillation of acid or saline.  Associations between BALF levels of each sTNFR and total protein in the 
acid aspiration model were evaluated by Pearson’s correlation analysis (data are normally distributed, P>0.1; 
Kolmogorov-Smirnov test with Dallal-Wilkinson-Lillie).  (A) Strong positive correlations were detected 
between BALF sTNFR p55 and total protein (r=0.869; P<0.0001), (B) and between BALF sTNFR p75 and 
total protein (r=0.903; P<0.0001).  These data suggest that pulmonary oedema induced by i.t. acid produces 
leakage of plasma sTNFRs into the alveoli, in a similar manner to in vivo high VT ventilation.   Each data 
point represents one animal; n=12/14. 
 
4.4.2 Intratracheal LPS increases BALF levels of sTNFR p75, but not p55.   
Acid aspiration-induced ALI produced considerable increases in BALF sTNFR levels that 
correlated with pulmonary oedema formation, suggesting that like the in vivo VILI model 
in chapter 3, plasma leakage is the predominant underlying mechanism.  However, neither 
model exhibits neutrophilic alveolitis, a common feature of clinical ARDS that may 
independently influence intraalveolar sTNFR levels.  I therefore investigated BALF 
sTNFRs in an in vivo mouse model of ALI induced by i.t. LPS.  This model produces 
substantial neutrophilic inflammation, but in the absence of pulmonary oedema, ruling out 
leakage of plasma sTNFRs into the alveolar space and allowing identification of other 
mechanisms that could contribute to increased intraalveolar sTNFR levels, such as 
intraalveolar sTNFR production.  Mice received i.t. instillation of either 20 ng or 20 µg of 
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LPS, or saline as a control and were terminated after 2 or 6 h.  These time points were 
chosen to study BALF sTNFR levels before and after neutrophil infiltration to investigate 
their contribution to soluble receptor levels.  Mice challenged with 20 ng LPS showed no 
signs of morbidity, while with 20 µg LPS they exhibited reduced mobility, hunching and 
piloerection. 
LPS challenge did not induce substantial pulmonary oedema at either 2 or 6 h, as 
measured by BALF total protein (Figure 4.3A).  A small, but statistically significant 
increase was observed in mice exposed to 20 µg LPS for 6 h, but levels were still very low 
(~0.2 mg/ml) compared to the high BALF protein levels (>2 mg/ml) observed in the VILI 
or acid aspiration models.  This model also has a comparatively large inflammatory 
component compared to VILI (BALF MIP-2: 2719446 pg/ml at 2 h after 20 ng i.t. LPS; 
n=7; vs. 20-100 pg/ml a similar VILI model to the one used in chapter 3 (88, 113)).  LPS 
induced intraalveolar neutrophil infiltration at 6 h, but not at 2 h (Figure 4.3B).  I found no 
increase in BALF levels of sTNFR p55 following LPS challenge at both doses and time 
points (Figure 4.3C), suggesting that production of this receptor subtype is negligible in 
the alveolar space.  In contrast, sTNFR p75 was markedly up regulated 2 h after challenge 
with 20 ng LPS, compared with saline controls (Figure 4.3D, P<0.05), indicating potential 
intraalveolar sTNFR p75 production.  Use of a higher dose (20 µg) and longer duration (6 
h) produced slightly larger but similar responses, suggesting that a near maximal p75 
response was rapidly achieved even with a subclinical LPS dose (20 ng).  Moreover, p75 
was elevated to a similar degree before and after neutrophil infiltration.  These data 
indicate that i.t. LPS challenge induces intraalveolar production of sTNFR p75, but not 
p55, independently of pulmonary oedema formation. 
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Figure 4.3.  Intratracheal LPS increased BALF levels of sTNFR p75, but not p55.  Mice were 
challenged i.t. with 20 ng or 20 µg of LPS in a 50 µl saline bolus.  Saline alone was used as a control.  After 
2 or 6 h, BALF was analysed for sTNFRs, total protein and neutrophil infiltration.  (A) LPS-challenged 
animals exhibited minimal increases in BALF total protein, except one group of mice (20 µg LPS, 6 h), 
which showed a small increase.  However, compared to the large increases seen in the VILI or acid 
aspiration models (see Figures 3.2B & 4.1B), this marginal increase is unlikely to be physiologically 
significant.  (B) Neutrophil numbers in BALF showed significant increases at 6 h.  (C) BALF sTNFR p55 
levels did not increase in any group.  (D) In contrast, BALF sTNFR p75 levels substantially increased in all 
groups, suggesting intraalveolar production of this receptor.  Dashed lines indicate baseline values from non-
treated mice. *P<0.05 vs. Saline; Kruskal-Wallis test with Dunn’s post-hoc analysis; n=4-6/each group. 
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4.4.3 Alveolar macrophage depletion attenuates LPS-induced sTNFR p75 increases in 
BALF.  
The LPS-induced pulmonary inflammation model suggests that sTNFR p75 can be 
produced in the alveolar space in response to i.t. LPS challenge.  However, the cellular 
source is not known.  Alveolar macrophages are potential producers of sTNFR p75 in the 
alveolar space, because monocytes/macrophages express high levels of TNFR p75 (150).  
Furthermore, sTNFR p75 levels were increased before significant neutrophil infiltration, 
suggesting that infiltration by these cells is not required for intraalveolar p75 production.  
To evaluate the contribution of alveolar macrophages to LPS-induced intraalveolar sTNFR 
p75 production, I depleted alveolar macrophages by pre-treatment with i.t. clodronate-
liposomes 48 h prior to LPS challenge. 
Consistent with the literature, flow cytometry of BALF and lung tissue cell 
samples demonstrated that pre-treatment with i.t. clodronate-liposomes produced 70-80% 
depletion of alveolar macrophage numbers (Figure 4.4A) (99).  Clodronate-liposome pre-
treatment significantly attenuated LPS-induced sTNFR p75 production by ~65% (P<0.05), 
implicating a major role for alveolar macrophages in intraalveolar sTNFR p75 production 
in this model (Figure 4.4B).  
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Figure 4.4.  Alveolar macrophage depletion attenuated LPS-induced sTNFR p75 increases in BALF. 
Mice were treated i.t. with a 50 µl bolus of clodronate-liposomes, and after 48 h were challenged i.t. with 20 
ng LPS for 2 h.  BALF and lungs were analysed by flow cytometry to assess the degree of macrophage 
depletion.  Alveolar macrophages were identified as CD11b
+
, F4/80
+
 events, confirmed with CD11c
+
 
staining (Figure 2.4).  (A) Mice pre-treated with clodronate-liposomes (Clod+LPS) produced ~70% 
depletion of macrophage numbers in BALF and ~80% depletion in lung suspensions, compared to non-pre-
treated, LPS challenged mice (LPS).  (B) Alveolar macrophage depletion significantly attenuated LPS-
induced sTNFR p75 production in BALF by ~65%, with no effect on p55. *P<0.05 Clod+LPS vs. LPS; 
Mann-Whitney tests; LPS sTNFR data same as Figure 4.3, dotted line indicates saline data from Figure 4.3; 
n=4-7/each group. 
 
4.4.4 Alveolar macrophages and RAW 264.7 cells produce sTNFRs upon LPS 
stimulation. 
In response to i.t. LPS, alveolar macrophages could directly produce sTNFRs by shedding 
or induce shedding from other cell types.  To investigate whether alveolar macrophages 
were directly shedding cell-surface TNFR p75 in response to LPS in vivo, flow cytometry 
was used to quantify cell-surface TNFR expression on macrophages obtained by lavage, 
and in lung single cell suspensions, from LPS treated mice (20 ng, 2 h).  Pulmonary 
epithelial TNFR expression was also investigated.  Untreated mice served as controls, 
since saline treated mice showed no discernable elevation of BALF sTNFR levels.  
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Identification of macrophages and epithelial cells was achieved using a variety of antigens 
(Figures 2.4 and 2.5). 
Cell-surface expression of TNFR p55 on pulmonary epithelial cells was not altered 
by LPS challenge (data not shown) and at baseline these cells have much lower TNFR p75 
expression than macrophages (Figure 2.8), suggesting against the pulmonary epithelium as 
major source of intraalveolar sTNFR p75 production.  Unexpectedly, expression of both 
TNFR p55 and p75 was reduced in both groups of macrophages following LPS challenge 
(Figure 4.5).  The current flow cytometry protocol cannot differentiate between the 
processes of receptor shedding and internalisation and because sTNFR p55 production 
was not observed in this model, this could reflect internalisation of receptor p55 and 
shedding of p75, since p75 exhibits a greater propensity to be shed (130, 150, 156, 158, 
183) and p55 to be internalised (156, 158, 159).  This would be consistent with selective 
intraalveolar production of sTNFR p75.  However, this could also reflect an artifact of the 
tissue processing procedure, caused by removal of macrophages from their native 
environment.  The alveolar space contains macrophage regulatory molecules (46), the 
absence of which could produce cell activation and non-specific TNFR shedding.  
Furthermore, mechanical disruption of tissue to create single cell suspensions could also 
produce non-specific receptor shedding, particularly since cell-surface TNFRs appear to 
be extremely labile antigens. 
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Figure 4.5.  Intratracheal LPS decreased TNFR expression on macrophages.  Mice were challenged i.t. 
with 20 ng LPS in a 50 µl saline bolus.  After 2 h, BALF was performed for recovery of alveolar 
macrophages and lungs were harvested and processed into single cell suspensions and quantified for cell-
surface TNFR expression by flow cytometry.   Untreated mice served as controls.  Macrophages were 
identified as described in Figures 2.4 and 2.5.  (A) LPS produced decreases in TNFR expression on 
macrophages obtained via lung lavage compared to those from untreated mice, although this was not quite 
statistically significant for p75 (P=0.057), due to the low number of observations.  (B) Residual lung 
macrophages in single cell suspensions after lavage also displayed a similar trend for reduced TNFRs, which 
was approaching statistical significance for p75 (P=0.057), but not for p55, again most likely due to the low 
number of observations. *P<0.05 vs. Untreated; Mann-Whitney tests; n=4-5/each group. 
 
 
For example, Table 4.2 demonstrates a significant loss of TNFR expression from alveolar 
macrophages even in the absence of any exogenous stimulation, consistent with 
constitutive shedding.  I therefore speculate that the observed decreases in TNFR 
expression on these cells are mainly due to artifacts of tissue processing.  
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Treatment Condition TNFR p55 expression (MFI) TNFR p75 expression (MFI) 
Saline On ice 80.8 247.5 
Saline 37°C 41.7 82.3 
LPS 37°C 51.4 61.4 
 
Table 4.2.  Alveolar macrophage TNFR shedding is extremely sensitive to temperature.  Saline lavage 
was performed for recovery of alveolar macrophages and divided into 3 samples.  One sample was treated 
with saline and placed on ice for 15 min.  Another was also treated with saline but incubated at 37°C for 15 
min.  The third sample was treated with 100 µg/ml LPS and incubated at 37°C for 15 min.  Cells were then 
recovered and cell-surface TNFR expression quantified by flow cytometry.  It is clear from the table that a 
large proportion of cell-surface TNFR expression is lost due to the higher physiological temperature.  
Interestingly, LPS decreased TNFR p75 expression further at 37°C, but not p55 expression.  n=1/each group. 
 
I therefore attempted to investigate direct sTNFR production, as opposed to cell-surface 
expression changes, by cultured primary alveolar macrophages in vitro. 
Alveolar macrophages were isolated from naïve mice and cultured for 24 h.  Media 
was replaced to remove background sTNFR levels produced by constitutive receptor 
shedding.  This was followed by stimulation with LPS (100 μg/ml) or saline.  After 2 h, 
supernatants were taken for quantification of sTNFR p55 and p75 by ELISA. 
Due to the low numbers of alveolar macrophages obtained, sTNFR levels were 
barely detectable.  Soluble p55 levels were at or below the detection threshold for the 
ELISA (<5 pg/ml) (Figure 4.6).  Moreover, sTNFR p75 levels were also potentially too 
low for reliable detection in saline treated cultures.  In LPS treated cultures, p75 levels 
were slightly increased and within reliable detection limits, although this was not 
statistically significant. 
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Figure 4.6.  LPS stimulation induced sTNFR p75 production from primary alveolar macrophages.  
Lavage was performed for recovery of alveolar macrophages, which were then cultured in RPMI 1640 for 
24 h.  Media was then replaced with fresh pre-equilibrated media and cells stimulated with LPS (100 μg/ml) 
or saline.  Supernatants were sampled 2 h later and sTNFR p55 and p75 levels quantified by ELISA.  (A) 
LPS produced minimal increases in sTNFR p55, with levels at or below the detection threshold.  (B) LPS 
stimulation increased supernatant levels of sTNFR p75, although this was not statistically significant. 
n=4/each group. 
 
Isolation of alveolar macrophages by saline lavage did not obtain sufficiently high 
numbers of cells for culture/stimulation.  I consequently investigated whether RAW 264.7 
cells (a mouse peritoneal macrophage cell line) would preferentially produce sTNFR p75 
in response to LPS. 
RAW cells were cultured in RPMI 1640 until confluent, media replaced and cells 
stimulated with LPS (0.1 µg/ml or 100 μg/ml) or saline for 2 h.  Supernatants were then 
sampled for quantification of sTNFR p55 and p75 by ELISA. 
RAW cell culture supernatant sTNFR p55 levels were increased following 
stimulation with 0.1 µg/ml and 100 µg/ml LPS, but this was not statistically significant, 
likely due to the low number of observations (Figure 4.7A).  Stimulation of RAW cells 
with 0.1 µg/ml of LPS produced an increase in supernatant sTNFR p75 levels, but this was 
also not significantly different (Figure 4.7B).  However, supernatant sTNFR p75 levels 
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were significantly increased following stimulation with 100 µg/ml LPS (Figure 4.7B; 
P<0.05).  This suggests that sTNFR p75 can be preferentially produced by macrophages in 
response to LPS stimulation consistent with other studies (149, 241).  However, RAW 
cells are a peritoneal macrophage cell line and thus caution should be exercised when 
extrapolating these data to the alveolar space.  Furthermore, in the alveolar space there are 
important inhibitory molecules not present in vitro that influence macrophage activation 
(46). 
 
Figure 4.7.  LPS stimulation increased sTNFR p55 and p75 release from RAW 264.7 cells after 2 h.  
RAW 264.7 cells were cultured in RPMI 1640.  Media was replaced with fresh pre-equilibrated media.  
Cells were stimulated with 0.1 µg/ml or 100 µg/ml LPS for 2 h and supernatants collected and quantified for 
sTNFRs by ELISA. (A) sTNFR p55 was increased following stimulation with both LPS doses, although 
neither was statistically significant.  (B) However, sTNFR p75 was significantly increased in supernatants 
by 100 µg/ml LPS treatment, with a similar trend with 0.1 µg/ml LPS.  *P<0.05 vs. Saline; Kruskal-Wallis 
test with Dunn’s post-hoc analysis; n=4/each group. 
 
4.4.5 Intratracheal LTA also increases BALF levels of sTNFR p75, but not p55.   
To investigate whether intraalveolar production of sTNFR p75 is specific to gram-
negative bacterial toxin challenges that stimulate toll-like receptor (TLR)-4 pathways (as 
with LPS) or was a more general manifestation of pulmonary inflammation in the absence 
of pulmonary oedema, I studied a model of ALI induced by i.t. LTA, a gram-positive 
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bacterial toxin that stimulates TLR-2.  Mice challenged with LTA exhibited slightly 
different clinical signs from LPS, with hunching between 3–5 h after challenge with both 
doses, appearing normal after this time. 
 LTA-challenged mice displayed very similar responses to LPS-challenged mice: 
LTA induced a minimal pulmonary vascular leak, with considerable intraalveolar 
neutrophil infiltration, albeit smaller than that observed with LPS and not statistically 
significant because of low observation numbers (Figure 4.8A & B).  Importantly, LTA 
induced large increases in BALF levels of sTNFR p75 at both doses and time points, 
although this was only statistically significant for 100 µg LTA at 6 h (Figure 4.8D), again 
suggesting intraalveolar production with a maximal response.  However, there were no 
increases in BALF sTNFR p55 levels (Figure 4.8C).  Thus, preferential intraalveolar 
production of sTNFR p75 is not specific to TLR4-mediated inflammation, but more likely 
to be a generalised inflammatory response following exposure to intraalveolar bacterial 
toxins.   
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Figure 4.8.  Intratracheal LTA increased BALF levels of sTNFR p75, but not p55. Mice were 
challenged i.t. with 10 µg or 100 µg of LTA in a 50 µl saline bolus.  Mice treated with saline served as 
controls (from LPS experiments).  After 2 or 6 h, BALF was analysed for sTNFRs, total protein and 
neutrophil infiltration.  (A) LTA challenge produced minimal increases in BALF total protein (minimal 
pulmonary oedema).  (B) Alveolar neutrophil infiltration was only observed after 6 h with 100 µg, although 
this was not statistically significant.  (C) LTA induced no increases in sTNFR p55.  (D) Substantial increases 
in sTNFR p75 were apparent in all groups, but was only statistically significant for mice challenged with 
100 µg LTA for 6 h.  The data indicate that intraalveolar sTNFR p75 production was induced by i.t. LTA, 
similar to i.t. LPS.  Dashed lines indicate baseline values from non-treated animals. *P<0.05 vs. Saline; 
Kruskal-Wallis test with Dunn’s post-hoc analysis; n=4/each group. 
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4.5 Discussion 
In ARDS, sTNFRs are elevated in BALF (19), and levels are also increased when patients 
are ventilated with higher VT (20).  Similarly, high VT ventilation produces increases in 
BALF sTNFR levels in mice (113).  Data from chapter 3 suggest that this is 
predominantly due to passive leakage of receptors from the circulation that occurs during 
pulmonary oedema formation, as opposed to active intraalveolar sTNFR production.  
However, this may be rather different from the clinical situation where there is also an 
underlying disease process. 
ALI/ARDS can be precipitated by a number of diverse insults, which contributes 
to its complexity.  Accordingly, it is not possible for any single animal model to simulate 
all the pathophysiological features of ALI (40).  Analyses integrating findings from 
various animal models, each of which reflects certain aspects of the diverse disease 
process, is therefore essential to obtain insights into the pathophysiology of ALI.  I 
consequently investigated the kinetics and sources of BALF sTNFRs in 3 different in vivo 
models of ALI to study the individual effects of 2 hallmarks of ARDS, i.e. pulmonary 
oedema and neutrophilic alveolitis. 
Acid aspiration-induced ALI was used to consolidate my in vivo VILI data, as this 
model also produces substantial pulmonary oedema formation, without neutrophilic 
alveolitis.  Pulmonary inflammation induced by i.t. LPS or LTA was used to investigate 
BALF sTNFR levels during neutrophilic alveolitis in the absence of significant pulmonary 
oedema formation.  The results demonstrated for the first time that acid aspiration, which 
like VILI features substantial pulmonary oedema formation, produced increases in BALF 
levels of both sTNFR p55 and p75, most likely via plasma leakage.  Conversely, 
intraalveolar inflammation induced by LPS/LTA resulted in alveolar macrophage-
mediated production of sTNFR p75 within the alveolar space in the absence of pulmonary 
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oedema. 
 
4.5.1 Intraalveolar sTNFR kinetics during acid aspiration-induced ALI 
The acid-induced ALI model showed substantial pulmonary oedema development after 3 
h.  This was accompanied by significant increases in BALF levels of sTNFR p55 and p75.  
Importantly, sTNFR levels strongly correlated with BALF total protein, much like the in 
vivo VILI model.  I therefore speculate that like VILI, leakage from the plasma 
compartment is the primary mechanism underlying the increases in BALF sTNFRs during 
acid aspiration.  Combined with the in vivo VILI data from chapter 3, it appears that 
BALF sTNFRs are increased whenever there is significant pulmonary oedema formation 
(provided plasma levels are sufficiently high).  Therefore, this model provides further 
evidence that plasma leakage is a major mechanism underlying elevated BALF sTNFR 
levels during ARDS. 
It was not practically feasible to study acid aspiration in the IPL to investigate 
intraalveolar sTNFR production and it is possible that acid aspiration-induced ALI may 
induce a small degree of intraalveolar production of sTNFRs that is masked by the 
development of substantial pulmonary oedema and sTNFR influx.  This is especially 
relevant to sTNFR p75 production, since alveolar macrophage activation and TLR-4 
signalling has been implicated in acid aspiration (232, 253) as well as mechanical 
ventilation (99, 100, 254, 255).  However, the current data suggest that i.t. acid and VILI 
are weak stimulators of alveolar macrophages with respect to sTNFR p75 
shedding/production, compared to i.t. bacterial toxin challenge. 
As with my VILI models, TNFR mRNA and cell-surface TNFRs were not studied 
during acid aspiration.  Both could be up regulated during aspiration-induced lung injury 
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and potentially have important influences on intraalveolar sTNFR levels in the long-term.  
However, in this acute model, these processes are unlikely to have any important 
influence.  
The in vivo acid aspiration model produces a clinically relevant model of aspiration 
of gastric contents, but also has some limitations.  Hydrochloric acid is the only 
constituent of the aspirate and is used at a very low pH.  This is different from the clinical 
scenario, where particulate matter and other immunogenic substances are present in a less 
acidic aspirate (40).  Despite this, acid aspiration models remain among the most clinically 
applicable models of ALI current in use, reproducing many of the features of clinical 
ARDS (40).  Moreover, this model was specifically used to reproduce one of the major 
hallmarks of ARDS, pulmonary oedema formation, and due to the timing of the model, 
without significant neutrophilic alveolitis. 
 
4.5.2 Intraalveolar sTNFR kinetics during bacterial toxin-induced pulmonary 
inflammation 
In contrast to acid aspiration (and VILI), in vivo models simulating intraalveolar 
neutrophilic inflammation induced by gram-negative (LPS) or gram-positive (LTA) 
bacterial toxin stimulation of TLRs, did not show a strong oedema component.  From 
observations in in vivo VILI and acid aspiration models, if the mechanisms governing 
intraalveolar sTNFR levels in LPS/LTA-induced pulmonary inflammation were the same, 
it would be anticipated that there would be negligible increases in BALF sTNFR levels.  
However, both LPS and LTA models exhibited a specific increase in BALF sTNFR p75, 
but not in p55, at 2 and 6 h after toxin challenge.  As both models produce minimal 
pulmonary oedema, increased BALF sTNFR p75 should have been produced by cells 
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within the alveolar space.  Infiltrating neutrophils were an unlikely source, in the light of 
the finding that sTNFR p75 levels were considerably increased prior to neutrophil 
infiltration and similar levels were observed after the appearance of neutrophils in the 
alveolar space, despite reports that neutrophils can produce sTNFRs (147, 156, 207, 209, 
248).  Alveolar macrophages were an obvious potential source and the substantial 
attenuation of LPS-induced increases in BALF sTNFR p75 by alveolar macrophage 
depletion provides further evidence for this.  It is worth noting that clodronate-liposome 
pre-treatment can result in the attenuation of pulmonary oedema formation (99) and hence 
plasma leakage, but since this is already minimal in this model, it is unlikely this 
contributes to the observed reduction in BALF sTNFR p75 levels. 
Macrophages could directly release sTNFR p75 into the alveolar space by 
shedding of cell-surface receptors in response to stimuli, or by secretion of stored (165) or 
de novo synthesised receptors.  It has been shown that both cell-surface and soluble p75 
and TNFR p75 mRNA can be increased simultaneously from/on cultured monocytes in 
response to IL-10 or LPS, suggesting transcriptional control of increased sTNFR p75 
levels (150).  However, this was over a much longer duration (for at least 17 h) and may 
be very different from the sTNFR increases observed as early as 2 h in the LPS/LTA 
models.  These rapid increases suggest that receptor shedding is far more likely than de 
novo production/control at the transcriptional/translational level.  Furthermore, secretion 
of sTNFRs in vesicles has only been shown for constitutive soluble p55 production and 
not for induced sTNFR p55 or p75 production (165, 166).  Expression of both TNFR p55 
and p75 on alveolar macrophages decreased following i.t. LPS challenge in vivo, but the 
likely explanation for this is a non-specific effect of tissue processing due to the fragile 
nature of macrophage TNFR expression. 
RAW 264.7 cells (and also primary alveolar macrophages) produced greater 
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quantities of sTNFR p75 compared to TNFR p55 in response to LPS.  The production of 
p55 by RAW cells is contrary to the observed specific increase in BALF sTNFR p75 in 
response to i.t. LPS/LTA in vivo, but similar data have previously been reported for RAW 
cells and primary human alveolar macrophages in vitro (149, 241).  However, production 
of sTNFR p55 may not reflect the response of alveolar macrophages to LPS in situ.  Cells 
are cultured in the absence of their native environment that may contain important 
inhibitory molecules such as surfactant proteins A and D in epithelial lining fluid and 
CD200, TGF, IL-10 and MUC1 on the pulmonary epithelium that exert 
immunosuppressive effects on alveolar macrophages and regulate LPS-TLR-4 activation 
(46).  Thus, caution is advised when extrapolating such in vitro data to the in vivo setting.  
Furthermore, RAW cells are transformed and such cells generally have a greater tendency 
to release soluble receptors than normal cells (216).  Despite this, sTNFR p75 was 
preferentially produced by macrophages upon stimulation with LPS in vitro, implicating 
them as a likely source of increased intraalveolar sTNFR p75 in vivo. 
From my data alveolar macrophages express higher levels of TNFR p75 than 
pulmonary epithelial cells (Figure 2.8).  Moreover, from the literature, pulmonary 
epithelial cell expression and shedding of p75 is inconsistent (21, 124, 161, 168, 183), and 
my flow cytometry indicated that pulmonary epithelial cells exhibited no changes in 
expression either receptor following i.t. LPS challenge.  I therefore speculate that alveolar 
macrophages are the primary source for intraalveolar production of sTNFR p75 during 
ALI induced by i.t. bacterial toxins. 
In contrast to the current data, it has also been reported that pulmonary epithelial 
cells release sTNFR p55.  A549 cells can release sTNFR p55 in response to pro-
inflammatory cytokines or PMA (21, 161), and human small airway epithelial cells 
produce sTNFR p55 in response to IL-1 (166).  Again, such in vitro studies may be 
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subject to significant artifacts, relating to the use of cell-lines, and/or the absence of 
important inhibitory molecules that would normally be present in vivo.   
Some in vivo studies have reported sTNFR p55 production in the alveolar space.  
For example, Pryhuber et al. suggested that in mice the lung airway parenchyma may 
produce sTNFR p55 during Pneumocystis carinii pneumonia (210).  However, substantial 
pulmonary oedema induced in this experimental model would not rule out plasma leakage 
as a source of soluble p55 in BALF.  Similarly, it has been suggested that i.t. LPS induces 
intraalveolar sTNFR p55 and p75 production in mice (256).  However, this study used two 
challenges, either PBS or LPS, 48 h apart, followed by another 4 h prior to sampling.  
Since permeability changes may occur at later time points (49, 51), plasma leakage of 
sTNFRs could occur.  Therefore, the authors cannot conclude that elevated BALF 
sTNFRs were the result of LPS-induced intraalveolar production, because this requires the 
use of time points where there is minimal dysfunction of the alveolar barrier.  Incidentally, 
in this study, BALF soluble p75 levels were 10-fold higher than p55.  If this were solely 
due to plasma leakage p75, levels would only be expected to be 3-fold higher than p55, as 
in the circulation at baseline (from my data).  Interpretation of this study with my findings 
suggests that the increased p75:p55 ratio reflects the combined effects of intraalveolar p75 
production and plasma leakage.  It has also been reported that i.t. administration of LPS, 
but not LTA to human volunteers marginally increased sTNFR p55 in the alveolar space 
after 6 h, but this study could not exclude alveolar barrier dysfunction (257). 
In less acute settings, there is evidence that cell-surface TNFR expression and 
sTNFR release are under transcriptional/translational control (150), and TNFR p75 mRNA 
can be induced at early time points (249).  TNFR p75 mRNA could be induced during the 
i.t. LPS/LTA models, and contribute to increased sTNFR p75.  The data suggest against 
this, because similar levels of sTNFR p75 were observed at 2 and 6 h.  However, over 
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longer durations, such as during clinical ALI, transcription of TNFR p75 may be 
important.  It therefore cannot be ruled out that a similar mechanism may produce 
increased intraalveolar levels of sTNFR p55 at later time points.  Whilst bacterial toxins 
may initiate induction of the TNFR genes, shedding of sTNFRs can occur extremely 
rapidly, as early 15 min (147), and it is therefore the most likely mechanism of increased 
BALF p75 levels following i.t. bacterial toxin challenge. 
My models of pulmonary inflammation induced by i.t. administration of LPS/LTA 
produce considerable intraalveolar inflammation.  Their closest clinical comparison is the 
inflammation induced by gram-negative and gram-positive pneumonia, for LPS and LTA 
respectively.  These models are arguably further removed from the clinical situation than 
the other models of ALI, because no significant lung injury develops, but this aspect 
enabled intraalveolar sTNFR kinetics to be studied during inflammation without the 
presence of significant plasma leak at the time points studied. 
 
4.5.3 Interpretation 
Data from the various models used in the current study indicate that sTNFR p55 and p75 
levels are differentially regulated in the alveolar space during ALI.  It could be argued that 
some differential regulation of sTNFR levels should be expected, due to the greater 
tendency of TNFR p75 expression to be induced (144, 150, 183, 189) and also to be shed 
(130, 150, 156, 158, 183) and differential intraalveolar elevation of sTNFRs i.e. specific 
up regulation of p75, has been reported in more chronic pulmonary inflammation, such as 
in sarcoidosis (212), although this is contentious (211).  Despite this, differential 
regulation of intraalveolar sTNFRs has not previously been reported in ALI and 
specifically associated with different pathophysiological features. 
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Intraalveolar p75 production is likely a generalised response to immune activation, 
as in addition to LPS, other inflammatory stimuli such as TNF, IL-1, IL-10, C5a and 
PMA can induce release of sTNFR p75 (129, 146, 150, 156, 183, 209) and preferential 
increase in p75 has been suggested as a marker of immune activation (180).  Increased 
intraalveolar production of sTNFR p75 could inhibit intraalveolar TNF signalling in the 
alveolar space, but potentially promote chronic TNF signalling by prolonging its half-life 
(223) or even induce reverse signalling (200).  Selective intraalveolar sTNFR p75 
production, if via cell-surface receptor shedding, could also drastically alter the ratio of 
p55:p75 on the surface of cells and may direct TNF signalling through p55.  TNFR p55 
plays a deleterious role during the development of pulmonary oedema formation during 
VILI in vivo, with p75 protecting against this.  Therefore, shedding of the protective p75 
receptor following LPS/LTA challenge may thus explain how bacteria/bacterial products 
sensitise the lung to the deleterious effects of mechanical ventilation (59, 104, 258). 
Like the in vivo VILI model, none of these models induced detectable intraalveolar 
production of sTNFR p55, suggesting that increased intraalveolar sTNFR p55 may simply 
reflect pulmonary oedema in ARDS.  The data of the present study do not completely 
exclude production by intraalveolar cells as a source of basal sTNFR p55, but given the 
vastly different stimuli used and the physiologically relevant nature of these models, I 
speculate that production/shedding of sTNFR p55 is not effectively increased within the 
alveolar space in vivo, and that increases in its levels mainly reflect the degree of 
pulmonary oedema during ALI. 
I have not investigated the clearance of intraalveolar sTNFRs in these models of 
ALI.  To my knowledge this has not been studied previously, but could potentially involve 
a number of mechanisms know to be present for other intraalveolar soluble proteins. 
Future work should include validation/exploration of these speculations in ALI 
151 
 
patients.  The reliability of increased sTNFR p55 as a marker of pulmonary oedema 
formation could be investigated by studying BALF p55 from healthy volunteers and 
patients with different severity/aetiologies of ALI and correlating this with other markers 
of pulmonary oedema e.g. BALF total protein/albumin.   To test whether increased BALF 
sTNFR p75 can be used to indicate intraalveolar inflammation, a similar approach could 
also be used, in conjunction with plasma sTNFR levels.  For example, a sTNFR p75:p55 
ratio in BALF greater than that observed in plasma could reflect intraalveolar 
inflammation, mediated by alveolar macrophages.  It is also possible that a relative 
increase in BALF sTNFR p75 could indicate ALI induced by a direct pulmonary insult, 
which could also be investigated.  Other further work could include investigation of the 
cellular mechanisms that regulate differential sTNFR production in order to establish why 
acid aspiration/VILI and i.t. bacterial toxin challenge produce such diverse effects on 
intraalveolar sTNFR production.  This could be due to differential activation of sheddases 
involved in sTNFR production and could be investigated by measuring TACE activity on 
alveolar macrophages in each of these models by introducing cells into a fluorescent 
resonance energy transfer peptide (FRET)-based assay, previously developed in this 
laboratory (259).  The assay involves the use of a synthetic peptide containing a donor 
fluorophore and a light-absorbing acceptor bound to either terminal.  Within the peptide is 
a TACE-specific cleavage sequence.  Under normal conditions, the acceptor internally 
quenches the fluorescence from the fluorophore.  Upon cleavage, this is lost and an 
increased fluorescence is observed.  Hence the activity of the cleavage enzyme is reflected 
by an increase in fluorescence. 
Non-essential future work could involve development of a new flow cytometry 
protocol to distinguish between TNFR shedding and internalisation on alveolar cells, in 
order to detect robust shedding of TNFR p75 following i.t. LPS/LTA.  This would likely 
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involve permeabilisation of cells to study both cell-surface and total cell-associated TNFR 
expression. The involvement of alveolar macrophages in LTA-induced intraalveolar 
sTNFR p75 elevation could also be investigated, but I predict similar data to LPS. 
In conclusion, the present study demonstrates that pulmonary oedema induced by 
acid aspiration increases both sTNFR p55 and p75 in BALF most likely via plasma 
leakage in a similar manner to injurious high VT ventilation, whereas bacterial toxin-
induced pulmonary inflammation causes specific intraalveolar production of sTNFR p75, 
mediated by alveolar macrophages.  Together, the data from these in vivo mouse models 
help to elucidate the kinetics of intraalveolar sTNFRs during various aetiologies of ALI.  
These results offer new insights into the differential regulation of individual sTNFRs 
within the alveolar space during ALI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
 
5.  PLASMA SOLUBLE TNFR 
KINETICS IN VILI 
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Plasma levels of sTNFRs are increased during injurious high VT ventilation in ALI 
patients and increased levels are associated with morbidity/mortality.  However, the 
biological relevance of these increases is not fully understood.  It has been suggested that 
increased plasma sTNFRs reflect decompartmentalisation of the intraalveolar milieu, but 
there are many other possible sources. 
To properly interpret raised plasma sTNFRs during VILI, identification of sources 
of receptors is required.  In this chapter I investigated the kinetics and sources of plasma 
sTNFRs during high VT ventilation using in vivo and ex vivo mouse models. 
In vivo injurious high VT mechanical ventilation increased plasma levels of sTNFR 
p55, and possibly sTNFR p75, before significant dysfunction of the alveolar barrier, 
suggesting against the alveolar space as a major source.  Furthermore, high VT ventilation 
reduced expression of TNFR p55 and p75 on pulmonary endothelial cells and lung-
marginated monocytes, suggesting high VT ventilation induced TNFR shedding.  This was 
investigated in an ex vivo mouse model of VILI using isolated perfused lungs (IPL).  Both 
sTNFR p55 and p75 were released into the perfusate during high VT ventilation, 
suggestive of production by the pulmonary circulation. 
These data suggest that sTNFRs can be up regulated in the circulation, 
independently of intraalveolar sTNFR levels, by direct effects of mechanical ventilation 
on the pulmonary vasculature.  Therefore, increased sTNFR levels during ALI, may not 
reflect systemic dissemination of the intraalveolar milieu, but rather activation of the 
pulmonary circulation.  These results provide important insights into the regulation and 
interpretation of systemic sTNFR levels during VILI and identify previously 
unappreciated mechanisms via which VILI can increase circulating sTNFR levels. 
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5.1 Background 
Elevated plasma and BALF levels of sTNFRs are associated with morbidity and mortality 
in ARDS patients (20, 21).   Plasma sTNFRs are also elevated when patients are ventilated 
with higher VT, associated with higher mortality (20, 21).  The relevance of these 
increases is not well defined, but the ability of sTNFRs to inhibit TNF activity could 
suggest generation of a systemic anti-inflammatory milieu in response to mechanical 
ventilation.  Parsons et al. proposed that in ARDS epithelial cell-derived sTNFRs are 
responsible for increased plasma levels, which would involve leakage of sTNFRs from the 
alveoli into the circulation and hence increased levels would reflect epithelial injury and 
dissemination of intraalveolar inflammation (21).  Conversely, plasma sTNFRs could also 
be increased by release from other tissues/organs, as in Crohn’s disease, ulcerative colitis 
and rheumatoid arthritis (214, 215). 
During VILI, in addition to alveolar epithelial cells, injury occurs to the pulmonary 
microvasculature (260).  I have shown that pulmonary endothelial cells express both 
TNFR p55 and p75 and it has previously been reported that activation of endothelial cells 
by IL-1 induces TNFR p55 shedding (166) and mechanical stretch of pulmonary 
endothelial cells induces inflammatory mediator production (95).  These cells may 
therefore represent an important source of raised plasma sTNFR levels during VILI. 
In chapter 3, I investigated the kinetics and sources of increased sTNFR levels in 
the alveolar space in response to high VT ventilation, identifying plasma as the primary 
source, as opposed to intraalveolar sTNFR production.  Furthermore, in chapter 4, I 
demonstrated that only sTNFR p75 was significantly produced in the alveolar space in 
response to i.t. bacterial toxin challenge.  I therefore speculate that it is unlikely that 
leakage of sTNFRs from the alveolar space is the predominant mechanism underlying 
elevated plasma sTNFR levels during pure VILI and potentially during clinical ARDS.  
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This is especially likely for sTNFR p55 because levels of this receptor were not 
significantly elevated in the alveolar space in any of the ALI models.  Identification of 
other sources is therefore required in order to interpret raised plasma sTNFR levels during 
VILI. 
 
5.2 Aims 
I investigated the expression of the individual sTNFRs in plasma during injurious high VT 
ventilation in both in vivo and ex vivo mouse models of VILI.  There were 2 main aims: 
1. Investigate the temporal expression (kinetics) of plasma sTNFRs during VILI in 
mice. 
2. Investigate possible sources of increased plasma sTNFRs during VILI. 
 
5.3 Protocols 
5.3.1 Models 
5.3.1.1 In vivo ventilator-induced lung injury 
To investigate plasma sTNFRs during injurious mechanical ventilation, I used plasma 
samples taken from the same animals subjected to the in vivo mouse model of VILI in 
chapter 3.  Briefly, following surgical preparation of animals and baseline measurements, 
mice were divided into 2 groups: 
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 Ventilation maintained with low VT (non-injurious) 
o VT:  8-9 ml/kg (determined by setting the initial PIP at 10 cmH2O) 
o PEEP:  2.5 cmH2O 
o Respiratory rate:  120 breaths/min 
o Recruitment manoeuvres:  sustained inflations (35 cmH2O for 5 s) 
every 30 min to prevent atelectasis 
o Gas:  medical air 
 Ventilation changed to high VT (injurious) 
o VT:  36-41 ml/kg (determined by setting the initial PIP at 35 
cmH2O) 
o PEEP:  none 
o Respiratory rate:  90 breaths/min 
o Recruitment manoeuvres:  none 
o Gas:  4% CO2 in air to achieve physiological blood gases 
 
Each group was further divided into 3: ventilation for 0.5, 1 or 2 h.  For mice in the 2 h 
high VT group, ventilation was continued for this duration or until PIP increased by ~30%.  
Airway pressures and BP were recorded throughout and respiratory system mechanics (Crs 
and Rrs) recorded every 30 min.  Upon termination, plasma samples were taken via cardiac 
puncture for quantification of sTNFR p55 and p75 by ELISA. 
A separate group of mice were ventilated with high VT for 2 h, and lung samples 
taken for quantification of cell-surface TNFRs on pulmonary endothelial cells and lung-
marginated leukocytes by flow cytometry, as described in chapter 2. 
 
 
158 
 
5.3.1.2 Ex vivo ventilator-induced lung injury 
To investigate the release of sTNFRs by the lungs into the circulation and rule out 
production by extra-pulmonary organs, an ex vivo isolated perfused lung system was used.  
Some perfusate samples were obtained from the same ex vivo experiments used in chapter 
3.  After equilibration of the system and baseline measurements, mice were divided into 2 
groups: 
 
 Ventilation maintained with low VT (non-injurious) 
o VT:  8 ml/kg (determined by setting the initial PIP at 10 cmH2O) 
o PEEP:  2.5-3 cmH2O 
o Respiratory rate:  120 breaths/min 
o Recruitment manoeuvres:  sustained inflations (20 cmH2O for 5 s) 
every 5 min 
o Gas:  medical air supplemented with 5% CO2 to achieve 
physiological gases in the lungs/perfusate 
 Ventilation changed to high VT (injurious) 
o VT:  20-25 ml/kg (determined by setting the initial PIP at 25 
cmH2O) 
o PEEP:  none 
o Respiratory rate:  80 breaths/min 
o Recruitment manoeuvres:  none 
o Gas:  medical air supplemented with 5% CO2 
 
Both groups were ventilated for 2 h, or until PIP increased by ~30%.  Airway pressure and 
pulmonary artery pressure were recorded throughout and perfusate gases recorded at the 
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start and end of the protocol.  Upon termination, perfusate samples were taken from the 
“reservoir” in the perfusion circuit downstream of the pulmonary circulation (as with 
perfusate gas analysis), for quantification of lung-generated sTNFR p55 and p75 by 
ELISA.  Fresh perfusate served as a negative control. 
 
5.4 Results 
5.4.1 In vivo injurious mechanical ventilation produces increases in plasma sTNFRs 
at 1 h 
To investigate the influence of pure injurious mechanical ventilation on plasma sTNFR 
kinetics, an in vivo mouse model of VILI was used.  This model produces significant lung 
injury after 2 h of high VT ventilation, as indicated by pulmonary oedema formation and 
decreased lung Crs (see chapter 3).  Mice were ventilated with either high or low VT for up 
to 2 h and plasma samples quantified for sTNFRs.  During in vivo mechanical ventilation, 
plasma sTNFR levels in mice cannot be compared between time points, due to potential 
changes in circulating blood volume and dilution effects of maintenance fluid infusion, as 
well as rapid renal clearance of sTNFRs (180, 261).  Consequently, comparisons were 
made between low and high VT groups in order to investigate the kinetics of plasma 
sTNFRs during VILI. 
Plasma levels of sTNFR p55 were not increased at either 0.5 or 2 h of high VT 
ventilation compared to low VT ventilation.  However, at 1 h of high VT ventilation 
sTNFR p55 was significantly increased compared to low VT ventilated animals (P<0.05, 
Figure 5.1A).  A similar, but not statistically significant increase was observed for sTNFR 
p75 (Figure 5.1B).  Data from chapter 3, suggests that high VT ventilation does not induce 
substantial production of sTNFRs in the alveolar space.  Although dysfunction of the 
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alveolar barrier may allow constitutively produced intraalveolar sTNFRs, present under 
normal conditions, to leak into the circulation, at 1 h of high VT ventilation there was only 
minimal alveolar barrier dysfunction in this model.  Therefore, increased plasma sTNFRs 
induced by high VT ventilation at 1 h are unlikely to originate in the alveolar space.  This 
suggests that injurious mechanical ventilation could have direct effects on systemic 
sTNFR levels independently from intraalveolar levels and alveolar barrier dysfunction. 
 
 
Figure 5.1.  Plasma levels of soluble TNFRs are increased at 1 h of injurious high VT ventilation in 
vivo.  Mice were ventilated with low VT (8-9 ml/kg, with the initial PIP set at ~10 cmH2O) or high VT (36-41 
ml/kg, with the initial PIP set at ~35 cmH2O) ventilation for up to 2 h.  Upon termination, plasma was 
quantified for sTNFRs by ELISA.  (A) High VT ventilation produced a significant increase in plasma sTNFR 
p55 at 1 h only.  (B) A similar trend was observed for sTNFR p75. *P<0.05 High VT vs. Low VT; t-tests 
(data are normally distributed, P>0.1; Kolmogorov-Smirnov test with Dallal-Wilkinson-Lillie); n=5-7/each 
group. 
 
5.4.2 In vivo injurious mechanical ventilation decreases pulmonary cell-surface 
TNFR expression at 2 h 
Increased plasma sTNFRs during VILI could originate from sources other than the 
alveolar space.  During high VT ventilation, pulmonary endothelial cells could be directly 
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activated by lung over-distension (260).  Furthermore, activated leukocytes marginate to 
the pulmonary vasculature during VILI (101, 104).  From my data, these cells all express 
cell-surface TNFRs (Figure 2.8).  I therefore investigated whether increases in plasma 
sTNFR levels were due to production within the pulmonary vasculature, i.e. shedding of 
cell-surface TNFRs from the pulmonary endothelium and/or lung-marginated leukocytes. 
In vivo, sTNFR p55 and p75 have very short plasma half-lives due to rapid renal 
clearance (20 min for p55) (180, 261).  This could explain the transient increase in plasma 
sTNFRs at 1 h with decreased levels at 2 h.  Production of sTNFRs, although present at 1 
h, may still be on going at 2 h, but is difficult to detect due to clearance.  Consequently, 2 
h may be a better time to study TNFR shedding, allowing greater time for receptor down-
regulation and potentially reflecting a point of maximal shedding.  This could therefore 
produce a clearer assessment of TNFR shedding during the protocol.  Accordingly, mice 
were ventilated with either high or low VT for 2 h, after which lungs were harvested for 
quantification of cell-surface TNFR expression by flow cytometry.  Cell types were 
identified as described in chapter 2 (Figures 2.5 and 2.6). 
 Pulmonary endothelial cells had significantly decreased levels of cell-surface 
TNFR p55 (P<0.05; Figure 5.2A), with a trend for decreased TNFR p75 following 2 h of 
high VT ventilation, consistent with TNFR shedding.  Similarly, lung-marginated 
monocytes had significantly decreased expression of TNFR p55 following high VT 
ventilation (P<0.05; Figure 5.2B), with a similar, but not statistically significant trend for 
p75, also suggestive of TNFR shedding.  However, lung-marginated neutrophils exhibited 
no discernable changes in expression of either TNFR subtype in response to high VT 
ventilation (Figure 5.2C).  This suggests that both the pulmonary endothelium and lung-
marginated monocytes, but not lung-marginated neutrophils, shed TNFRs in response to 
high VT ventilation. 
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Figure 5.2.  Cell-surface TNFR expression on pulmonary endothelial cells and lung-marginated 
monocytes is decreased at 2 h of injurious high VT ventilation in vivo.  Mice were ventilated with low VT 
(8-9 ml/kg) or high VT (36-41 ml/kg) ventilation for 2 h.  Upon termination, lungs were harvested and 
processed for identification of pulmonary cells and quantification of cell-surface TNFR expression by flow 
cytometry. (A) High VT ventilation produced a significant decrease in both cell-surface TNFRs on 
pulmonary endothelial cells, consistent with receptor shedding, although this was only statistically 
significant for TNFR p55, mostly likely due to the low number of observations.  (B) Similarly, high VT 
ventilation also decreased cell-surface expression of TNFR p55 on lung-marginated monocytes, with a 
similar trend for TNFR p75.  (C) However, lung-marginated neutrophils showed no change in cell-surface 
TNFR expression in response to high VT ventilation. *P<0.05 High VT vs. Low VT; Mann-Whitney tests; 
n=3-7/each group. 
 
 
 
5.4.3 Ex vivo injurious mechanical ventilation increases perfusate sTNFRs at 2 h 
To investigate whether decreases in pulmonary endothelial and lung-marginated monocyte 
TNFR expression following high VT reflected sTNFR production via shedding, and could 
be detected in the circulation, I investigated sTNFR production by the pulmonary 
circulation in response to high VT ventilation.  An ex vivo isolated perfused lung model of 
VILI was used.  This model allows investigation of sTNFR release by the pulmonary 
circulation without influences of sTNFR clearance and potential systemic sTNFR 
production, which could occur from other organs in vivo.  Isolated perfused lungs were 
ventilated with high or low VT for 2 h, and perfusate quantified for sTNFRs by ELISA. 
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As expected, fresh perfusate contained no detectable levels of either sTNFR 
(values below ELISA detection threshold for both p55 and p75; n=10).  Perfusate from 
lungs ventilated with high VT had considerably increased levels of sTNFR p55 and p75, 
compared with perfusate from lungs ventilated with low VT (P<0.05, Figure 5.3A and B), 
with the greatest difference for soluble p55, consistent with in vivo plasma data at 1 h.  
Perfusate sTNFR levels were much lower than plasma sTNFR levels following in vivo 
VILI experiments because perfusate is not recirculated i.e. it passes through the pulmonary 
circulation only once before sampling.  These data strongly suggest that sTNFRs are 
produced by the pulmonary circulation in response to high VT ventilation and this 
production is sustained up to 2 h. 
 
 
Figure 5.3.  Perfusate levels of sTNFRs are increased at 2 h of injurious high VT ventilation in the ex 
vivo isolated perfused lung.  Lungs were perfused with a buffer devoid of sTNFRs in a non-recirculating 
manner, and subjected to low VT (8 ml/kg) or high VT (20-25 ml/kg) ventilation for 2 h.  Upon termination, 
perfusate was sampled and quantified for sTNFRs by ELISA.  (A) High VT ventilation produced 
considerable increases in sTNFR p55, consistent with the in vivo VILI model (Figure 5.1).  (B) Similarly, 
sTNFR p75 was significantly increased in perfusate.  This suggests that high VT ventilation can induce 
sTNFR production from the pulmonary circulation. *P<0.05 High VT vs. Low VT; Mann-Whitney tests; 
n=4/each group. 
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5.5 Discussion 
The effect of VILI on systemic inflammation is controversial.  Experimental VILI studies 
investigating the release of inflammatory mediators from the lung into the circulation have 
reported conflicting findings (87, 91, 137).  However, clinically there is evidence to show 
that ventilation with high VT produces increases in levels of various circulating mediators 
(7, 20).  It has also been reported that plasma levels of sTNFRs are increased in ARDS 
patients ventilated with traditionally high VT that are associated with mortality (20, 21), 
but the functional relevance of increased sTNFR levels is not understood. 
It has been suggested that plasma sTNFR levels increase in ARDS due to 
decompartmentalisation of alveolar epithelial-derived sTNFRs into the circulation (21).  
However, since sTNFRs are primarily produced by proteolytic cleavage of cell-surface 
receptors, and these are widely expressed, many cell types could contribute to increases in 
plasma.  Pulmonary endothelial cells are prime candidates for production of sTNFRs in 
this model.  It is well-established that due to interdependence of the lung parenchyma, 
expansion of the lungs causes stretching of the vasculature (74).  It has also been shown 
that injurious mechanical ventilation produces injury to the pulmonary microvasculature 
(260).   Moreover, from my data, endothelial cells express TNFRs and it has been reported 
in vitro that endothelial cells stimulated with IL-1 produce sTNFRs (166) and 
mechanical stretch of endothelial cells results in IL-6, IL-8 and MCP-1 production (95).  
Lung-marginated leukocytes are another potential source because they adhere to the 
endothelium via adhesion molecules such as integrins and selectins (101, 104), and hence 
experience some mechanical force when the endothelium is stretched.  It has been reported 
that THP-1 monocytic cells produce IL-8 when subjected to mechanical stretch in vitro 
(98).  Neutrophils and monocytes also produce sTNFRs upon stimulation (129, 130, 146, 
147, 150-152, 156, 207) and monocytes are thought to be a major source of circulating 
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sTNFRs (146).  It has also been reported that neutrophil adherence promotes sTNFR 
production (209, 248). 
It is important to understand the sources of plasma sTNFRs in order to 
appropriately interpret raised levels in ARDS patients and identify which cells/tissues are 
activated.  Release of sTNFRs and subsequent changes in cell-surface TNFR expression 
could modulate TNF signalling and play an important role in systemic inflammation and 
multiple organ failure associated with ARDS.  Consequently, in vivo and ex vivo mouse 
models of VILI were used in order to investigate kinetics and sources of plasma sTNFRs 
during injurious ventilation. 
 
5.5.1 Plasma sTNFR kinetics during VILI 
High VT mechanical ventilation in mice produced significant increases in plasma levels of 
sTNFR p55 at 1 h, with a similar trend for sTNFR p75.  Data from chapter 3 suggest that 
in this model high VT does not induce detectable intraalveolar sTNFR production.  
Furthermore, at 1 h of high VT ventilation there is minimal alveolar barrier dysfunction.  
Consequently, increases in plasma sTNFRs seem to reflect a direct systemic effect of 
injurious ventilation, as opposed to leakage of intraalveolar receptors into the circulation.  
Neither sTNFR was increased at 2 h of high VT ventilation, which could be due to receptor 
clearance, since sTNFRs have short plasma half-lives.  Soluble TNFR production may 
occur to some degree at 2 h.  This is supported by the ex vivo IPL VILI data, showing 
increased sTNFRs in perfusate at 2 h. 
Increases in plasma sTNFR levels induced by high VT ventilation could have 
numerous sources, but the pulmonary vasculature and marginated leukocytes were likely 
contributors.  I therefore investigated the expression of cell-surface TNFRs on the 
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pulmonary endothelium and lung-marginated leukocytes to assess their potential 
contribution to plasma sTNFR kinetics during VILI.  Both pulmonary endothelial cells 
and lung-marginated monocytes exhibited decreased cell-surface TNFR expression 
following 2 h of high VT ventilation.  This suggests that these cells down regulate cell-
surface TNFR expression in response to high VT ventilation, consistent with receptor 
shedding and sTNFR production.  High VT ventilation did not alter lung-marginated 
neutrophil TNFR expression, suggesting that lung-marginated neutrophils are more 
resistant to TNFR shedding than lung-marginated monocytes and endothelial cells in this 
model.  This also suggests that the observed TNFR expression on endothelial cells and 
monocytes are not due to tissue processing artifacts. 
Hawari et al. showed that full-length TNFR p55 is constitutively released from 
endothelial cells in exosome-like vesicles, capable of binding TNF, but without any 
intrinsic signalling properties (165).  Release of full-length p55 required metalloprotease 
activity, but was independent of proteolytic cleavage.  This direct release from 
intracellular stores would show little effect on cell-surface TNFR p55 expression by flow 
cytometry.  Hawari et al. also reported that full-length sTNFR p55 was the predominant 
form of sTNFR p55 in the human circulation under normal conditions, but did not study 
forms of sTNFR p55 in any pathophysiological conditions where plasma sTNFRs may be 
increased (165).  A subsequent study by this group showed that stimulation of endothelial 
cells with IL-1 induced shedding of sTNFR p55, but did not increase the release of full-
length TNFR p55 (166).  Hence constitutive circulating levels of sTNFR p55 may be full 
length TNFR p55, but elevated plasma sTNFRs, as in this study, could reflect receptor 
shedding, although this requires further investigation. 
Down regulation of TNFR expression may reflect shedding, but also receptor 
internalisation, which cannot be completely ruled out.  However, because changes in 
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surface TNFR expression were accompanied by increases in plasma sTNFRs, I speculate 
that this predominantly reflects shedding of cell-surface receptors. 
I then investigated sTNFR release from the pulmonary circulation in response to 
high VT ventilation in isolated perfused lungs.  This allowed investigation of sTNFR 
production by the lung vasculature separately from potential systemic sTNFR production 
and clearance mechanisms.  High VT ventilation increased perfusate levels of both sTNFR 
p55 and p75 following ventilation with high VT for 2 h, suggesting production by the 
pulmonary endothelium/lung-marginated leukocytes.  However, using a similar model von 
Bethman et al. reported that sTNFRs were not elevated in perfusate following injurious 
ventilation (87).  This disparity could be due to the differences in ventilation between their 
study and the present study.  Constant VT ventilation was employed in the present study, 
but von Bethman et al. used pressure-controlled ventilation, producing a gradual decline in 
the VT delivered (87).  Consequently, their model produced a very mild injury, without 
alveolar oedema formation. 
It is possible that sTNFRs present the alveolar space under baseline conditions, 
enter the circulation in the current model following compromise of the alveolar barrier 
during high VT ventilation.  However, data from chapter 3 would suggest against this, as 2 
h of high VT ventilation did not alter BALF sTNFR levels in IPL. 
Plasma levels of sTNFRs are increased in many inflammatory conditions where 
the lungs are not the prime site of inflammation (213-215, 219, 220).  Therefore, other 
cells/tissues in systemic organs could contribute to increased circulating receptor levels 
during VILI.  Consistent with endothelial and monocyte p55 shedding in this project, it 
has been suggested that both baseline and increased levels of plasma sTNFR p55 are 
generally produced by parenchymal cells, with leukocytes also contributing (180, 210).  
Similarly, consistent with decreases in p75 expression on lung marginated-monocytes and 
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endothelial cells in this project, it has been suggested that leukocytes are mainly 
responsible for baseline and increased plasma levels of sTNFR p75, with parenchymal 
cells contributing (180, 210).  Since I have shown that alveolar macrophages are involved 
in p75 production in the alveolar space, albeit not in VILI, macrophages that reside in 
extra pulmonary tissues could contribute to increased plasma sTNFR p75 levels in VILI.  
Such cell populations could include Kupffer cells in the liver and splenic macrophages.  
This could also be true for circulating leukocytes and leukocytes marginated to the 
vasculature of other organs.  It is also possible that parenchymal cells in other organs 
could potentially contribute to increased sTNFRs levels during VILI.  However, 
production of sTNFRs by non-pulmonary cells is likely to occur via indirect mechanisms 
involving systemic dissemination of inflammation, as opposed to the direct activation 
likely to be responsible for increased plasma sTNFRs in the current study. 
The increased plasma sTNFRs in the in vivo VILI model are arguably relatively 
small.  However, in ALI patients ventilated with higher vs. lower VT ventilation, Parsons 
et al. also showed rather small differences in sTNFRs levels that were significant for p55, 
but not p75, a finding consistent with my data, albeit over much longer duration (3 days 
vs. 1 h) (21).  Plasma levels of sTNFRs also increase early in the current model (at 1 h).  
Given the early kinetics, the increases seen in the current model may reflect the initial 
shedding or first “wave” of sTNFRs from the surface of activated cells.  Indeed, systemic 
sTNFR production appears to be multi-phasic i.e. waves of sTNFR production have been 
reported experimentally during bacteraemia/endotoxaemia (205, 208) and clinically, in 
isolated perfused limbs during high dose TNF treatment (224), with the first wave 
appearing up to 1 h, similar to the plasma increases observed in the current study. 
Soluble TNFR levels are influenced by both transcriptional/translational and post-
translational mechanisms, i.e. shedding (150).  In the context of the present study, the 
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changes in sTNFR levels are detectable after 1 h.  TNFR mRNA could be elevated at this 
time point (249), but this is unlikely to be true for cell-surface TNFR expression.  Indeed, 
after 2 h, cell-surface TNFRs on lung-marginated neutrophils were not increased and lung-
marginated monocytes and pulmonary endothelial cells actually had decreased TNFR 
expression.  VILI could induce up regulation of TNFR genes in the lung, with long-term 
effects on systemic sTNFR levels, but these potential effects are unlikely to be detectable 
in this acute VILI model. 
 
5.5.2 Interpretation 
The current study suggests that plasma levels of sTNFRs during injurious high VT 
mechanical ventilation are increased independently from the intraalveolar milieu via direct 
effects on the pulmonary circulation. The data suggest that sTNFRs are shed from the 
pulmonary endothelium and lung-marginated monocytes, activated in response to 
injurious high VT ventilation, as opposed to passive leakage of receptors from the alveolar 
space into the circulation.  This is in contrast to the published literature, where it has been 
suggested that sTNFRs in the circulation are up regulated in ventilated ARDS patients due 
to leakage of pulmonary epithelial-derived sTNFRs from the alveolar space (21).  In pure 
VILI at least, this does not seem to be necessary because injurious mechanical ventilation 
can have direct systemic effects before significant alveolar barrier dysfunction by inducing 
shedding of receptors in the pulmonary circulation, which could potentially also occur for 
other mediators that are thought to originate in the alveolar space.  This is in stark contrast 
to the traditional view of biotrauma and decompartmentalisation of mediators from the 
airspaces. 
This is the first time that cell-surface TNFR expression has been studied in pure 
170 
 
VILI and data suggest this induces shedding of TNFRs from pulmonary endothelial cells 
and lung-marginated monocytes, leading to increased sTNFR levels.  Despite these 
interesting findings, the precise role of increased sTNFRs in plasma remains unclear.  In 
view of my data, increased plasma sTNFR levels in VILI could at least partly be 
interpreted as activation of the pulmonary microvasculature and lung-marginated 
monocytes.  This could be an anti-inflammatory mechanism, as increases in sTNFR levels 
could in the short term prevent further systemic TNF signalling, and shedding could also 
render pulmonary vascular cells less responsive/more tolerant to further TNF stimulation.   
Comparison of this data with intraalveolar sTNFR data from chapter 3, suggest 
that high VT ventilation produces differential effects on sTNFR levels in the alveolar and 
microvascular compartments.  Whilst sTNFR production within the alveolar space during 
VILI was absent, this does not seem to be true in the pulmonary circulation, where 
endothelial cells and monocytes shed cell-surface TNFRs.  This may reflect an anti-
inflammatory response in the pulmonary circulation that is lacking in the airways, where 
an inflammatory milieu is maintained.  Such localisation of the inflammatory response, 
with a systemic anti-inflammatory response has been suggested to be a general 
phenomenon, that serves to concentrate inflammation to the site of insult and prevent 
aberrant systemic inflammatory responses (262).  It is also worth noting that VILI results 
in increased circulating sTNFR p55 levels, unlike in the alveolar space where neither 
VILI, acid aspiration, nor LPS/LTA i.t. instillation caused intraalveolar production of p55.  
This potentially reflects different propensities of p55 shedding from different cell types, 
i.e. intraalveolar cells retain cell-surface TNFR p55, but it is shed on intravascular cells.  
This could be due to differences in TNFR expression or by different degrees of sheddase 
activity on these cells, or their susceptibility to activation by insults such as mechanical 
stretch. 
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Systemic sTNFRs are cleared by the kidneys (218, 263).  Renal function and 
sTNFR clearance were not investigated in this acute VILI model.  However, in a more 
chronic (8 h), two-hit model of VILI and acid aspiration, injurious mechanical ventilation 
induced kidney apoptosis (42), and clinically, injurious mechanical ventilation is 
associated with renal failure (83), which could contribute to increased circulating levels of 
sTNFRs (263). 
Future directions for this work could include further investigation of TNFR 
shedding by the pulmonary circulation, as my current TNFR expression data for 
pulmonary endothelial cells and monocytes by flow cytometry does not exclude receptor 
internalisation.  This could be investigated using the ex vivo IPL VILI model, whilst 
perfusing lungs with hydroxamate-based inhibitors such as BB94, which block TACE as 
well as other matrix metalloproteases that could be involved in TNFR shedding, and 
assessing sTNFR production and cell-surface TNFR expression in the pulmonary 
circulation.  This could also be used with permeabilised cells to determine receptor 
internalisation. 
In conclusion, I have shown that injurious mechanical ventilation in the absence of 
any underlying inflammation can increase plasma sTNFR levels.  This effect seems to be 
at least partly due to production within the pulmonary vasculature, via shedding of cell-
surface TNFRs by pulmonary endothelial cells and lung-marginated monocytes, as 
opposed to leakage of intraalveolar sTNFRs into the circulation, as is currently thought.  It 
is by no means certain that this is the sole source of increased plasma levels of sTNFRs, 
but the difference in production of sTNFRs induced by high VT vs. low VT ventilation in 
the IPL compared to in vivo suggest that this is an important source.  Increased plasma 
sTNFRs in the short term may facilitate negative regulation of TNF signalling.  These 
novel findings help further elucidate the effects of VILI on the pulmonary and systemic 
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circulations and identify a potential previously unappreciated mechanism via which 
ventilation can influence the expression of circulating mediators such as sTNFRs. 
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6.  PULMONARY TNFR 
EXPRESSION BY 
IMMUNOHISTOCHEMISTRY 
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I have successfully characterised TNFR expression on a variety of lung cells using flow 
cytometry.  However, this technique has a number of limitations.  To further investigate 
pulmonary TNFR expression and consolidate my flow cytometry data, I used another 
technique, immunohistochemistry. 
I attempted to further elucidate baseline expression of TNFR p55 and p75 in fixed 
and non-fixed normal WT lung tissue using immunohistochemistry, by both fluorescent 
and non-fluorescent techniques.  Substantial staining of ICAM-1 was observed compared 
to isotype stained sections.  Staining of TNFR p55 was also observed compared to isotype 
stained sections.  However, validation with TNFR KO tissue showed that this staining was 
non-specific.  Changing the technique and antibodies produced no detectable staining of 
TNFR p55.  TNFR p75 expression was not observed. 
TNFR staining by immunohistochemistry was largely unsuccessful despite many 
attempts to optimise protocols, but has potentially important implications for interpreting 
other studies.  My initial TNFR p55 staining would be assumed to be specific had I not 
attempted to validate this with a biological negative control.  Many studies do not validate 
TNFR expression, yet claim to show specific staining.  Consequently, my data suggests 
caution when interpreting non-validated immunostaining of cell-surface TNFRs. 
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6.1 Background 
Cell-surface TNFR expression is ubiquitous.  All nucleated cells are thought to express 
one or both of the two receptor subtypes to some degree (116).  Development of a flow 
cytometry protocol to quantify cell-surface TNFRs on pulmonary cells during this project 
provides further evidence for this (chapter 2).  Furthermore, this data helped address the 
controversy surrounding TNFR expression in the lungs under normal conditions and was 
also used to study pulmonary TNFR expression during ALI of different aetiologies. 
Flow cytometry provides sensitive quantitative data on cellular antigen expression. 
However, the technique I developed for TNFR quantification on lung cells has 4 main 
limitations.  Firstly, there is a large degree of tissue processing involved, since flow 
cytometry can only be performed on single cells.  Generation of a single cell suspension 
from a solid tissue could have adverse effects on cell-surface TNFR expression, even in 
the presence of protease inhibitors that decrease the potential for receptor shedding.  
Secondly, flow cytometry relies on the availability of cell-type-specific antigens to 
identify different cell populations.  This is especially relevant for identification of 
pulmonary epithelial and endothelial cells using my flow cytometry protocol, as pan-
epithelial and pan-endothelial markers were used to study TNFR expression without 
investigation of the various pulmonary epithelial and endothelial subpopulations, such as 
alveolar type I and type II cells and bronchial epithelium, and pulmonary microvasculature 
endothelial cells and those from larger pulmonary vessels.  Thirdly, flow cytometry 
quantifies antigen expression on cells as a whole, without localising expression to areas of 
the cell surface, e.g. basolateral vs. apical/luminal surfaces.  This may be important in vivo 
in terms of TNFR shedding and sTNFR production.  For example, shedding of TNFRs 
would more effectively contribute to sTNFR levels in plasma or lung epithelial lining fluid 
if they were expressed on the apical/luminal surface.  Fourthly, flow cytometry does not 
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provide information regarding the localisation of stained cells within organs/tissues.  
Hence further investigation of TNFR expression in the lungs using different methods is 
required for validation of my previous data and precise localisation of pulmonary TNFR 
receptor expression, but also desirable to increase understanding of TNFR expression. 
 
6.2 Aims 
I investigated TNFR expression in normal WT mouse lungs using immunohistochemistry.  
There were 2 main aims: 
1. Develop an immunohistochemistry protocol for staining of antigens in lung tissue. 
2. Validate previous flow cytometry data by studying the expression/localisation of 
TNFRs in lung tissue. 
 
6.3 Protocols 
6.3.1 Staining of cell-surface TNFRs by immunohistochemistry 
The immunohistochemistry protocol is outlined in chapter 2.  Briefly, following isoflurane 
overdose, mice were tracheostomised, exsanguinated and 700 µl of either 4% 
paraformaldehyde or 50% OCT embedding medium in D-PBS was instilled into the lungs 
via an endotracheal tube.  Excised lungs instilled with 4% paraformaldehyde were fixed 
further in 4% paraformaldehyde for 24-48 h, cryoprotected in 30% sucrose, and frozen in 
100% OCT.  Lungs instilled with 50% OCT were snap frozen in 100% OCT without 
fixation.  Frozen tissue blocks were sectioned and stained with the appropriate antibodies 
(unconjugated or fluorescent dye-conjugated primary anti-TNFR p55, anti-TNFR p75 or 
anti-ICAM-1 and fluorescent dye-conjugated or HRP-conjugated secondary antibodies 
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where appropriate) before mounting and visualisation of slides by fluorescence or light 
microscopy. 
 
6.4 Results 
6.4.1 Measurement of cell-surface TNFRs on lung tissue by immunohistochemistry 
Despite numerous attempts, immunohistochemical staining of TNFRs in WT lungs was 
unsuccessful.  However, these experiments raise important questions regarding studies 
that claim to show immunohistochemical detection of TNFRs in normal lung tissue and 
therefore the results will be described in detail. 
I investigated the cell-surface expression of TNFRs in WT lung tissue, to assess 
their localisation under normal conditions.  Tissues from TNFR KO mice served as 
biological negative controls.  Expression of lung TNFR p55 was the primary focus due to 
its ubiquitous expression.  Immunofluorescence was first used since it is akin to flow 
cytometry and was thought to give clearer indications of the extent of receptor expression 
than non-fluorescent techniques. 
In fixed lung sections, ICAM-1 staining was observed in both WT and TNFR KO 
tissue compared to the isotype control (Figure 6.1A).  Similarly, in WT animals, TNFR 
p55 staining was observed in lung sections compared to those stained with isotype control 
antibodies (Figure 6.1B).  However, this “positive” TNFR p55 staining was also observed 
in TNFR p55 KO tissue, known not to express p55 by genotyping and flow cytometry, 
indicating that this signal cannot have been specific to TNFR p55 (Figure 6.1C). This 
suggests that the primary anti-TNFR p55 antibody was non-specifically binding.  
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Figure 6.1.  Staining for TNFR p55 in murine lung tissue is not specific using immunofluorescence.  
WT or TNFR p55 KO mice were euthanised and their lungs harvested, fixed and embedded.  Following 
sectioning, lungs were stained with a primary anti-TNFR p55 antibody and washed, followed by staining 
with a fluorescent-conjugated secondary antibody.  WT lungs were also stained with ICAM-1 as a positive 
control and isotype control antibodies served as negative controls.  All photomicrographs show signals from 
primary antibodies incubated at 1:500, with secondary antibody at 1:200.  (A) ICAM-1 staining showed 
positive staining in WT lungs at levels much higher than the TNFR p55 signal, which was likely to be 
specific as ICAM-1 is expressed at very high levels in the lung parenchyma. (B) WT lung sections showed 
positive staining for TNFR p55 compared to the isotype control.  (C) However, this pattern of “positive” 
staining was also observed in TNFR p55 KO lungs and therefore cannot be truly specific for TNFR p55.  
Photomicrographs are representative; n=2-4/each group. 
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Antibody concentrations were altered, but did not increase the signal:noise ratio of 
staining.  Consequently, a second anti-TNFR p55 primary antibody (this time raised in 
goat) was used, but there was negligible staining on both WT and TNFR DKO lung tissue 
with this antibody regardless of the concentration used (Table 6.1).  This provides further 
evidence that the initial primary antibody produced non-specific staining.  TNFR p75 
staining was also negligible and similar results were acquired using a non-fixed lung 
tissue. 
An alternative staining protocol was also tested that employed the use of directly 
conjugated fluorescent primary antibodies for TNFR p55, p75 and ICAM-1 with the 
appropriate isotype controls, previously used for flow cytometry.  These antibodies had 
already been shown to be specific for TNFRs (chapter 2).  Non-fixed WT and TNFR DKO 
lung sections exhibited positive staining for ICAM-1, but TNFR staining was negligible in 
both (Table 6.1). 
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Strain Fixation  Antibody (host) Detection method Signal strength (vs. isotype) 
TNFR p55 
WT Yes TNFR p55 (rabbit) Fluorescence and DAB ++ 
p55 KO Yes TNFR p55 (rabbit) Fluorescence and DAB ++ 
WT No TNFR p55 (rabbit) Fluorescence and DAB ++ 
p55 KO No TNFR p55 (rabbit) Fluorescence and DAB ++ 
WT Yes TNFR p55 (goat) Fluorescence - 
DKO Yes TNFR p55 (goat) Fluorescence - 
WT No TNFR p55 (goat) Fluorescence - 
DKO No TNFR p55 (goat) Fluorescence - 
WT No TNFR p55 (hamster) Fluorescence - 
DKO No TNFR p55 (hamster) Fluorescence - 
TNFR p75 
WT Yes TNFR p75 (rat) Fluorescence and DAB - 
DKO Yes TNFR p75 (rat) Fluorescence and DAB - 
WT No TNFR p75 (hamster) Fluorescence - 
DKO No TNFR p75 (hamster) Fluorescence - 
ICAM-1 
WT Yes ICAM-1 (rabbit) Fluorescence and DAB +++ 
DKO Yes ICAM-1 (rabbit) Fluorescence and DAB +++ 
WT No ICAM-1 (rabbit) Fluorescence +++ 
DKO No ICAM-1 (rabbit) Fluorescence +++ 
WT No ICAM-1 (rat) Fluorescence + 
DKO No ICAM-1 (rat) Fluorescence + 
 
Table 6.1.  Summary of immunohistochemical techniques used and results.  It is clear from the table 
that there was no true positive staining of TNFRs in lung tissue, because the TNFR KO signals are similar in 
strength to those observed in WT lung tissue; - : negative staining; + : weak positive staining; ++ : moderate 
positive staining; +++ : strong positive staining. 
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The technique was altered in an attempt to reduce aberrant staining/negate the 
interference of tissue autofluorescence that could influence the signal:noise ratio and mask 
true positive staining.  Consequently, the immunofluorescence approach was changed to 
light microscopy, using an HRP-conjugated secondary antibody in conjunction with a 3, 
3-diaminobenzidine (DAB) enzymatic immunohistochemistry protocol.  In WT lung 
sections, staining was observed between TNFR p55 stained and isotype controls (Figure 
6.2A), but this difference was again observed in TNFR KO tissue like the 
immunofluorescence data (Figure 6.2B), indicating false positive staining.  TNFR p75 
staining was negligible and non-fixed tissue exhibited similar staining patterns (Table 6.1). 
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Figure 6.2.  Staining for TNFR p55 in murine lung tissue is not specific using the DAB protocol.  WT 
or TNFR p55 KO mice were euthanised and their lungs harvested, fixed and embedded.  Following 
sectioning, lungs were stained with a primary anti-TNFR p55 antibody and washed, followed by staining 
with an HRP-conjugated secondary antibody and development with a DAB substrate kit.  Isotype control 
antibodies served as negative controls. All photomicrographs show signals from primary antibodies 
incubated at 1:500, with secondary antibody at 1:200.  (A) WT lung sections showed positive staining for 
TNFR p55 compared to the isotype control.  (B) However, this was also observed in TNFR p55 KO lungs 
and thus cannot be specific for TNFR p55.  Photomicrographs are representative; n=4/each group. 
 
Immunohistochemical staining of membrane-bound TNFR receptors was 
unsuccessful, despite the use of three different antibodies, both light and fluorescence 
microscopy detection techniques, and numerous attempts to optimise protocols 
(summarised in Table 6.1).  I have drawn this conclusion because tissue that does not 
express TNFRs (TNFR p55 KO or DKO mouse lung samples) produced as strong a signal 
as WT tissue (where TNFRs should be present), indicating false positive staining/non-
specific antibody binding.  This staining was observed throughout sections, indicating that 
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it was not related to specific cell types.  The low signal:noise ratio suggests that TNFRs 
generally are expressed a very low levels in lung tissue, which can be detected by flow 
cytometry, but not immunohistochemistry.  Furthermore, sections exhibited positive 
staining for ICAM-1 that is known to be highly expressed in the lung parenchyma (247), 
which suggests that the technique was robust for detection of this antigen. 
 
6.5 Discussion 
Flow cytometry provides quantitative TNFR expression data on pulmonary cells, but has 
various limitations.  I consequently attempted to validate my previous pulmonary TNFR 
expression data obtained using this technique and further investigate the localisation of 
TNFR expression in the lung, using immunohistochemistry. 
 An immunohistochemistry protocol was developed using both fluorescent and non-
fluorescent techniques on fixed and non-fixed frozen tissue.  The immunohistochemistry 
technique required a great deal of development to produce the best tissue morphology and 
used a number of staining protocols.  However, despite seemingly positive TNFR p55 
staining in WT lungs compared to an isotype control, experiments using TNFR KO tissue 
showed that this staining was not specific for this receptor.  The staining was observed 
throughout lung tissue sections suggesting that this non-specific/false positive staining 
was irrespective of cell type.  Using a different primary antibody did not resolve this.  
Similarly, TNFR p75 could not be detected.  Further immunohistochemical staining of 
lung tissue with antibodies used previously for flow cytometry, which I have shown are 
specific for the respective TNFR subtypes, also showed negligible TNFR staining.  
Consequently, the negligible level of TNFR staining observed is likely to be reliable.  The 
use of a DAB-based detection technique using light microscopy, as opposed to 
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immunofluorescence, produced similar results to the original immunofluorescence 
protocol.  There were no apparent differences between fixed and non-fixed tissue 
preparations. 
Successful staining was observed for ICAM-1 on lung tissue.  This indicated that 
the staining procedure itself was robust for detection of certain antigens expressed at high 
levels.  I therefore concluded that the immunohistochemistry technique was inappropriate 
for studying cell-surface TNFRs, since the low level of TNFR expression on the lung 
parenchyma was apparently below the detection threshold of immunohistochemistry. 
 This conclusion is supported by my investigations into TNFR expression using 
flow cytometry.  These data show that on the lung parenchyma, i.e. pulmonary epithelial 
and endothelial cells, both receptors are difficult to detect, requiring the presence of 
protease inhibitors and low temperatures to preserve TNFR expression.  Since this 
technique is more sensitive, and only shows low TNFR levels, it is likely that 
immunohistochemical detection of cell-surface TNFRs is extremely difficult. 
 Many studies have used immunohistochemical techniques in order to determine 
TNFR expression in various cells/tissues.  However, studies often fail to provide 
appropriate biological negative controls for proper validation of positive staining.  For 
example, Al-Lamki et al. investigated TNFR expression in human kidneys and Kristensen 
et al. investigated TNFR expression human skin, and both showed positive staining of 
TNFRs under normal conditions using a variety of anti-TNFR antibodies compared to 
isotype antibodies or non-immune serum as negative controls (191, 264).  Similarly, 
Ermert et al. showed expression of both TNFRs in human and rat lung tissue (168).  
Expression of TNFR p75 was expressed on the vast majority of cells studied and TNFR 
p55 was expressed on pulmonary endothelial cells, various epithelial cell types, albeit not 
on alveolar epithelial cells, and leukocytes, but the authors used omission of the primary 
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antibody or non-specific serum as negative controls (168).  From my data, it is clear that 
such controls may not always be sufficient to assess true positive TNFR staining, because 
I also observed differences between isotype control antibodies and anti-TNFR p55 
antibodies in TNFR p55 KO tissue.  Conversely, Fontaine et al. investigated TNFR 
expression in the mouse retina and validated their staining using TNFR subtype deficient 
mice, but found negligible levels of both receptors under baseline conditions (160).  Thus, 
the use of proper biological negative controls demonstrated that baseline levels of TNFRs 
were too low to detect in retinal tissue, similar to my conclusion of TNFR expression in 
murine lungs. 
My data suggest that the use of appropriate biological negative controls is essential 
when developing a novel immunohistochemistry protocol.  Had I not used this control, I 
would have assumed that staining with my initial TNFR p55 primary antibody was 
specific for TNFR p55.  If possible, such controls should always be employed, however, it 
is appreciated that this is far easier for murine based staining, due to the availability of 
transgenic KO mice.  In other species, a similar use of biological negative controls could 
be employed, by using cells/tissues known to be deficient in the antigen of interest.  
Alternatively, a variety of antibodies could be used to provide further evidence for specific 
staining, if similar staining patterns are observed.  However, the use of biological negative 
control tissue is the only way to truly validate the specificity of antibodies.  My findings 
therefore cast doubt on some studies that claim to show positive staining of TNFRs under 
normal conditions, but do not use appropriate controls.  Caution should be exercised when 
interpreting such data. 
In conclusion, flow cytometry is a more robust technique for quantification of cell-
surface TNFR expression in the lung tissue compared to immunohistochemistry, because 
TNFRs are expressed at very low levels under normal conditions.  I have also found that 
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the use of biological negative controls when quantifying such low levels of antigen is 
essential practice for many types of immunostaining. 
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7.  TNFR-DEPENDENT ALVEOLAR 
FLUID REABSORPTION 
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Differential TNFR signalling has been reported in a number of disease states.  TNFR p55 
and p75 play deleterious and protective roles, respectively, in the formation of pulmonary 
oedema during VILI in mice.  However, the mechanisms underlying this have not been 
elucidated.  One possible mechanism underlying p75-mediated protection against 
pulmonary oedema formation is the reabsorption of lung fluid. 
In this chapter I attempted to elucidate the potential role of TNFR p75 in lung fluid 
reabsorption by developing an in vivo model to assess fluid reabsorption, using i.t. fluid 
instillation in ventilated WT and TNFR p75 KO mice.  I primarily focussed on respiratory 
system elastance (Ers) to assess lung water content.  Some studies have used similar 
parameters previously, but none have used lung mechanics to assess fluid reabsorption in 
in vivo mouse preparations. 
The model was first established using WT mice with pharmacological agents 
known to inhibit (amiloride) or enhance (salbutamol) lung fluid reabsorption incorporated 
into the instilled fluid.  Following fluid instillation, WT mice treated with amiloride had 
larger increases in lung elastance and total lung water, as measured by lung wet:dry (W:D) 
weight ratios, compared to salbutamol treated mice.  Lung Ers correlated with W:D weight 
ratios, suggesting that Ers reflects total lung water.  Following fluid instillation, TNFR p75 
KO mice, exhibited increased elastance compared with WT mice, suggestive of an 
impaired ability to clear lung fluid.  Due to limited availability of TNFR p75 KOs, W:D 
values were not obtained. 
These data are rather preliminary and require further investigation/validation, but 
suggest that TNFR p75 promotes the reabsorption of lung fluid, which could contribute to 
its protective effect against the development of pulmonary oedema formation induced by 
injurious high VT ventilation. 
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7.1 Background 
TNFR p55 and p75 are responsible for mediating the majority of the complex roles of 
TNF. How these receptors produce such a variety of biological effects is not fully 
understood.  Each receptor can act via intracellular signalling pathways with significant 
overlap, but also via apparent receptor-specific pathways (116, 159, 171-177). 
The majority of studies have focussed on the role of TNFR p55, with most 
signalling attributed to this receptor (116).  This could be due in part to the use of sTNF in 
vitro studies, which is a poor activator of TNFR p75 compared to cell-surface TNF (125).  
However, the importance of TNFR p75 in both physiological and pathophysiological 
processes has been highlighted by some studies (15, 184, 191, 192, 195, 196).  
Furthermore, it has been shown that under certain conditions TNFR p75 plays a 
distinct and even opposing role to that of p55.  Ebach et al. investigated the role of TNF in 
a caecal ligation and puncture model of sepsis (197).  They found that TNFR p55 KO 
mice had prolonged survival and less hypothermia, with the opposite effect for TNFR p75 
KO mice, suggesting that p75 may play a protective role.  TNFR p75 KO mice also had 
increased peritoneal and serum levels of TNF, indicating that this receptor is involved in 
regulation of TNF levels.  Similarly, Higuchi et al. showed using transgenic mice that 
over-express cardiac TNF, in conjunction with TNFR subtype KO mice, that the absence 
of TNFR p55 reduced heart failure, improving survival (198).  Conversely, the absence of 
TNFR p75 was deleterious, with mice developing exacerbated heart failure with reduced 
survival, which could be due to loss of sequestration of TNF by sTNFR p75.  Fontaine et 
al. investigated the role of TNFR in a retinal ischemia model, again with TNFR KO, but 
also TNF KO mice (160).  TNF deficiency did not affect total cell loss, but in TNFR p55 
KO mice there was reduced neurodegeneration, whereas this was enhanced in TNFR p75 
KO mice.  Furthermore, Kelly et al. showed that following cardiac ischaemia/reperfusion 
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injury in isolated rat hearts, the administration of stem cells expressing TNFR p75, but not 
p55, improved cardiac function compared to stem cells expressing p55 only or both 
receptors (199).  These studies generally show protective roles for TNFR p75, acting 
against the deleterious roles of TNFR p55. 
Wilson et al. showed that this opposition can occur in pure mechanical VILI (113).  
In this model, WT mice developed substantial pulmonary oedema formation following 
ventilation with injurious high VT.  TNFR p55 KO mice did not develop significant 
oedema formation following high VT ventilation, whereas p75 KO mice had significantly 
worse oedema development in comparison to p55 KO, WT and DKO mice.  TNFR p75 
KO mice also had reduced survival, whilst TNFR p55 KO mice all survived until the end 
of experiments.  Importantly, mice expressing neither TNFR were remarkably similar to 
WT mice.  This indicated a direct opposition in p55 vs. p75 signalling mechanisms, as 
opposed to the observed differences between TNFR KO animals being due to loss of 
protective soluble receptors, previously suggested for sTNFR p75 (197, 198).  However, 
the mechanisms underlying differential TNFR signalling in VILI have not been 
investigated. 
It is well established that TNF is involved in increased barrier permeability (140, 
141).  Ferrero et al. showed that TNFR p55 activation induced cytoskeletal changes and 
increased endothelial permeability (228) and Mizgerd et al. showed that TNFR p55 and 
IL-1R1 are involved in oedema formation during pneumonia in mice (52).  All of these 
studies are consistent with the deleterious role of TNFR p55 in pulmonary oedema 
formation in VILI.  Conversely, Fukuda et al. showed in vitro that sodium transport, 
implicated in fluid reabsorption, was mediated by TNFR p55 and p75-dependent and -
independent mechanisms (237).  Despite this, no studies have specifically investigating 
the role of TNFR p75 in lung fluid reabsorption in vivo.  Consequently, I investigated 
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whether differential TNFR signalling observed in VILI was due to differences in lung 
fluid reabsorption, specifically focussing on the role of TNFR p75. 
 
7.2 Aims 
Previous methods of studying lung fluid reabsorption have used a variety of measurements 
to determine the degree of reabsorption including instillate protein/tracer concentration 
changes and lung weights (109, 233-238).  Often in situ or ex vivo preparations are used 
(233, 234, 238) that lack the physiological relevance of in vivo studies.  Some studies have 
used lung mechanics to assess fluid reabsorption (233, 234).   However, no studies have 
used this approach with in vivo mouse preparations.  If mainly reflective of lung water 
content, altered lung mechanics may be a sensitive and powerful tool to assess lung fluid 
reabsorption in vivo.  I therefore developed an in vivo mouse model to assess fluid 
reabsorption in ventilated mice and investigated the role of TNFR p75 in lung fluid 
reabsorption using TNFR p75 KO mice.  There were 2 main aims: 
1. Development and validation of a model to assess lung fluid reabsorption 
2. Investigation of the role of TNFR p75 in lung fluid reabsorption using TNFR p75 
KO mice.  TNFR p75 KO mice were expected to exhibit impaired lung fluid 
reabsorption compared to WT mice. 
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7.3 Protocols 
7.3.1 In vivo mouse model to assess lung fluid reabsorption 
This model is described in detail in chapter 2.  Briefly, anaesthetised mice were ventilated 
with non-injurious ventilation (VT: 8-9 ml/kg; PEEP: 2.5 cmH2O, respiratory rate: 120 
breaths/min, sustained inflations (35 cmH2O for 5 s) every 15 min to prevent atelectasis) 
using oxygen to prevent hypoxia) and instilled i.t. with a custom-made instillate that 
mimics plasma/oedema fluid in terms of osmolarity (~340 mOsmoles/ml (87)) and pH.  
Instillate consisted of 50 ml D-PBS supplemented with 1.63 mmol of NaCl and 5% BSA, 
with pH adjusted to ~7.3 using 2 M NaOH.  Ventilation was maintained for 1 h, because it 
has previously been shown that a lung fluid reabsorption can be detected at early time 
points (233, 234, 237).  Lung mechanics were recorded throughout and compared to 
values taken at baseline before instillation.  During development of the model, amiloride 
(1 mM) or salbutamol (0.1 mM or 1 mM) was incorporated into the instillate to inhibit or 
enhance fluid reabsorption, respectively.  Upon termination, lungs were harvested and 
assessed for W:D lung weight ratios to determine total lung water. 
 
7.4 Results 
7.4.1 Development of in vivo mouse model to assess lung fluid reabsorption 
I first developed an in vivo model in which fluid reabsorption from the lungs could be 
assessed via quantification of total lung water and changes in respiratory mechanics in 
ventilated mice. 
Anaesthetised ventilated mice were instilled with an isotonic solution and 
ventilation maintained with low VT, to avoid injury, for 1 h, with recruitment manoeuvres 
193 
 
every 30 min.  In the first set of experiments, ventilated mice received 50 µl of instillate.  
Lung mechanics were recorded throughout with special emphasis placed on lung elastance 
(Ers).  Upon termination, mice were euthanised and lungs removed for quantification of 
total lung water using W:D lung weight ratios. 
In such acute experiments elastance changes likely reflect water content within the 
lungs.  This may be a sensitive marker of lung water content with a further advantage that 
it would allow continuous assessment of fluid reabsorption.  Consequently, I attempted to 
validate lung elastance as a marker of lung fluid in this model.  This involved 
incorporation of pharmacological agents into the instillate that are known to either inhibit 
or promote fluid reabsorption from the lungs and assess % elastance changes from 
baseline values and W:D lung weight ratios.  Amiloride (1 mM in 50 µl instillate) and 
salbutamol (0.1 mM in 50 µl instillate) were used, because these or similar compounds 
have been shown to inhibit and enhance lung fluid reabsorption, respectively (109, 233-
238). 
Following instillation, all mice exhibited increases in Ers and PIP, which peaked at 
0.5 h, decreasing after 1 h, which could indicate fluid in the airways that is redistributed 
following recruitment of the lungs (Table 7.1).  At 1 h, Ers changes were greater in the 
amiloride group compared to untreated controls, but similar to control levels in the 
salbutamol treated group, although at 0.5 h, salbutamol values were lower than control.  
Rrs was increased in the control and amiloride groups at 0.5 h, and was decreased at 1 h, 
unlike the salbutamol treated group that showed a gradual decrease in Rrs, which could 
indicate reduced lung fluid in the airways of salbutamol treated mice.  Blood gases 
deteriorated in both treated groups, but the decrease in pO2 was more pronounced in 
amiloride treated animals compared to salbutamol treatment (Table 7.1), suggesting that 
salbutamol improved oxygenation, consistent with the literature (31).  Conversely, 
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salbutamol treated mice tended to have higher pCO2, which could be due to an increased 
metabolic rate that has been reported to be induced by salbutamol inhalation in humans 
(265).  Mice administered with instillate containing amiloride had significantly larger 
increases in elastance, expressed as a percentage change from baseline values, compared 
to mice that were administered with instillate containing salbutamol (Figure 7.1A).  This 
was mirrored in W:D values, with amiloride treated mice exhibiting significantly higher 
values compared with salbutamol treated animals (Figure 7.1B).  To show that both 
elastance and W:D ratios were related to the volume of instillate in the lungs, a larger 
bolus of instillate (100 µl) was used.  A higher concentration of salbutamol (1 mM) was 
also investigated. 
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pO2 (mmHg) 497±36 - 453±41 
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PIP (cmH2O) 10.8±0.2 18.2±1.4 15.6±2.4 
Rrs (cmH2O · ml
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 s
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) 2.25±0.05 2.70±0.48 2.33±0.11 
Ers (% from baseline) 0 182.9±28.6 115.7±26.9 
pO2 (mmHg) 489±19 - 292±64 
pCO2 (mmHg) 32±1 - 58±8 
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PIP (cmH2O) 11.1±0.17 17.2±0.8 12.8±1.0 
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) 2.27±0.06 2.38±0.12 2.29±0.16 
Ers (% from baseline) 0 147.4±18.9 48.2±15.6 
pO2 (mmHg) 467±30 - 377±47 
pCO2 (mmHg) 30±2 - 69±7 
 
Table 7.1.  Physiological parameters in in vivo mouse lung fluid reabsorption model for amiloride and 
salbutamol treated WT animals.  Following baseline measurements, ventilated WT mice were instilled i.t. 
with isotonic instillate (50 or 100 µl), with or without amiloride (1 mM) or salbutamol (0.1 or 1 mM), and 
ventilation maintained for 1 h.  Generally, PIP, Rrs and Ers increased following instillation and decreased 
after 0.5 h.  Decreased pO2 and increased pCO2 were observed in both treated groups compared to controls.  
Values are means±SD; (-): not done; n=4-6/each group. 
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The larger fluid bolus produced increases in Ers, Rrs and PIP at 0.5 h, generally higher than 
with the 50 µl bolus, which decreased at 1 h (Table 7.1).  At 1 h, Ers changes were greater 
in the amiloride group compared to untreated controls, and lower in the salbutamol treated 
group.  Blood gases showed a similar pattern of decline to the 50 µl bolus groups, and 
oxygenation was again less severe for the salbutamol group than the amiloride treated 
group.  There were significant differences in both lung elastance changes and W:D weight 
ratios between amiloride and salbutamol treated groups (Figure 7.1C and D).  Moreover, 
values for W:D were generally higher with 100 µl than when 50 µl was used. 
 
Figure 7.1.  WT mice treated with i.t. instillation of isotonic fluid containing salbutamol or amiloride 
exhibit differences in lung elastance and lung W:D weight ratios.  Mice were anaesthetised, 
tracheostomised and ventilated with low VT (9 ml/kg) ventilation.  After instrumentation and stabilisation, 
baseline lung mechanics were measured and lungs were instilled with an isotonic solution containing 5% 
BSA and either amiloride (1 mM) or salbutamol (0.1 or 1 mM), in a 50 or 100 µl bolus.  Ventilation was 
maintained for 1 h and lung mechanics recorded throughout.  Mice were sacrificed by anaesthetic overdose 
administered via the arterial line.  (A) Amiloride treated mice in the 50 µl group exhibited a significantly 
greater increase in % elastance change from baseline values after 1 h, compared to salbutamol treated mice.  
(C) This was also observed in the 100 µl group.  (B) For the 50 µl group, there were significant differences 
in lung W:D weight ratios between amiloride and salbutamol treated animals after 1 h, with amiloride values 
being significantly greater than salbutamol values.  (D) This was also observed in the 100 µl group, where 
values in both groups tended to be higher, due to the larger fluid bolus.  *P<0.05; Mann-Whitney tests: n=4-
6. 
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Using amiloride and salbutamol treated groups, both 50 µl and 100 µl protocols 
showed positive correlations between elastance changes from baseline and W:D values 
after 1 h of ventilation (Figure 7.2).  This suggests that elastance changes reflect total lung 
fluid and can therefore be used to assess the degree of lung fluid reabsorption in vivo.   
 
 
 
Figure 7.2.  Changes in lung elastance and W:D weight ratios positively correlated in mice treated 
with amiloride or salbutamol.   Associations between lung elastance and W:D weight ratios in the in vivo 
lung fluid reabsorption model were evaluated by Pearson’s correlation analysis using data from both 
amiloride and salbutamol treated animals (data are normally distributed, P>0.1; Kolmogorov-Smirnov test 
with Dallal-Wilkinson-Lillie).  (A) A positive correlation was observed in animals administered with 50 µl 
of instillate containing either amiloride (1 mM) or salbutamol (0.1 mM) and (B) in mice administered with 
100 µl of instillate containing either amiloride (1 mM) or salbutamol (1 mM) (r=0.583 for 50 µl and r=0.900 
for 100 µl; P<0.01), suggesting that increases in lung elastance reflect total lung fluid levels and hence the 
degree of fluid reabsorption.  Each data point represents one animal; n=8/9. 
 
7.4.2 TNFR subtypes in lung fluid reabsorption 
TNFR p55 promotes the formation of pulmonary oedema during pure VILI, whereas p75 
protects against this.  I investigated whether TNFR p75-mediated protection from 
pulmonary oedema formation was due to enhancement of lung fluid reabsorption.  I 
hypothesised that TNFR p75 KO mice would exhibit inhibited reabsorption of an instillate 
introduced into the lungs. 
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WT and TNFR p75 KO mice were instilled with isotonic fluid, without 
pharmacological agents.  The 50 µl protocol was used initially. 
Like amiloride and salbutamol treated WT mice, both WT and TNFR p75 KO 
mice showed increases in Ers, Rrs and PIP, which peaked at 0.5 h and decreased after 1 h 
(Table 7.2). 
 
 Baseline 0.5 h 1 h 
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PIP (cmH2O) 9.4±0.3 14.5±1.5 11.4±1.2 
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-1
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-1
) 1.71±0.08 1.83±0.24 1.61±0.13 
Ers (% from baseline) 0 100±35.7 38.3±9.8 
pO2 (mmHg) 475±61 - 480±55 
pCO2 (mmHg) 38±5 - 54±8 
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PIP (cmH2O) 9.4±0.3 15.3±1.2 13.0±0.5 
Rrs (cmH2O · ml
-1
 s
-1
) 1.67±0.06 1.89±0.22 1.76±0.18 
Ers (% from baseline) 0 105±20.6 65.3±19.2 
pO2 (mmHg) 446±49 - 466±49 
pCO2 (mmHg) 41±3 - 54±7 
 
Table 7.2.  Physiological parameters in in vivo mouse lung fluid reabsorption model for WT and 
TNFR p75 KO animals.  Following baseline measurements, ventilated WT and TNFR p75 KO mice were 
challenged i.t. with isotonic instillate, without additional agents, via the endotracheal tube.  Ventilation was 
maintained with low VT (9 ml/kg) for 1 h.  Both WT and TNFR p75 KO mice exhibited increases in PIP, Rrs 
and Ers following fluid instillation.  These variables decreased between 0.5 and 1 h.  Oxygenation was well 
maintained, but both WT and TNFR p75 KO mice showed increased pCO2 after 1 h.  WT data same as 50 µl 
data from Table 7.1.  Values are means±SD; n=5-6/each group. 
 
After 1 h, TNFR p75 KO animals had significantly larger increases in lung 
elastance, compared to WTs (Figure 7.3).  This suggested that TNFR p75 KOs had an 
impaired ability to clear the instillate from the lungs. 
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Unfortunately, I was unable to consolidate the 50 µl KO data or expand this using 
the 100 µl protocol due to issues with TNFR p75 KO availability, due in part to breeding 
issues, but also infection of KOs with Aspiculuris tetraptera (pinworm).  However, from 
my preliminary data I speculate that the absence of TNFR p75 inhibits lung fluid 
reabsorption as measured by lung elastance changes. 
 
 
Figure 7.3.  TNFR p75 deficient mice exhibit increased lung elastance following i.t. instillation of 
isotonic fluid compared to WT mice.  Mice were anaesthetised, tracheostomised and ventilated with low 
VT (9 ml/kg) ventilation.  After instrumentation and stabilisation, baseline lung mechanics were measured 
and lungs were instilled with 50 µl of an isotonic solution.  Ventilation was maintained for 1 h with periodic 
measurement of lung mechanics.  Upon termination, mice were sacrificed by anaesthetic overdose 
administered via the arterial line.  After 1 h, TNFR p75 KOs exhibited a significantly greater increase in % 
elastance change from baseline values compared to WT mice.  *P<0.05; Mann-Whitney tests: n=5-6/each 
group. 
 
 
7.5 Discussion 
Differential TNFR signalling has been implicated in various pathologies including during 
pulmonary oedema development in VILI (113).  The mechanisms that underlie the 
reported deleterious effects of p55 and the protective effects of p75 in pulmonary oedema 
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development are yet to be investigated, but may involve TNFR p55-mediated alveolar 
barrier dysfunction and/or TNFR p75-mediated lung fluid reabsorption/barrier 
maintenance, given that TNF has been implicated in both fluid reabsorption and barrier 
dysfunction.  Elia et al. used a synthetic peptide that mimics the lectin-like domain of TNF 
situated at the tip of the molecule, in an in situ flooded mouse lung model and ex vivo 
flooded isolated rat lung model (234) and Braun et al. used this in in vivo and in situ rat 
models of alveolar flooding (233).  Both showed that this induced fluid reabsorption in the 
lungs in a receptor-independent manner.  Similarly, Fukuda et al. showed that a mutant 
TNF lacking the lectin-like domain, failed to enhance lung fluid reabsorption in rats in 
vivo, but also showed that TNF-stimulated sodium ion transport occurred via TNFR-
dependent and –independent pathways (237).  Despite this, the study did not investigate 
the individual involvement of TNFR p55 and p75 in lung fluid reabsorption.  I therefore 
investigated lung fluid reabsorption as a potential mechanism underlying the differential 
TNFR signalling previously observed in VILI. 
This investigation is somewhat incomplete due to the lack of TNFR p75 KO 
animals.  I have developed a model of lung fluid reabsorption where enhancing or 
reducing fluid reabsorption from the lungs using pharmacological agents in mechanically 
ventilated animals produces changes in lung mechanics and W:D values.  The introduction 
of amiloride, which specifically blocks sodium channels and has been used extensively in 
previously published fluid reabsorption models (109, 235-238), inhibited fluid 
reabsorption from the lungs.  The use of salbutamol, a 2-adrenergic agonist, enhanced 
fluid reabsorption, as measured by both elastance changes and W:D weight ratios.  Other 
adrenergic agonists have previously been shown to enhance fluid reabsorption and have 
also been used extensively in similar models (109, 233, 236-238).  They are thought to 
promote lung fluid reabsorption by up regulating sodium ion transport across alveolar type 
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II cells through epithelial sodium channels, via increased cAMP and Na
+
/K
+
 ATPase 
pump activity (11).  Fluid then passively follows through aquaporins on type I cells (1).  
Importantly, values for lung W:D weight ratios and % elastance change from baseline 
positively correlated, suggesting that in this model elastance changes can be used to 
measure water content in the lungs.  Accordingly, TNFR p75 KO mice exhibited greater 
elastance changes than WTs 1 h following fluid instillation.  This is consistent with 
reduced lung fluid reabsorption. 
The strength of this model relies on whether changes in lung elastance from 
baseline levels reflect lung water content.  Positive correlations between elastance changes 
and W:D values in WT animals treated with either salbutamol or amiloride is evidence for 
this.  Unfortunately, I was not able to reliably assess changes in W:D values between WTs 
and p75 KOs, due to animal availability issues.   
 Lung elastance was chosen as an appropriate variable that could be used to assess 
lung water content, because unlike PIP and Rrs, it is not influenced by fluid in the lung 
airways.  Lung elastance is the reciprocal of compliance, defined as the pressure change 
per unit of volume change (74), reflecting the stiffness of the lungs.  Compliance, 
resistance and airway pressure have been used previously to reflect mouse lung fluid 
reabsorption, albeit to my knowledge not in vivo (234).  Importantly, elastance could be 
influenced by factors other than lung fluid including pulmonary fibrosis, atelectasis and 
increased pulmonary venous pressure (74).  Of these, atelectasis is the only variable likely 
to be present in this model.  However, lung recruitment manoeuvres such as sustained 
inflations were employed in this study.  These are used periodically to re-inflate any 
collapsed lung units, minimising the risk of atelectasis. 
It is worth considering that despite differences between TNFR p75 KO and WT 
mice in this model, there could be lack of activation of TNFR p75-mediated fluid 
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reabsorption as I have not introduced exogenous TNF into the lungs.  However, this 
approach was used because TNF could potentially complicate the model, by inducing 
injury/inflammation and alveolar barrier permeability changes, but also potentially by 
inducing fluid reabsorption via its lectin-like domain.  Despite this, future investigations 
could use exogenous TNF in the instillate. 
Given the preliminary nature of these data, speculation on the mechanisms 
underlying p75-mediated fluid reabsorption may be premature, but this could occur via 
two main mechanisms.  Either a direct induction of fluid reabsorption mechanisms e.g. 
through ion channel up regulation, or by indirect effects such as cytoprotection of the 
alveolar barrier, especially type II cells that mediate fluid reabsorption.  However, given 
data from the current model, where there should be minimal lung damage, I speculate that 
p75 up regulates fluid reabsorption pathways in this model. 
Using an in vivo mouse model of lung fluid reabsorption I have shown that 
following i.t. fluid administration, TNFR p75 KO mice exhibited changes in lung 
mechanics compared to WT mice consistent with impaired fluid reabsorption from the 
lung.   However, these results are somewhat preliminary due to the lack of availability of 
TNFR p75 KO mice.  Immediate future work requires further validation of changes in 
elastance as an appropriate marker of lung fluid reabsorption, by correlating this with 
other indicators of fluid reabsorption e.g. changes in the concentration of a tracer 
compound in the instillate, and additional TNFR p75 KO data, using the 100 µl fluid 
instillation protocol.  The use of TNFR p55 KO mice and TNFR DKO mice are also 
required to consolidate the current data.  Antagonistic antibodies directed against TNFR 
p55 and p75 to acutely inhibit TNFR subtype signalling could also be used for further 
validation. 
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Though not recommended for immediate investigation, the mechanisms underlying 
differential TNFR signalling in VILI could also involve dysfunction of the alveolar 
epithelial/endothelial barrier.  Since Etk, a tyrosine kinase that is specifically activated by 
TNFR p75, but not p55 (177), has been implicated in enhancement of epithelial barrier 
integrity in vitro (190), its potential involvement in the protective effect of TNF p75 
against pulmonary oedema formation could therefore be investigated.  Moreover, the 
deleterious effects of TNFR p55 in oedema formation during VILI could involve alveolar 
barrier dysfunction via p38 MAPK (79, 228).  These mechanisms could be investigated by 
measuring the phosphorylated (activated) forms for Etk and p38 MAPK in lung 
parenchymal cells following VILI, using flow cytometry and with specific inhibitors of 
these signalling pathways.  Given that apoptosis has been implicated in pulmonary 
oedema formation during VILI (78), the involvement of TNFR p55 and p75 signalling in 
this process could also be investigated, using flow cytometry or tissue sections to assess 
pulmonary apoptosis using terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL)/annexin V and propidium iodide staining. 
In conclusion, these preliminary findings suggest that when instilled with fluid i.t., 
TNFR p75 KO mice show physiological changes consistent with inhibited lung fluid 
reabsorption.  Therefore, TNFR p75-mediated enhancement of lung fluid reabsorption is a 
potential mechanism via which differential TNFR signalling may occur, but it is important 
to note that this may not be the only protective effect of TNFR p75 signalling.  These data 
require further investigation, but here I provide for the first time evidence that TNFR p75 
could be involved in promotion of lung fluid reabsorption in vivo. 
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8.  DISCUSSION 
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TNF signalling represents a complex system influenced by many factors, including 
distinct signalling pathways associated with each TNFR and modulation of signalling by 
the soluble TNF receptors (sTNFRs).  Increased levels of sTNFRs in the systemic and 
alveolar compartments have been implicated in ALI/VILI.  Differential signalling of 
TNFRs has also been implicated in VILI.  In this project I investigated kinetics and 
sources of sTNFRs and the mechanisms underlying differential TNFR signalling in 
VILI/ALI.  This discussion chapter will summarise my major findings and discuss their 
implications. 
   
8.1 Background 
The relationship between ligands and their respective receptors may seem simple, but TNF 
signalling is rather more complex.  This is due to a number of factors, including the 
presence of cell-surface and soluble forms of TNF and its two receptors, through which 
the majority of TNF’s cellular effects are mediated.  Importantly, what governs the 
specific role of TNF in a given physiological context is not well defined. 
Whether receptors signal cooperatively (via either ligand passing from TNFR p75 
to p55 or by interactions between receptor-associated intracellular pathways) or signal in 
an opposing manner (via separate pathways) could play an important role in directing 
cellular responses to TNF.  TNFR p55 and p75 can act in opposition during VILI, with 
p55 promoting the formation of pulmonary oedema and p75 conferring protection against 
this (113), by as yet unknown mechanisms.  In such differential signalling, the relative 
degree of TNFR p55 vs. p75 signalling could be key to the overall biological effect of 
TNF.  This could be influenced by cell-surface TNFR p55 and p75 expression, governed 
by the balance between rates of de novo cellular receptor production/export to the cell 
206 
 
surface and cell-surface receptor shedding, producing sTNFRs. 
Soluble TNFRs can have potentially different roles depending on their 
concentration, with low levels facilitating and high levels antagonising TNF signalling 
(180, 224), but are generally considered anti-inflammatory.  Clinically, mechanical 
ventilation with high VT increases plasma and BALF levels of sTNFRs in ALI patients 
(20, 21) and experimentally high VT ventilation alone increases BALF sTNFR levels 
(113).  It has been suggested that such increases reflect lung inflammation/injury, because 
increased receptor levels in BALF and plasma are associated with morbidity/mortality in 
ALI patients (20, 21).  Despite these observations, the true relevance of these increases is 
not fully understood. 
Understanding the mechanisms underlying increased sTNFR levels during 
injurious mechanical ventilation would not only provide important information regarding 
the relevance and interpretation of increases, but also help elucidate cell-surface receptor 
expression changes via shedding.  This could indicate the degree of receptor activation and 
also regulate p55 vs. p75 expression, modulating TNF signalling toward either deleterious 
or protective responses.    Studying the kinetics of sTNFRs during VILI may therefore be 
essential to fully interpret sTNFR increases and evaluate the role of TNFR-mediated 
signalling. 
This project therefore had two main aims: firstly, to investigate the kinetics and 
sources of sTNFRs in the alveolar space and plasma during VILI, and secondly, to 
investigate mechanisms underlying differential TNFR signalling in VILI, using in vivo 
mouse models. 
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8.2 Soluble TNFRs in VILI/ALI 
In the first aim of this project I initially investigated intraalveolar sTNFR kinetics in VILI.  
Due to the interesting data, this was extended to include a number of other ALI models.   I 
found that sTNFRs are differentially regulated in the alveolar space during ALI, and 
depending on the physiological context, increases in individual soluble receptor subtypes 
can indicate specific aspects of the pathophysiology of lung injury. 
Using in vivo and ex vivo models of VILI, I found that sTNFR p55 and p75 were 
increased within the alveolar space following high VT ventilation primarily due to 
pulmonary oedema formation, with receptors leaking into the alveoli from the plasma 
across a compromised pulmonary epithelial/endothelial barrier.  This suggests that high 
VT ventilation does not induce sTNFR production/shedding within the alveolar space.  
Investigation of intraalveolar sTNFR kinetics in acid aspiration-induced ALI that like 
VILI, produced substantial pulmonary oedema formation, showed similar data, suggesting 
that this phenomenon was not entirely model-specific, but may occur whenever there is 
pulmonary oedema formation/plasma leak.  Using models of bacterial toxin-induced 
pulmonary inflammation that exhibited significant neutrophilic inflammation with only 
minimal oedema, I showed that sTNFR p75 can be increased within the alveolar space 
independently of plasma leakage.  This was suggestive of intraalveolar production.  
Depletion of alveolar macrophages reduced intraalveolar p75 production, suggesting this 
was mediated in part by alveolar macrophages.  Furthermore, macrophages preferentially 
produced sTNFR p75 in response to LPS stimulation in vitro. 
Extrapolation of these data to the clinical scenario has limitations, but suggests that 
during clinical ALI both sTNFRs can be up regulated in the alveolar space, but by separate 
processes.  These data aid interpretation of increased BALF sTNFRs in ARDS patients 
and advocate the potential use of increased BALF receptors as markers in the clinical 
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setting.  Increased BALF levels of sTNFR p55 could be used to assess the degree of 
pulmonary vascular leak/pulmonary oedema formation.  Similarly, a relative increase in 
BALF sTNFR p75 to p55 levels, compared with plasma sTNFR p75 to p55 could indicate 
the presence of alveolar macrophage-mediated intraalveolar inflammation.   Increases in 
BALF p75 levels could also potentially indicate ALI as a result of a direct pulmonary 
insult.  To my knowledge, this is the first time that the individual sTNFRs have been 
associated with separate disease processes in the pathophysiology of ALI, and could 
therefore be used as individual markers to aid in the diagnosis and management of ALI 
patients. 
Useful diagnostic and prognostic markers for ARDS have been investigated for 
decades and are required despite the benefits of low VT ventilation, because there is no 
apparent safe limit for ventilation settings (71, 266, 267).  Furthermore, markers could 
enable improved clinical decision making and utilisation of healthcare resources (266).   
However, useful markers ideally require many properties, including: specificity for 
ARDS/VILI, a direct influence of VILI on marker levels, and detectable changes that are 
acute enough to provide useful information for the management of patients (267).  In 
addition to these properties, it is important to understand the mechanisms responsible for 
up regulation of proposed markers, otherwise increased levels could easily be 
misinterpreted.  In the case of sTNFRs, I have shown that levels can be up regulated in the 
alveolar space by two mechanisms that reflect completely different processes.  Increased 
sTNFRs in either plasma or BALF are not specific to ALI, but this is also true for other 
proposed markers such as RAGE, KL-6 and surfactant proteins (6, 25, 26).  Soluble 
TNFRs in BALF could possibly fulfil some of the required criteria as useful markers, but 
this can only be determined by clinical investigation. 
Changes in sTNFR levels could also be a surrogate marker for the degree of cell-
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surface TNFR activation, because cell-surface TNFRs can be shed in response to TNF, 
which could modulate further TNFR signalling.  For example, receptor shedding could 
desensitise cells to further TNF activation and preferential shedding of one of the TNFR 
subtypes, could drastically alter the p55:p75 ratios on the surface of cells, in favour of 
deleterious p55 signalling or protective p75 signalling.  This possibility is especially 
interesting in my bacterial toxin models that show macrophage-mediated intraalveolar 
production of sTNFR p75.  Macrophage soluble p75 production by shedding, if not 
replaced, could reduce cell-surface TNFR p75 expression on these cells and depending on 
whether p75 elicits a protective effect via alveolar macrophages, this could explain how 
inflammatory insults predispose the lungs to the injurious effects of mechanical ventilation 
(59, 104, 258). 
Plasma sTNFR kinetics in VILI were markedly different from those within the 
alveolar space.  Unlike intraalveolar levels, increased plasma sTNFR levels peaked at 1 h 
during high VT ventilation in vivo, before the formation of substantial pulmonary 
oedema/alveolar barrier dysfunction.  This suggests that plasma sTNFRs were elevated 
independently of levels within the alveolar space, by production within the pulmonary 
and/or systemic circulation.  Expression of cell-surface TNFRs on the pulmonary 
endothelium and lung-marginated monocytes was significantly decreased following high 
VT ventilation, which strongly suggests receptor shedding from the pulmonary circulation 
as an underlying mechanism.  Furthermore, using the ex vivo VILI model, increases were 
observed in perfusate levels of both sTNFR p55 and p75 following high VT ventilation, 
suggesting that cells in the pulmonary circulation can indeed contribute to circulating 
sTNFR levels during VILI. 
These data suggest that VILI can induce elevation of increased sTNFRs in plasma 
by direct effects on the pulmonary circulation, independently of the degree of alveolar 
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barrier dysfunction and hence independently of sTNFR levels within the alveolar space, in 
contrast to previous suggestions (21).  This is somewhat in opposition to the general 
consensus of biotrauma, where soluble mediators produced the airspaces disseminate 
systemically across a compromised alveolar barrier (22-24).  Similar mechanisms could 
potentially occur for other systemic soluble mediators during VILI that may contribute to 
systemic inflammation and multiple organ failure.  This is supported by in vitro studies 
that show mechanical stretch of endothelial cells can result in production of various 
inflammatory mediators (95).  To my knowledge, this is the first time that sTNFR levels in 
plasma have been shown to be increased by a purely mechanical insult that does not 
require decompartmentalisation of the alveolar milieu from the airspaces.  This could 
represent an anti-inflammatory mechanism that develops in response to high VT 
mechanical ventilation.  These data could also indicate that increased plasma sTNFR 
levels at least partly reflect the degree of cellular activation in the pulmonary circulation in 
response to lung stretch and thus reflect pulmonary intravascular inflammation/activation, 
as opposed to intraalveolar inflammation and lung injury, as previously suggested (21). 
High VT ventilation in vivo induced increased sTNFR levels in BALF and plasma, 
consistent with the clinical literature.  However, comparison of data from chapters 3 and 5, 
indicate that VILI produces these increases via distinct mechanisms.  Pure VILI did not 
produce detectable increases in intraalveolar sTNFR production, with increases primarily 
due to plasma leakage, but induced production of sTNFR p55 and possibly p75 from the 
pulmonary circulation.  Assuming that VILI induces the same degree of cell stretch among 
different cell populations, regulation of sTNFR production seems to be also tissue/cell 
specific, in addition to the differences in receptor subtype production.  This is a further 
facet to differential sTNFR regulation, i.e. not only is there differential intraalveolar 
production of p55 and p75 in LPS/LTA vs. acid aspiration and VILI (from chapter 4), but 
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also differential sTNFR production between biological compartments, with the same insult 
(VILI) inducing production in one compartment, but not another.  This is also similar with 
LPS, as in the LPS/LTA models, there is intraalveolar production of p75 only, while it has 
been reported that endotoxaemia induces increases in both sTNFR p55 and p75 in plasma 
(205, 208, 213). 
In pure mechanical VILI, the absence of sTNFR production within the alveolar 
space could be interpreted as a lack of an anti-inflammatory response to the pro-
inflammatory milieu in response to high VT ventilation.  Conversely, the production of 
sTNFRs by the pulmonary circulation, albeit to a relatively small degree, is suggestive of 
a systemic anti-inflammatory milieu.  Elevated levels of sTNFRs could neutralise TNF 
activity in both the alveolar space and plasma, but depending on timing this effect may be 
limited in vivo as TNF is up regulated in BALF only during the early phase of VILI (88). 
I have shown that increases in BALF sTNFR levels are associated with specific 
aspects of ALI/VILI.  My data may help explain why increased BALF sTNFRs are 
associated with morbidity and mortality in ARDS patients.  ALI/VILI are inflammatory 
conditions, therefore increased sTNFR p75 in BALF could be an anti-inflammatory 
response, reflecting the degree of intraalveolar inflammation that is known to be 
associated with poor outcome in ARDS (18).  Similarly, BALF sTNFRs are increased in 
pulmonary sarcoidosis, a chronic (as opposed to acute) inflammatory condition, 
potentially also by intraalveolar production by leukocytes including alveolar macrophages, 
and possible plasma leakage, but there is disparity between studies showing selective 
increases in p75 and increases in both sTNFRs in the alveolar space (211, 212).  This may 
indicate that intraalveolar sTNFR p75 production is general feature of pulmonary 
inflammation.  Conversely, at least in the acute situation, sTNFR p55 elevation in BALF 
may not be due to inflammation, but may reflect pulmonary oedema, which would have 
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deleterious effects on patient survival in ARDS by decreasing gas exchange. 
In summary, changes in sTNFRs can represent various aspects of the 
pathophysiology of ALI and a clear understanding of this could advocate their use in the 
clinical setting as useful markers.  These findings therefore require further clinical 
investigation. 
 
8.3 Cell-surface TNFR expression 
In chapters 3, 4 and 5, I studied the kinetics of both cell-surface and soluble TNFR 
expression during ALI.  However, this first required development of a technique to 
reliably detect TNFR expression in lung tissue.  Using flow cytometry, I showed low 
expression of TNFRs on lung parenchymal cells, with higher levels on pulmonary 
leukocytes.  Protease inhibitors were required for preservation of TNFR expression, since 
TNFRs are extremely labile.  Consolidation of this technique using immunohistochemistry 
proved difficult.  “Positive” staining was observed for TNFR p55 in both WT and TNFR 
KO tissue and thus could not be specific.  Using other antibodies, both TNFR p55 and p75 
expression was undetectable.  This technique therefore does not seem to be suitable for 
TNFR detection.  Since many studies do not validate TNFR staining with biological 
negative controls such as TNFR KO tissue, it is possible that they do not show true 
positive TNFR staining.  In contrast, TNFR expression data obtained using flow 
cytometry showed that both receptors are expressed in lung tissue to varying degrees, 
generally consistent with the literature. 
My flow cytometry data shows a general dominance of TNFR p75 on alveolar 
cells.  Despite the higher levels of this “protective” receptor, high VT ventilation produces 
significant lung injury.  This could be partly explained by the increased levels of 
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intraalveolar sTNF during VILI (57, 88, 90, 92) that preferentially activates the 
“deleterious” p55 receptor.  It is also worth noting that the site of differential TNFR 
signalling has not been elucidated and could involve both intraalveolar and intravascular 
compartments.  These considerations are important for the development of possible TNFR 
p75 agonistic or p55 antagonistic therapies, to reduce pulmonary oedema formation in 
ventilated ARDS patients.  Given that intraalveolar TNF signalling is important in the 
pathogenesis of VILI (89, 92), TNFRs expressed on pulmonary epithelial cells and 
alveolar macrophages are likely to be involved, and because the integrity of the epithelial 
barrier ultimately determines fluid clearance, surfactant production and alveolar flooding, 
this may present a more prudent target for future therapeutic interventions. 
To my knowledge, this is the first time flow cytometry has been used to assess 
TNFR expression on a wide array of primary pulmonary cells, including leukocytes and 
parenchymal cells.  I have successfully characterised TNFR expression on lung 
marginated neutrophils and monocyte subpopulations, and pulmonary macrophages, 
epithelial and endothelial cells, under normal conditions and during ALI.  The protocol 
could also easily be used to study TNFR expression other tissues and will be a useful tool 
for future research. 
 
8.4 Mechanisms of differential TNFR signalling 
Finally, I investigated potential mechanisms of differential TNFR signalling in pulmonary 
oedema development induced by injurious high VT ventilation, by investigating the role of 
TNFR p75 in lung fluid reabsorption.  I developed an in vivo mouse model to assess lung 
fluid reabsorption in WT and TNFR p75 KO mice.  This model employed i.t. bolus 
delivery of fluid to ventilated mice.  This was initially used in conjunction with various 
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pharmacological agents, known to influence fluid reabsorption.  WT mice treated with 
amiloride, known to inhibit lung fluid reabsorption, had a greater amount of lung water 1 h 
following fluid instillation, compared to salbutamol treated mice, as shown by W:D 
weight ratios.  These correlated positively with lung elastance changes, suggesting that 
this reflected lung water content and could be used to assess lung fluid reabsorption.  
TNFR p75 KO mice that received a control isotonic fluid bolus had larger changes in lung 
elastance compared to WT mice that received the same instillate.  I was unable to obtain 
sufficient data for W:D lung weight ratios due to the availability of KOs, but the changes 
in lung mechanics in TNFR p75 KO animals were consistent with impaired lung fluid 
reabsorption.  This suggests that lung fluid reabsorption may be one of the mechanisms 
underlying differential TNFR signalling in VILI, with TNFR p75 promoting (and/or p55 
inhibiting) the reabsorption of fluid from the lung airspaces. 
The lectin-like domain of TNF has been implicated in fluid reabsorption (233, 234, 
237), but the individual contributions of p55 and p75 have not been investigated and their 
importance in fluid reabsorption may have been overlooked.  Combined with the 
deleterious and protective effects of p55 and p75 in pulmonary oedema formation, 
respectively, these data suggest TNF promotes fluid reabsorption via activation of TNFR 
p75 in addition to via its lectin-like domain.  This could suggest some degree of 
redundancy, but apparent overlap in biological function is by no means uncommon in 
TNF biology. 
These preliminary data require additional experiments and further validation.  
However, my data provide for the first time in vivo evidence that TNFR p75 may promote 
fluid reabsorption and identifies a mechanism by which differential TNFR signalling may 
occur in VILI, supporting the published data. 
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8.5 Concluding Remarks 
This project has addressed a wide array of aspects of TNFR biology in VILI and ALI of 
other aetiologies.  Firstly, I have identified mechanisms underlying intraalveolar sTNFR 
increases during ALI.  I found that TNFR p55 and p75 both leak into the alveolar space 
from plasma during pulmonary oedema formation in VILI, but also following acid 
aspiration and presumably whenever substantial pulmonary oedema occurs.  My data also 
suggest that VILI, and possibly acid aspiration, do not induce detectable sTNFR 
production in the alveolar space.  However, sTNFR p75, not p55, is produced within the 
alveolar space in the presence of substantial pulmonary inflammation in response to 
bacterial toxins.  These interesting findings could be extrapolated to the clinical situation 
and thus help interpret raised sTNFRs in the BALF of ALI patients.   
Secondly, I have investigated elevated plasma sTNFRs induced by pure VILI.  I 
found that increased levels are unlikely to originate from the alveolar space as previously 
suggested.  In this model, production of both sTNFR p55 and p75 was partly induced from 
the pulmonary circulation, by the pulmonary endothelium and lung-marginated 
monocytes.  My data thus suggest that VILI can have direct effects on systemic mediator 
levels independently from the intraalveolar milieu.  This could reflect generation of a 
systemic anti-inflammatory milieu, but this mechanism could occur for other mediators in 
vivo and potentially contribute to deleterious systemic effects of injurious ventilation that 
may ultimately lead to multiple organ failure. 
 Thirdly, I established a reliable method of assessing cell-surface TNFR expression 
in lung tissue, using flow cytometry.  This helped address some of the controversy in the 
published literature regarding pulmonary TNFR expression, and was also used to study 
cell-surface TNFR expression kinetics in my ALI models. 
 Fourthly, I investigated potential mechanisms that underlie differential TNFR 
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signalling in VILI.  My data, although rather preliminary, suggest that TNFR p75 
promotes, or TNFR p55 inhibits, reabsorption of fluid from the lungs.  Hence this 
mechanism may help explain the different roles of TNFR p55 and p75 in the development 
of pulmonary oedema formation induced by injurious high VT ventilation. 
 This project contributes a large quantity of interesting data to the fields of ALI and 
TNFR biology.  Some of the data is potentially very clinically applicable and requires 
further investigation.  I have also developed novel methodologies that enable investigation 
of pulmonary TNFR expression and lung fluid reabsorption, which could also have far 
reaching applications in future research. 
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